

List of tables

Table 1 Study characteristics for randomised controlled trials reporting effectiveness outcomes

2

Table 2 Additional study characteristics for randomised controlled trials reporting effectiveness outcomes

47

Table 1 Study characteristics for randomised controlled trials reporting effectiveness outcomes

Study	Study Sponsor	Study Design	Study Duration (weeks)	Duration of Drug Treatment (weeks)	Location	Willing to Quit?	Smokeless Tobacco?	Total N	Females N (%)	White %	Study Arms
Abdullah 2013¹	Hong Kong Council on Smoking and Health (COSH)	Parallel RCT	52	2	Hong Kong, China	Yes	No	562	122 (27)		1. NRT Choice + Individual + Telephone Short Counselling 2. NRT Choice + Individual + Telephone Short Counselling
Abelin 1989²		Parallel RCT	52	12	Switzerland	Yes	No	199	80 (40)		1. NRT Patch (24hrs) 2. Placebo
Ahluwalia 1998³	American Cancer Society Career, Marion Merrell Dow, Inc., Emory Medical Care Foundation	Parallel RCT	24	10	Georgia, USA	Yes	No	410	267 (65)	0	1. NRT Patch (24hrs) High 2. Placebo
Ahluwalia 2002⁴	National Cancer Institute	Parallel RCT	27	7	USA	Yes	No	600	420 (70)	0	1. Bupropion Standard + Individual + Telephone Long Counselling 2. Placebo + Individual + Telephone Long Counselling
Ahluwalia 2006⁵	National Cancer Institute at the National Institutes of Health	Parallel RCT	26	8	Kansas, USA	Yes	No	755	505 (67)	0	1. NRT Gum Standard + Individual + Telephone Short Counselling 2. NRT Gum Standard + Individual + Telephone Short Counselling 3. Placebo + Individual + Telephone Short Counselling 4. Placebo + Individual + Telephone Short Counselling
Anderson 2018⁶	California Tobacco Control Program, California Department of Public Health (CDPH), Funding Opportunity Number 1B1CMS33090 1 from the Centers for Medicare & Medicaid Services, an umbrella grant from the Centers for Medicare & Medicaid Services to the California Department of Health Care	Parallel RCT	28	28	California, USA	Yes	No	3816	2583 (68)	59	1. Usual Care + Telephone Long Counselling 2. NRT Patch (24hrs) + Telephone Long Counselling 3. NRT Patch (24hrs) + Telephone Long Counselling

	Services (grant 1B1CMS33088 3- 01-00)										
Andrews 2016⁷	National Health, Lung & Blood Institute of the National Institutes of Health	Cluster RCT	52	8	Georgia and South Carolina, USA	Yes	No	409	409 (100)		1. NRT Patch (24hrs) + Individual + Group Long Counselling 2. Waitlist
Anthenelli 2013⁸	Pfizer	Parallel RCT	52	12	USA (9 centres) and 24 centres across Bosnia & Herzegovina, Croatia, Germany, Hungary, Romania, Russian Federation, Spain	Yes	No	525	329 (63)		1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Anthenelli 2016A⁹	Pfizer and GlaxoSmithKline	Parallel RCT	52	12	Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Mexico, New Zealand, Russian Federation, Slovakia, South Africa, Spain, USA	Yes	No	4028	1985 (49)	83	1. Varenicline Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. NRT Patch (24hrs) High + Individual Short Counselling 4. Placebo + Individual Short Counselling
Anthenelli 2016B⁹	Pfizer and GlaxoSmithKline	Parallel RCT	52	12	Argentina, Australia, Brazil, Bulgaria, Canada, Chile, Denmark, Finland, Germany, Mexico, New Zealand, Russian Federation, Slovakia, South Africa,	Yes	No	4116	2524 (61)	81	1. Varenicline Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. NRT Patch (24hrs) High + Individual Short Counselling 4. Placebo + Individual Short Counselling

Anthonisen 1994¹⁰	Division of Lung Diseases of the National Heart, Lung, and Blood Institute. The Salt Lake City Center: National Center for Research Resources	Parallel RCT	754	24	Spain, USA Baltimore, Birmingham, Cleveland, Detroit, Los Angeles, Pittsburgh, Portland, Rochester, Salt Lake City, USA and Winnipeg, Canada	Yes	No	5887	2178 (37)	95	1. NRT Gum Standard 2. Usual Care (Three arms collapsed into two arms)
Areechon 1988¹¹	Merrell Dow (Bangkok, Thailand) and A.B. Leo, Helsingborg, Sweden	Parallel RCT	24	12	Thailand	Yes	No	200	11 (6)		1. NRT Gum Standard 2. Placebo
Aryanpur 2016¹²	National Research Institute of Tuberculosis and Lung Diseases and Shahid Beheshti University of Medical Sciences, Abidi pharmaceutical company provided bupropion drug (Wellban) fund.	Parallel RCT	24	9	Tehran, Iran	Yes	No	210	18 (9)	0	1. Usual Care 2. Usual Care + Individual Counselling 3. Bupropion Standard + Individual Counselling
Aubin 2004¹³	GlaxoSmithKline (GSK) France	Parallel RCT	26	7	France	Yes	No	506	280 (56)		1. Placebo + Individual + Telephone Short Counselling 2. Bupropion Standard + Individual + Telephone Short Counselling
Aubin 2008¹⁴	Pfizer Inc	Parallel RCT	52	12	Belgium, France, Netherlands, UK, USA	Yes	No	757	379 (51)	93	1. Varenicline Standard + Individual + Telephone Short Counselling 2. NRT Patch (24hrs) High + Individual + Telephone Short Counselling
Baker 2006¹⁵	National Health and Medical Research Council, Rotary, and Community Health and	Parallel RCT	52	10	Sydney, Australia and the Newcastle region of NSW, Australia	Yes	No	298	142 (48)		1. NRT Patch (24hrs) High + Individual Long Counselling 2. Usual Care

	Tuberculosis Australia											
Baker 2016¹⁶	National Heart, Lung, and Blood Institute, National Cancer Institute	Parallel RCT	52	12	Wisconsin, USA	Yes	No	1086	566 (52)	67	1. NRT Patch (24hrs) + Individual + Telephone Short Counselling 2. Varenicline Standard + Individual + Telephone Short Counselling 3. NRT Combo + Individual + Telephone Short Counselling	
Baldassarri 2018¹⁷	Yale School of Medicine, Section of Pulmonary, Critical Care, and Sleep Medicine and the National Heart, Lung, and Blood Institute	Parallel RCT	24	16	Connecticut, USA	Yes	No	40	21 (53)	65	1. NRT Patch (24hrs) + Individual Long Counselling 2. Electronic Cigarette High + NRT Patch (24hrs) + Individual Long Counselling	
Batra 2005¹⁸	Pfizer Consumer Healthcare, Helsingborg, Sweden	Parallel RCT	56	52	Tübingen, Germany and Zürich, Switzerland	No	No	364	148 (41)		1. NRT Gum High 2. Placebo	
Bernstein 2015¹⁹	National Cancer Institute of the National Institutes of Health	Parallel RCT	52	6	Connecticut, USA	Yes	No	780	407 (52)	39	1. Usual Care 2. NRT Combo + Individual + Telephone Short Counselling	
Binnie 2007²⁰	Local NHS Smoking Cessation Services (Smoking Concerns, Glasgow, UK) and the dental school	Parallel RCT	52		Glasgow, UK	Yes	No	118	82 (69)		1. NRT Choice 2. Usual Care	
Bjurlin 2013²¹		Parallel RCT	52		Illinois, USA	Yes	No	179		16	1. Usual Care 2. No Drug Treatment + Individual Short Counselling 3. NRT Choice + Individual Short Counselling	
Blondal 1989²²	Icelandic Ministry of Health and Social Security, Reykjavik	Parallel RCT	104	12	Reykjavik, Iceland		No	182	104 (57)		1. NRT Gum High + Group Long Counselling 2. Placebo + Group Long Counselling	
Blondal 1997²³	Icelandic Ministry of Health and Social Security, and Pharmacia & Upjohn	Parallel RCT	104	12	Reykjavik, Iceland	Yes	No	158	87 (55)		1. NRT Nasal Spray Standard + Group Long Counselling 2. Placebo + Group Long Counselling	

	(equipment, drugs)										
Blondal 1999²⁴	Pharmacia and Upjohn provided the drugs and placebo	Parallel RCT	312	52	Reykjavik, Iceland		No	239	159 (67)		1. NRT Combo Standard + Group Counselling 2. NRT Patch (16hrs) Standard + Group Counselling
Bohadana 2000²⁵	Pharmacia & Upjohn Consumer Healthcare, Helsingborg, Sweden	Parallel RCT	52	26	Lorraine, France	Yes	No	400	204 (51)		1. NRT Combo Standard + Individual Short Counselling 2. NRT Inhalator Standard + Individual Short Counselling
Bolliger 2000²⁶	Pharmacia and Upjohn Consumer Healthcare, Sweden	Parallel RCT	104	76	Basel and Lausanne, Switzerland	No	No	400	210 (53)		1. NRT Inhalator Standard + Individual Counselling 2. Placebo + Individual Counselling
Bolliger 2007²⁷		Parallel RCT	52	12	Cape Town, South Africa	Yes	No	100	40 (40)		1. NRT Mouth Spray Standard + Individual Short Counselling 2. NRT Gum Standard + Individual Short Counselling 3. NRT Inhalator Standard + Individual Short Counselling
Bolliger 2011²⁸	Pfizer	Parallel RCT	24	12	Brazil, Venezuela, Mexico, Colombia, Costa Rica, South Africa, Egypt, UAE, Lebanon, Saudi Arabia, Lebanon	Yes	No	593	233 (39)	31	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Bonevski 2018²⁹	National Health and Medical Research Council (NHMRC) of Australia (631055)	Parallel RCT	24		New South Wales, Australia	Yes	No	618	210 (49)		1. No Drug Treatment 2. NRT Choice + Individual + Telephone Short Counselling
Boyle 1992³⁰		Parallel RCT	24	6	Oregon, USA	Yes	Yes	100	3 (3)		1. NRT Gum Standard + Group Long Counselling 2. Placebo + Group Long Counselling
Brown 2007³¹	National Institutes of Health	Parallel RCT	52	12	Rhode Island, USA	Yes	No	524	249 (48)	92	1. Placebo + Group Long Counselling 2. Placebo + Group Long Counselling 3. Bupropion Standard + Group Long Counselling 4. Bupropion Standard + Group Long Counselling
Buchkremer 1988³²	Deutsche Forschungsgemeinschaft	Parallel RCT	52	8	Germany	Yes	No	131	66 (50)		1. NRT Patch (24hrs) Low + Group Counselling 2. Placebo + Group Counselling 3. No Drug Treatment + Group Counselling
Buchkremer 1989³³		Parallel RCT	61	7	Munster, Germany	Yes	No	131			1. NRT Patch (24hrs) + Counselling 2. Placebo + Counselling 3. No Drug Treatment + Counselling

Bullen 2010 ³⁴	Health Research Council and the Heart Foundation of New Zealand	Parallel RCT	24	10	New Zealand	Yes	No	1100	661 (60)		1. NRT Choice + Telephone Counselling 2. NRT Choice + Telephone Counselling
Bullen 2013 ³⁵	Health Research Council of New Zealand	Parallel RCT	25	13	Auckland, New Zealand	Yes	No	657	405 (62)		1. Electronic Cigarette High + Telephone Short Counselling 2. NRT Patch (24hrs) High + Telephone Short Counselling 3. Placebo + Telephone Short Counselling
Burns 2016 ³⁶	Pfizer and the Colorado Department of Public Health and Environment	Parallel RCT	28	8	Colorado, USA	Yes	No	1495	897 (60)	78	1. NRT Patch (24hrs) + Telephone Counselling 2. NRT Patch (24hrs) + Telephone Counselling
Caldwell 2014 ³⁷	Health Research Council of New Zealand. Active Zonic mouth-spray was provided by Niconovum	Parallel RCT	55	26	Wellington and Christchurch, New Zealand	Yes	No	1423	763 (54)	71	1. NRT Combo High + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling
Caldwell 2016 ³⁸	The Health Research Council of New Zealand	Parallel RCT	28	24	Wellington, New Zealand	Yes	No	502	254 (51)		1. NRT Combo High + Individual + Telephone Short Counselling 2. NRT Patch (24hrs) High + Individual + Telephone Short Counselling
Caldwell 2018 ³⁹	National Cancer Institute of the National Institutes of Health (NIH)	Cluster RCT	208	8	Georgia, USA	Yes	No	110	89 (81)		1. No Drug Treatment + Individual + Telephone Short Counselling 2. NRT Patch (24hrs)
Campbell 1983 ⁴⁰	Health Education Council and Lundbeck Ltd, who also supplied the chewing gum	Parallel RCT	52	24	UK		No	1618	599 (37)		1. Usual Care 2. Usual Care 3. Placebo 4. NRT Gum Standard
Campbell 1987 ⁴¹	Chest, Heart and Stroke Association	Parallel RCT	52		UK	Yes	No	836	510 (61)		1. NRT Gum Standard 2. Placebo
Campbell 1991 ⁴²	Pharmacia LEO	Parallel RCT	52	12	UK	Yes	No	212	93 (44)		1. NRT Gum 2. Placebo
Campbell 1996 ⁴³	Ciba-Geigy Ltd.	Parallel RCT	52	12	UK	Yes	No	234	126 (54)		1. NRT Patch (24hrs) 2. Placebo
Caponnetto 2013 ⁴⁴	Lega Italiana AntiFumo	Parallel RCT	52	12	Catania, Italy	No	No	300	110 (36)		1. Electronic Cigarette Low 2. Electronic Cigarette Low 3. Placebo
Carpenter 2011 ⁴⁵	National Institute on Drug Abuse	Parallel RCT	26	6	South Carolina, USA	No	No	943	605 (64)	88	1. NRT Lozenge + Telephone Counselling 2. No Drug Treatment + Telephone Counselling

Carson 2014 ⁴⁶	Department of Respiratory Medicine, Queen Elizabeth Hospital, Adelaide, Australia	Parallel RCT	52	12	Adelaide, Australia	Yes	No	392	126 (32)	96	1. Varenicline Standard + Telephone Short Counselling 2. No Drug Treatment + Telephone Short Counselling
Chan 2011 ⁴⁷	Health and Health Services Research Fund, Hong Kong SAR	Parallel RCT	24	8	Hong Kong, China	No	No	1154	208 (18)	0	1. NRT Choice + Individual Short Counselling 2. NRT Choice + Individual Short Counselling 3. No Drug Treatment + Individual Short Counselling
Chengappa 2014 ⁴⁸	The National Institute of Mental Health (NIMH) of the NIH. Pfizer provided drug/placebo and an investigator-initiated grant	Parallel RCT	24	12	Pittsburgh, Pennsylvania, USA	Yes	No	60	41 (69)	66	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Cinciripini 1996 ⁴⁹	DHHS, and by Ciba Geigy Corporation and Marion Merrell Dow	Parallel RCT	56	12	Texas, USA	Yes	No	64	45 (70)	89	1. No Drug Treatment + Group Long Counselling 2. NRT Patch (24hrs) High + Group Long Counselling
Cinciripini 2013 ⁵⁰	NIDA, NCI; varenicline supplied by Pfizer	Parallel RCT	24	12	Houston, Texas, USA	Yes	No	294	114 (39)	67	1. Varenicline Standard + Individual + Telephone Long Counselling 2. Bupropion Standard + Individual + Telephone Long Counselling 3. Placebo + Individual + Telephone Long Counselling
Cinciripini 2018 ⁵¹	United States National Institutes of Health (NIH) and by The University of Texas MD Anderson's Cancer Center, funded by the National Cancer Institute (NCI)	Parallel RCT	53	12	Houston, Texas, USA	Yes	No	385	160 (42)	62	1. Varenicline Standard + Bupropion Standard + Individual + Telephone Short Counselling 2. Varenicline Standard + Individual + Telephone Short Counselling 3. Placebo + Individual + Telephone Short Counselling
Clavel 1985 ⁵²	Haut Comite d'Aide a la Lutte Contre le Cancer, France and A B Leo and Co, Sweden, for	Parallel RCT	56		France	Yes	No	651	332 (51)		1. NRT Gum Standard + Group Long Counselling 2. No Drug Treatment + Group Long Counselling

	financial support and for supplying the gum										
Clavelchapelon 1992⁵³		Parallel RCT	56	24	Villejuif and Saint-Louis, France	Yes	No	996	448 (45)		1. NRT Gum Standard 2. Placebo
Collins 2004⁵⁴	National Cancer Institute, National Cancer Institute/National Institute on Drug Abuse and the General Clinical Research Center Program of the National Center for Research Resources, National Institutes of Health	Parallel RCT	24	10	D.C., New York, USA	Yes	No	670			1. Bupropion Standard + Group + Telephone Long Counselling 2. Placebo + Group + Telephone Long Counselling
Cooney 2007⁵⁵	National Institute on Alcoholism and Alcohol Abuse and by the Department of Veterans Affairs	Parallel RCT	26	8	Connecticut, USA	Yes	No	133		66	1. NRT Patch (24hrs) High + Individual Long Counselling 2. No Drug Treatment + Individual Short Counselling
Cooney 2009⁵⁶	National Institute on Alcohol Abuse and Alcoholism and the Department of Veterans Affairs	Parallel RCT	52	24	Connecticut, USA	Yes	No	96	28 (29)	90	1. NRT Combo High + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling
Cooper 2005⁵⁷		Parallel RCT	52	9	USA	Yes	No	441	441 (100)	86	1. Placebo + Group Long Counselling 2. NRT Gum Standard + Group Long Counselling
Cooperman 2017⁵⁸	National Institute on Drug Abuse (NIDA) Grant K23DA025049	Parallel RCT	24	12	New Jersey, USA	Yes	No	83	48 (58)	75	1. NRT + Individual Long Counselling 2. No Drug Treatment

Covey 2007⁵⁹	National Institute on Drug Abuse, National Alliance for Research on Schizophrenia and Affective Disorders and the Suzanne C. Murphy Foundation	Open Label followed by Parallel RCT	48	24	New York, USA	Yes	No	294	131 (45)	70	1. Bupropion Standard + NRT Gum Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. NRT Gum Standard + Individual Short Counselling 4. Placebo + Individual Short Counselling
Cox 2012⁶⁰	federally funded; National Cancer Institute, National Institutes of Health, National Institute for Minority Health and Disparities	Parallel RCT	26	7	Missouri, USA	Yes	No	540	357 (66)	0	1. Bupropion Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Croghan 2003⁶¹	Public Health Service and the National Cancer Institute	Parallel RCT	24	6	USA	Yes	No	1384	803 (58)		1. NRT Patch (16hrs) Standard 2. NRT Nasal Spray Standard 3. NRT Combo Standard
Cropsey 2015⁶²	National Cancer Institute and NIH	Parallel RCT	52	12	Alabama, USA	Yes	No	500	165 (33)	32	1. Bupropion Standard 2. Bupropion Standard + Individual Long Counselling
Cummings 2011⁶³	New York State Department of Health	Parallel RCT	28	6	New York, USA	Yes	No	2806	1563 (56)		1. NRT Patch (24hrs) + Telephone Short Counselling 2. NRT Patch (24hrs) + Telephone Short Counselling 3. NRT Patch (24hrs) + Telephone Short Counselling
Cummins 2016⁶⁴	National Cancer Institute	Parallel RCT	24	8	California, USA	Yes	No	1270	550 (43)	51	1. NRT Patch (24hrs) High + Telephone Long Counselling 2. No Drug Treatment + Telephone Long Counselling
Cunningham 2016⁶⁵	Canadian Institutes of Health Research, Centre for Addiction and Mental Health, the Centre for Addiction and Mental Health Foundation, the Canada Foundation for	Parallel RCT	24	5	Canada	Yes	No	1000	511 (51)		1. NRT Patch (24hrs) High 2. No Drug Treatment

Innovation,
the Ontario
Ministry of
Research and
Innovation,
the Endowed
Chair in
Addictions for
the
Department of
Psychiatry,
Public Health
Agency of
Canada,
Canadian
Institutes of
Health
Research
Institute of
Neurosciences
, Mental
Health and
Addiction and
Institute of
Population
and Public
Health,
Ontario
Ministry of
Health and
Long Term
Care

Dale 1995⁶⁶	Lederle Laboratories, Pearl River, NY	Parallel RCT	52	8	Minnesota, USA	Yes	No	71	39 (55)		1. NRT Patch (24hrs) + Individual + Group Long Counselling 2. NRT Patch (24hrs) Low + Individual + Group Long Counselling 3. NRT Patch (24hrs) High + Individual + Group Long Counselling 4. NRT Patch (24hrs) High + Individual + Group Long Counselling
Dale 2002⁶⁷		Parallel RCT	24	12	Minnesota, USA	Yes	Yes	68	1 (2)	100	1. Bupropion Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Dale 2007⁶⁸	National Cancer Institute	Parallel RCT	52	12	Minnesota, West Virginia, USA	Yes	Yes	225	0 (0)	98	1. Bupropion Standard 2. Placebo
Dalsgaard 2004⁶⁹	GlaxoSmithKline, Denmark	Parallel RCT	26	7	Eastern part of Denmark, Denmark	Yes	No	336	250 (75)		1. Bupropion Standard + Individual Counselling 2. Placebo + Individual Counselling
Daughton 1991⁷⁰	ALZA Corp, Palo Alto, Calif, Merrell Dow Research Institute,	Parallel RCT	24	4	California and Omaha, USA	Yes	No	158	84 (53)		1. NRT Patch (24hrs) Low + Individual + Group Short Counselling 2. NRT Patch (16hrs) Low + Individual + Group Short Counselling 3. Placebo + Individual + Group Short Counselling

	Cincinnati, Ohio										
Daughton 1998⁷¹	Marion Merrell Dow Inc, Kansas City, Mo.	Parallel RCT	52	10	Nebraska, USA	Yes	No	369	221 (60)		1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Daughton 1999/TNSG 1991⁷²	Alza Corp.	Two Parallel RCTs	268	12	Indiana, Minnesota, Nebraska, California, Vermont, West Virginia, Missouri, Oregon, USA	Yes	No	935	564 (60)		1. NRT Patch (24hrs) High + Group Long Counselling 2. NRT Patch (24hrs) Standard + Group Long Counselling 3. NRT Patch (24hrs) Low + Group Long Counselling 4. Placebo + Group Long Counselling
Dautzenberg 2001⁷³	Novartis Consumer Health	Parallel RCT	26	12	France	Yes	No	436	227 (52)		1. NRT Lozenge Low 2. Placebo
Davidson 1998⁷⁴	Elan Pharmaceutical Research Corporation, Gainesville, Ga	Parallel RCT	24	6	Maryland, Illinois, USA	Yes	No	802	431 (54)	89	1. NRT Patch (24hrs) High 2. Placebo
De Dios 2012⁷⁵	NCI, NIDA	Parallel RCT	24	12	Rhode Island and Southern Massachusetts, USA	Yes	No	32	17 (53)	0	1. NRT Patch (24hrs) Standard + Individual Long Counselling 2. Varenicline Standard + Individual Long Counselling 3. Placebo + Individual Long Counselling
Dogar 2018⁷⁶	GRAND 2014, supported by Pfizer	Parallel RCT	25	12	Punjab, Pakistan	Yes	No	510	81 (16)		1. Varenicline Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Ebbert 2007⁷⁷	National Cancer Institute	Parallel RCT	24	8	Minnesota, USA	Yes	Yes	42		98	1. Placebo + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling 3. NRT Patch (24hrs) High + Individual Short Counselling 4. NRT Patch (24hrs) High + Individual Short Counselling
Ebbert 2009⁷⁸	National Cancer Institute	Parallel RCT	24	12	Minnesota, USA	Yes	Yes	270	6 (2)	96	1. NRT Lozenge High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Ebbert 2010⁷⁹	National Cancer Institute	Parallel RCT	24	12	Minnesota and Oregon, USA	Yes	Yes	60	0 (0)	93	1. Placebo + Telephone Short Counselling 2. NRT Lozenge High + Telephone Short Counselling
Ebbert 2011⁸⁰	National Cancer Institute	Parallel RCT	24	12	Minnesota and Wisconsin, USA	Yes	Yes	76	0 (0)	97	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Ebbert 2013⁸¹	National Institutes of Health	Parallel RCT	24	8	Minnesota, USA	Yes	Yes	52	0 (0)	94	1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Ebbert 2014⁸²	National Institutes of Health (NIH)	Parallel RCT	52	12	Minnesota, USA	Yes	No	506	239 (47)	93	1. Varenicline Standard + Bupropion Standard + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling
Ebbert 2015⁸³	Pfizer	Parallel RCT	52	24	USA, Australia, Canada,	Yes	No	1510	659 (44)	62	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling

					Czech Republic, Egypt, Germany, Japan, Mexico, Taiwan, UK							
Ebbert 2017⁸⁴	Pfizer	Parallel RCT	24	12	Minnesota, USA	Yes	No	93	56 (60)	87	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling	
Ehrsam 1991⁸⁵		Parallel RCT	52	9	Basel, Zurich, Switzerland	Yes	No	112			1. NRT Patch (24hrs) 2. Placebo	
Eisenberg 2013⁸⁶	Canadian Institutes of Health Research and the Heart and Stroke Foundation of Quebec	Parallel RCT	52	9	Canada, USA, Bangladesh, Iran, Pakistan, India, Tunisia	Yes	No	392	65 (17)		1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling	
Eisenberg 2016⁸⁷	Pfizer	Parallel RCT	24	12	USA and Canada	Yes	No	302	76 (25)		1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling	
Ellerbeck 2018⁸⁸	Award CER-1306-0901 from the Patient-Centered Outcomes Research Institute (PCORI), Clinical and Transitional Science Award UL1TR000001 from the NIH–National Center for Advancing Translational Science (NCATS)	Parallel RCT	52	52	Missouri, USA	Not necessarily motivated to quit	No	398	238 (60)	70	1. NRT Combo + Individual + Telephone Short Counselling 2. NRT Combo + Individual + Telephone Short Counselling	
Etter 2002⁸⁹	Swiss National Science Foundation and the Swiss Federal Office of Public Health	Parallel RCT	264	24	Geneva, Vaud, and Valais, Switzerland	No	No	923	477 (52)		1. NRT Choice Standard 2. Placebo 3. No Drug Treatment	
Etter 2009⁹⁰	Swiss National Science Foundation	Parallel RCT	52	12	Geneva, Vaud, Switzerland	Yes	No	314	132 (42)		1. NRT Gum High 2. NRT Gum High	
Evins 2001⁹¹	National Association for Research on	Parallel RCT	24	12	Massachusetts, USA	Yes	No	19	7 (39)	89	1. Bupropion Low + Group Long Counselling 2. Placebo + Group Long Counselling	

Schizophrenia and Affective Disorders (NARSAD), Glaxo Wellcome Inc. provided Bupropion HCl sustained release and identical placebo tablets

Evins 2005 ⁹²	NARSAD and NIDA	Parallel RCT	24	12	Massachusetts, USA	Yes	No	57	14 (27)		1. Bupropion Standard + Group Counselling 2. Placebo + Group Counselling
Evins 2007 ⁹³	Massachusetts Department of Mental Health	Parallel RCT	52	12	Massachusetts, USA	Yes	No	51			1. Bupropion Standard + NRT Combo High + Group Long Counselling 2. NRT Combo High + Group Long Counselling
Evins 2014 ⁹⁴	National Institute on Drug Abuse, Pfizer, Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Treatment Strategies for Smoking Cessation in Patients with Schizophrenia to the North Suffolk Mental Health Association	Open treatment (varenicline) followed by Parallel RCT	64	52	Massachusetts, Michigan, New Hampshire, Indiana, Alabama, Minnesota, USA	Yes	No	87	32 (37)	74	1. Varenicline Standard + Group Long Counselling 2. Placebo + Group Long Counselling
Fagerstrom 1982 ⁹⁵		Parallel RCT	24	4	Sweden	Yes	No	100	59 (59)		1. NRT Gum Standard + Individual Counselling 2. Placebo + Individual Counselling
Fagerstrom 1984 ⁹⁶		Parallel RCT	52	12	Sweden	Yes	No	145	81 (56)		1. NRT Gum 2. NRT Gum 3. No Drug Treatment 4. No Drug Treatment
Fagerstrom 2010 ⁹⁷	Pfizer	Parallel RCT	26	12	Norway and Sweden	Yes	Yes	432	46 (11)	100	1. Varenicline Standard 2. Placebo
Fee 1982 ⁹⁸	LEO Laboratories, Sweden	Parallel RCT	52	5	Tayside, Scotland, UK	Yes	No	352			1. NRT Gum Standard + Group Counselling 2. Placebo + Group Counselling

FernandezArias 2014 ⁹⁹	University Complutense of Madrid	Parallel RCT	52	10	Madrid, Spain	Yes	No	291	138 (47)		1. NRT Patch (16hrs) Standard + Group Long Counselling 2. No Drug Treatment + Group Long Counselling 3. NRT Patch (16hrs) Standard + Individual Short Counselling
Ferry 1992 ¹⁰⁰		Parallel RCT	24	12	USA	Yes	No	42	0 (0)		1. Bupropion Standard + Group Counselling 2. Placebo + Group Counselling
Ferry 1994 ¹⁰¹		Parallel RCT	52	12	California, USA	Yes	No	190			1. Bupropion Standard + Long Counselling 2. Placebo + Long Counselling
Fiore 1994A ¹⁰²	Elan Pharmaceutical Research Corporation	Parallel RCT	24	8	Wisconsin, USA	Yes	No	88	50 (57)		1. NRT Patch (24hrs) High + Group Long Counselling 2. Placebo + Group Long Counselling
Fiore 1994B ¹⁰²	Elan Pharmaceutical Research Corporation	Parallel RCT	24	6	Wisconsin, USA	Yes	No	112	76 (68)		1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Fiore 2004 ¹⁰³	National Cancer Institute and National Cancer Institute	Parallel RCT	52	8	Wisconsin, USA	Yes	No	1869	1091 (58)	66	1. NRT Patch (24hrs) 2. NRT Patch (24hrs) + Telephone Counselling 3. NRT Patch (24hrs) + Individual + Telephone Short Counselling
Fortmann 1995 ¹⁰⁴	National Heart, Lung, and Blood Institute	Parallel RCT	52		California, USA	Yes	No	1044	438 (42)	80	1. NRT Gum Standard 2. No Drug Treatment 3. NRT Gum Standard 4. No Drug Treatment
Fossati 2007 ¹⁰⁵	Mario Negri Institute, Milan, Italy, GlaxoSmithKline	Parallel RCT	52	7	Northern Italy, Italy	Yes	No	593	238 (40)		1. Bupropion Standard + Telephone Counselling 2. Placebo + Telephone Counselling
Fouz-Rosón 2017 ¹⁰⁶	Fundación Neumosur within the 'Asociación de Neumología y Cirugía Torácica del SUR', Grifols	Parallel RCT	52	8	Seville, Spain	Yes	No	485	196 (41)		1. Varenicline Standard + NRT Gum Standard + Individual + Telephone Long Counselling 2. Varenicline Low + NRT Gum Standard + Individual + Telephone Long Counselling
Gallagher 2007 ¹⁰⁷	Arizona Biomedical Research Commission	Parallel RCT	36	16	Arizona, USA	Not necessarily motivated to quit	No	180	86 (48)	76	1. No Drug Treatment 2. NRT Patch (24hrs) High 3. No Drug Treatment
Gariti 2009 ¹⁰⁸	National Institute on Drug Abuse	Parallel RCT	52	9	Pennsylvania, USA	Yes	No	260	148 (57)		1. Bupropion Standard + Individual Short Counselling 2. NRT Patch (24hrs) + Individual Short Counselling 3. Bupropion Standard + Individual Short Counselling 4. NRT Patch (24hrs) + Individual Short Counselling
Garvey 2000 ¹⁰⁹	National Institute on Drug Abuse, Department of Veterans Affairs	Parallel RCT	52	23	Massachusetts, USA	Yes	No	608	310 (51)	81	1. Placebo + Individual Short Counselling 2. NRT Gum Standard + Individual Short Counselling 3. NRT Gum High + Individual Short Counselling

George 2002¹¹⁰	National Institute on Drug Abuse, U.S. Department of Veterans Affairs, National Alliance for Research on Schizophrenia and Depression	Parallel RCT	34	9	Connecticut, USA	Yes	No	32	14 (44)	63	1. Bupropion Standard + Group Long Counselling 2. Placebo + Group Long Counselling
George 2008¹¹¹	National Institute on Drug Abuse (NIDA), National Alliance for Research in Schizophrenia and Depression (NARSAD)	Parallel RCT	28	9	Connecticut, USA	Yes	No	59	23 (40)	48	1. Bupropion Standard + NRT Patch (24hrs) High + Group Long Counselling 2. NRT Patch (24hrs) High + Group Long Counselling
Gifford 2004¹¹²	National Institutes of Health, National Cancer Institute, National Institutes of Health, National Institute on Drug Abuse and the Department of Veterans Affairs	Parallel RCT	52	7	Nevada, USA	Yes	No	76	45 (59)	77	1. No Drug Treatment + Individual + Group Long Counselling 2. NRT Patch (24hrs) High + Group Long Counselling
Gilbert 1989¹¹³	US National Institutes of Health	Parallel RCT	52	12	Canada	Yes	No	223			1. NRT Gum Standard + Individual Counselling 2. No Drug Treatment + Individual Counselling
Ginsberg 1992¹¹⁴	American Cancer Society and the National Institute on Drug Abuse	Parallel RCT	52	2	California, USA	Yes	No	99	53 (54)		1. NRT Gum Standard 2. NRT Gum Standard + Counselling 3. NRT Gum Standard + Counselling
Glavas 2003A¹¹⁵		Parallel RCT	260	3	Split-Dalmatia, Croatia	Yes	No	112	74 (66)		1. NRT Patch (24hrs) 2. Placebo
Glavas 2003B¹¹⁶		Parallel RCT	30	6	Croatia	Yes	No	160	86 (54)		1. NRT Patch (24hrs) 2. NRT Patch (24hrs)

GlaxoSmithKline 2009 ¹¹⁷	GlaxoSmithKline	Parallel RCT	24	12		Yes	No	723	23 (3)		3. Placebo 4. Placebo 1. NRT Lozenge Standard 2. Placebo 3. NRT Lozenge High 4. Placebo
Glover 2002 ¹¹⁸	Pharmacia & Upjohn	Parallel RCT	52	24	West Virginia, USA	Yes	No	241	130 (54)		1. NRT Sublingual Tablet + Individual Short Counselling 2. Placebo + Individual Short Counselling
Goldstein 1989 ¹¹⁹	American Cancer Society, National Heart, Lung, and Blood Institute	Parallel RCT	24	10	Rhode Island, USA	Yes	No	107	47 (44)		1. NRT Gum Standard + Group Long Counselling 2. NRT Gum Standard + Group Long Counselling 3. NRT Gum Standard + Group Long Counselling 4. NRT Gum Standard + Group Long Counselling
Gonzales 2001 ¹²⁰	GlaxoWellcome Inc, Research Triangle Park, NC	Parallel RCT	52	12	USA	Yes	No	450	231 (51)	93	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Gonzales 2006 ¹²¹	Pfizer	Parallel RCT	52	12	USA	Yes	No	1025	471 (46)	79	1. Varenicline Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. Placebo + Individual Short Counselling
Gonzales 2014 ¹²²	Pfizer	Parallel RCT	52	12	USA, Australia, Belgium, Canada, Czech Republic, France, Germany, UK	Yes	No	498	249 (50)	93	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Gorecka 2003 ¹²³		Parallel RCT	52	8	Poland		No	70	30 (43)		1. NRT Patch (16hrs) Standard + Counselling 2. Bupropion Standard + Counselling
Gourlay 1995 ¹²⁴	Ciba-Geigy Australia, the Anti Cancer Council of Victoria, and the Victorian Health Promotion Foundation	Open Label followed by Parallel RCT	26	12	Melbourne, Australia	Yes	No	629	362 (58)		1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Graham 2017 ¹²⁵	National Cancer Institute	Parallel RCT	36	4	USA	Yes	No	5290	3217 (61)	80	1. No Drug Treatment 2. No Drug Treatment 3. NRT Choice 4. NRT Choice
Grant 2007 ¹²⁶	National Institute on Alcohol Abuse and Alcoholism	Parallel RCT	24	9	Nebraska, USA	Yes	No	58	9 (16)	58	1. NRT Patch (24hrs) High + Group Long Counselling 2. Bupropion Standard + NRT Patch (24hrs) High + Group Long Counselling
Gross 1995 ¹²⁷	National Institute on Drug Abuse	Parallel RCT	24	12	USA	Yes	No	177	90 (51)		1. NRT Gum Standard + Group Counselling 2. NRT Gum Standard + Group Counselling 3. NRT Gum Standard + Group Counselling 4. No Drug Treatment + Group Counselling

Haas 2015¹²⁸	National Cancer Institute and National Institutes of Health [NIH], Aerosmith Endowment Fund for Prevention and Treatment of AIDS and HIV Infections, the Verizon Foundation, Thrive in 5/Boston Mayor's Office Ready Families Program, the Highland Street Foundation, and the Boston Foundation, Boston Children's Hospital and the Boston Public Health Commission.	Parallel RCT	36	6	Massachusetts, USA	Not necessarily motivated to quit	No	707	482 (68)	62	1. NRT Patch (24hrs) + Telephone Short Counselling 2. Usual Care
Haggström 2006¹²⁹		Parallel RCT	26	8.57	Porto Alegre, Brazil	Yes	No	156	67 (43)		1. Placebo + Individual + Telephone Short Counselling 2. Bupropion Standard + Individual + Telephone Short Counselling
Hajek 2019¹³⁰	National Institute for Health Research (NIHR) Health Technology Assessment Programme (project number, 12/167/135) and by a grant (A16893) from the Cancer Research UK Prevention Trials Unit	Parallel RCT	52	12	London, Leicester, and East Sussex, UK	Yes	No	886	424 (48)		1. Electronic Cigarette High + Individual Counselling 2. NRT Choice + Individual Counselling

Hall 1985 ¹³¹	National Institute on Drug Abuse	Parallel RCT	52	24	California, USA	Yes	No	120	56 (47)		1. NRT Gum Standard + Long Counselling 2. NRT Gum Standard + Group Counselling 3. No Drug Treatment + Long Counselling
Hall 1987 ¹³²	National Institute on Drug Abuse	Parallel RCT	52	52	California, USA	Yes	No	139	65 (47)	94	1. NRT Gum Standard + Long Counselling 2. NRT Gum Standard + Group Long Counselling 3. Placebo + Long Counselling 4. Placebo + Group Long Counselling
Hall 1996 ¹³³	National Institute on Drug Abuse and the Department of Veterans Affairs.	Parallel RCT	60	12	California, USA	Yes	No	207	108 (52)	92	1. NRT Gum Standard + Group Counselling 2. Placebo + Group Counselling
Hall 2002 ¹³⁴	National Institute on Drug Abuse and the National Cancer Institute, Bethesda	Parallel RCT	52	12	USA	Yes	No	220	64 (29)	81	1. Placebo + Individual Short Counselling 2. Placebo + Individual + Group Long Counselling 3. Bupropion Standard + Individual Short Counselling 4. Bupropion Standard + Individual + Group Long Counselling (Four out of six arms extracted)
Hall 2006 ¹³⁵	National Institute on Drug Abuse	Parallel RCT	76	10	California, USA	Not necessarily motivated to quit	No	322	224 (70)	68	1. No Drug Treatment 2. NRT Patch (24hrs) + Individual Long Counselling
Hall 2009 ¹³⁶	NIH/NIDA	Parallel RCT	104	52	California, USA	Yes	No	402	161 (40)	77	1. Bupropion Standard + NRT Gum + Group Counselling 2. Bupropion Standard + NRT Gum + Individual + Group Long Counselling 3. Bupropion Standard + NRT Gum + Individual + Group Long Counselling 4. Bupropion Standard + NRT Gum + Group Counselling
Hall 2011 ¹³⁷	National Institute on Drug Abuse	Open Label followed by Parallel RCT	104	52	California, USA	Yes	No	407	159 (39)	70	1. No Drug Treatment 2. Placebo 3. Bupropion Standard 4. Placebo + Individual Long Counselling 5. Bupropion Standard + Individual Long Counselling
Halpern 2018 ¹³⁸	Grant from the Vitality Institute to the University of Pennsylvania Center for Health Incentives and Behavioral Economics	Parallel RCT	52	24	Pennsylvania, USA	Yes	No	6006	3076 (51)		1. Usual Care 2. Mixed 3. Electronic Cigarette Low 4. Mixed 5. Mixed
Hand 2002 ¹³⁹	Author's endowment fund	Parallel RCT	52	3	Cardiff, Wales, UK	Yes	No	245	133 (54)		1. No Drug Treatment + Individual Long Counselling 2. NRT Combo High + Individual Long Counselling
Hanioka 2010 ¹⁴⁰	Fukuoka Dental College Grant and the Japanese	Parallel RCT	52	6	Hiroshima, Nagasaki, Japan	Yes	No	56	16 (29)		1. NRT Patch (24hrs) High + Individual Short Counselling 2. No Drug Treatment

Harackiewicz 1988 ¹⁴¹	Ministry of Health, Labor and Welfare Merrell Dow Pharmaceuticals, Inc., Cincinnati, OH.	Parallel RCT	52	24	New York, USA	Yes	No	197	124 (63)		1. NRT Gum Standard 2. No Drug Treatment 3. No Drug Treatment
Hatsukami 1996 ¹⁴²	NIH	Parallel RCT	52	12	Minnesota, USA	Yes	Yes	215	0 (0)		1. NRT Gum Standard + Group Long Counselling 2. Placebo + Group Long Counselling 3. NRT Gum Standard + Individual Short Counselling 4. Placebo + Individual Short Counselling
Hatsukami 2000 ¹⁴³	National Institutes of Health	Parallel RCT	62	10	Minnesota, USA	Yes	Yes	402	4 (1)	96	1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Hatsukami 2004 ¹⁴⁴	GlaxoSmithKline, Research Triangle Park, North Carolina	Parallel RCT	52	26	USA	Yes	No	609	267 (44)	86	1. Bupropion Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Hays 1999 ¹⁴⁵	Elan Pharmaceuticals Research Corp, Gainesville, Ga.	Parallel RCT	24	6	Illinois, California, Minnesota, USA	Yes	No	958	478 (50)	83	1. Placebo 2. NRT Patch (24hrs) High 3. NRT Patch (24hrs) High
Hays 2001 ¹⁴⁶	Glaxo Wellcome, Inc., Research Triangle Park, North Carolina	Open Label followed by Parallel RCT	104	52	Minnesota, California, Rhode Island, Oregon, Massachusetts, USA	Yes	No	429	219 (51)	97	1. Placebo + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling
Hays 2009 ¹⁴⁷	National Institute on Alcohol Abuse and Alcoholism	Open Label followed by Parallel RCT	76	52	USA	Yes	No	110	24 (22)		1. Placebo + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling
Herrera 1995 ¹⁴⁸		Parallel RCT	104		Caracas, Venezuela	Yes	No	322	138 (43)		1. NRT Gum Standard + Individual + Group Long Counselling 2. NRT Gum High + Individual + Group Long Counselling 3. Placebo + Individual + Group Long Counselling 4. NRT Gum Standard + Individual + Group Long Counselling
Hertzberg 2001 ¹⁴⁹	Glaxo Wellcome, Inc., and the National Cancer Institute	Parallel RCT	24	12	North Carolina, USA	Yes	No	15	0 (0)	60	1. Bupropion Standard + Individual Counselling 2. Placebo + Individual Counselling
Heydari 2012 ¹⁵⁰	Masih Daneshvari Hospital Research Institute, Tehran	Parallel RCT	52	8	Tehran, Iran	Yes	No	272	112 (41)		1. No Drug Treatment + Individual Short Counselling 2. NRT Patch (16hrs) Standard + Individual Short Counselling 3. Varenicline Standard + Individual Short Counselling

Heydari 2013 ¹⁵¹		Parallel RCT	24	6	Tehran, Iran	Yes	No	424			1. NRT Combo High + Individual Counselling 2. No Drug Treatment + Individual Counselling
Hilberink 2011 ¹⁵²		Cluster RCT	52		Nijmegen and Maastricht, The Netherlands	Yes	No	697	356 (51)		1. Usual Care 2. NRT Choice + Individual + Telephone Counselling 3. Bupropion + NRT Choice + Individual + Telephone Counselling
Hilleman 1994 ¹⁵³		Parallel RCT	24	12	Nebraska, USA	Yes	No	208	114 (55)		1. NRT Patch (24hrs) High + Individual Long Counselling 2. NRT Patch (24hrs) High + Individual Long Counselling
Hjalmarson 1984 ¹⁵⁴		Parallel RCT	104	104	Göteborg, Sweden	Yes	No	206	116 (56)		1. NRT Gum Standard + Group Counselling 2. Placebo + Group Counselling
Hjalmarson 1994 ¹⁵⁵	Kabi Pharmacia AB, Helsingborg, Sweden	Parallel RCT	52	52	Göteborg, Sweden	Yes	No	248	142 (57)		1. NRT Nasal Spray Standard + Group Long Counselling 2. Placebo + Group Long Counselling
Hjalmarson 1997 ¹⁵⁶	Pharmacia & Upjohn, Helsingborg, Sweden	Parallel RCT	52	24	Göteborg, Sweden	Yes	No	247	158 (64)		1. NRT Inhalator Standard + Group Long Counselling 2. Placebo + Group Long Counselling
Hollis 2007 ¹⁵⁷	National Cancer Institute	Parallel RCT	52	8	Oregon, USA	Yes	No	4614	2768 (60)	90	1. No Drug Treatment + Telephone Short Counselling 2. No Drug Treatment + Telephone Long Counselling 3. No Drug Treatment + Telephone Long Counselling 4. NRT Patch (24hrs) + Telephone Short Counselling 5. NRT Patch (24hrs) + Telephone Long Counselling 6. NRT Patch (24hrs) + Telephone Long Counselling
Holt 2005 ¹⁵⁸	GlaxoSmithKline	Parallel RCT	52	7.4	Wellington and Kapiti, New Zealand	Yes	No	134	96 (72)	0	1. Bupropion Standard + Individual + Telephone Counselling 2. Placebo + Individual + Telephone Counselling
Horst 2005 ¹⁵⁹	The American Legacy Foundation and the Via Christi Foundation	Open Label followed by Parallel RCT	36	36	Kansas, USA	Yes	No	50			1. NRT Patch (24hrs) High + Group Long Counselling 2. Placebo + Group Long Counselling
Howard-Pitney 1999 ¹⁶⁰	National Cancer Institute	Parallel RCT	24	6	California, USA	Yes	Yes	410	4 (1)	95	1. NRT Patch (16hrs) Standard + Telephone Counselling 2. Placebo + Telephone Counselling
Huber 1988 ¹⁶¹		Parallel RCT with Waitlist arm	52		Munich, Germany	Yes	No	225			1. NRT Gum 2. No Drug Treatment + Group Counselling 3. NRT Gum + Group Counselling 4. Waitlist
Hughes 1989 ¹⁶²	National Institute on Drug Abuse, Washington, DC.	Parallel RCT	52	52	Minnesota, USA	Yes	No	315	176 (56)		1. NRT Gum Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Hughes 1990 ¹⁶³	National Institute on Drug Abuse	Parallel RCT	36	36	Minnesota, USA	Yes	No	78	42 (54)		1. Placebo + Individual Short Counselling 2. NRT Gum Low + Individual Short Counselling 3. NRT Gum Standard + Individual Short Counselling 4. NRT Gum High + Individual Short Counselling
Hughes 1999 ¹⁶⁴	ALZA and Hoechst Marion Rouse, the	Parallel RCT	52	16	USA and Australia	Yes	No	1039	520 (50)	96	1. Placebo + Individual + Group Long Counselling 2. NRT Patch (24hrs) High + Individual + Group Long Counselling

	National Institute on Drug Abuse										3. NRT Patch (24hrs) High + Individual + Group Long Counselling 4. NRT Patch (24hrs) High + Individual + Group Long Counselling
Hughes 2003 ¹⁶⁵	National Institute on Drug Abuse	Parallel RCT	24	12	Vermont and Minnesota, USA	Yes	No	115	37 (32)	93	1. NRT Patch (24hrs) High + Individual + Group Long Counselling 2. Placebo + Individual + Group Long Counselling
Hughes 2010 ¹⁶⁶	US National Institute on Drug Abuse	Parallel RCT	29	15	South Carolina and New Mexico, USA	Yes	No	750	405 (54)	82	1. NRT Lozenge + Telephone Short Counselling 2. NRT Lozenge + Telephone Short Counselling 3. NRT Lozenge + Telephone Short Counselling
Hughes 2011 ¹⁶⁷	Pfizer Inc., University of Nebraska Medical Center	Parallel RCT	24	8	Vermont, Nebraska, USA	No	No	220	90 (41)	91	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Hurt 1990 ¹⁶⁸	Elan Pharmaceuticals Research Corporation, Gainesville, Georgia, and Athlone, Ireland	Parallel RCT	56	18	Minnesota, USA	Yes	No	70	37 (53)		1. NRT Patch (24hrs) High 2. NRT Patch (24hrs) High
Hurt 1994 ¹⁶⁹	Study was supported by Lederle Laboratories, NY.	Parallel RCT	52	8	Minnesota, Florida, Arizona, USA	Yes	No	240	127 (53)	100	1. NRT Patch (24hrs) High + Individual + Telephone Counselling 2. Placebo + Individual + Telephone Counselling
Hurt 1997 ¹⁷⁰	Glaxo Wellcome	Parallel RCT	52	7	Minnesota, California, West Virginia, USA	Yes	No	615	336 (55)	96	1. Placebo + Individual Short Counselling 2. Bupropion Low + Individual Short Counselling 3. Bupropion Low + Individual Short Counselling 4. Bupropion Standard + Individual Short Counselling
Hurt 2003 ¹⁷¹	National Cancer Institute	Open Label followed by Parallel RCT	60	32	USA	Yes	No	370	211 (57)	87	1. Bupropion Standard 2. Placebo 3. Bupropion Standard 4. Placebo
Hurt 2018 ¹⁷²	National Institutes of Health, Pfizer	Parallel RCT	24	12	Minnesota, USA	Yes	No	33	12 (36)	91	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
ICRF 1994 ¹⁷³	Ciba Pharmaceuticals	Parallel RCT	52	12	Oxfordshire, UK	Not necessarily motivated to quit	No	1686	929 (55)		1. NRT Patch (24hrs) High 2. Placebo
Ikonomidis 2017 ¹⁷⁴	Hellenic Cardiac Society	Parallel RCT	52	12	Athens, Greece	Yes		188	86 (45)		1. Varenicline Standard 2. NRT Combo Standard
Jamrozik 1984 ¹⁷⁵	Oxford District Research Committee and Nuffield Dominions Trust	Parallel RCT	24	24	Oxfordshire, UK	Yes	No	200			1. NRT Gum Standard 2. Placebo

Jarvis 1982 ¹⁷⁶	Medical Research Council and Department of Health and Social Security	Parallel RCT	52	52	London, UK	Yes	No	116	64 (55)		1. NRT Gum Standard + Group Long Counselling 2. Placebo + Group Long Counselling
Jensen 1991 ¹⁷⁷		Parallel RCT	52	26	Aarhus, Denmark	Yes	No	496		100	1. NRT Gum Standard + Group Counselling 2. Placebo + Group Counselling
Johns 2016 ¹⁷⁸	DM wayanad institute of Medical Science	Parallel RCT	52	6	Kalpetta, India			300			1. Usual Care 2. No Drug Treatment + Individual Short Counselling 3. NRT + Individual Short Counselling
Johns 2017 ¹⁷⁹		Parallel RCT	52	6	Meppady, India	Yes	No	300			1. Usual Care 2. No Drug Treatment + Counselling 3. NRT Choice + Counselling
Johns 2017 ¹⁸⁰		Parallel RCT	52	6	Trikakara-kochi, India			300			1. No Drug Treatment + Counselling 2. Varenicline Standard + Counselling 3. Varenicline Standard + Counselling
Jorenby 1995 ¹⁸¹	Elan Pharmaceutica l Research Corporation	Parallel RCT	26	8	Wisconsin and Minnesota, USA	Yes	No	504	267 (53)	98	1. NRT Patch (24hrs) High + Individual Short, Group Long, or No Counselling 2. NRT Patch (24hrs) High + Individual Short, Group Long, or No Counselling (Six arms collapsed into two arms across treatments)
Jorenby 1999 ¹⁸²	Glaxo Wellcome	Parallel RCT	52	9	Arizona, California, Nebraska, Wisconsin, USA	Yes	No	893	464 (52)	93	1. Placebo + Individual + Telephone Short Counselling 2. NRT Patch (24hrs) High + Individual + Telephone Short Counselling 3. Bupropion Standard + Individual + Telephone Short Counselling 4. Bupropion Standard + NRT Patch (24hrs) High + Individual + Telephone Short Counselling
Jorenby 2006 ¹⁸³	Pfizer Inc	Parallel RCT	52	12	USA	Yes	No	1027	433 (42)	84	1. Varenicline Standard + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. Placebo + Individual Short Counselling
Joseph 1996 ¹⁸⁴	Hoechst Marion Roussel	Parallel RCT	52	10	Minnesota, Missouri, California, Colorado, North Carolina, Washington, Oregon, Nevada, USA	Yes	No	584	8 (1)		1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Joseph 2004 ¹⁸⁵	National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the Veterans Affairs (VA) Health Services Research and Development	Wait-list RCT	76	52	Minnesota, USA	Yes	No	499	157 (32)	76	1. NRT Choice High + Individual + Telephone Long Counselling 2. Waitlist

	Center for Chronic Disease Outcomes Research											
Joseph 2011 ¹⁸⁶	National Cancer Institute/National Institute on Drug Abuse	Parallel RCT	76	52	Minnesota, USA	Yes	No	443	267 (60)	95	1. NRT Choice + Telephone Long Counselling 2. NRT Choice + Telephone Long Counselling	
Joyce 2008 ¹⁸⁷	Centers for Medicare and Medicaid Services (CMS)	Cluster RCT	52	24	Alabama, Florida, Ohio, Oklahoma, Missouri, Nebraska, and Wyoming, USA	Yes	No	7354	2811 (38)	92	1. Usual Care 2. No Drug Treatment + Individual Short Counselling 3. NRT Patch (24hrs) High + Telephone Counselling	
Kalman 2006 ¹⁸⁸	National Institute on Drug Abuse	Parallel RCT	36	12	Massachusetts, USA	Yes	No	130	21 (16)	85	1. NRT Patch (24hrs) High + Group Long Counselling 2. NRT Patch (24hrs) High + Group Long Counselling	
Kalman 2011 ¹⁸⁹	National Institute of Drug Abuse, National Institute on Alcohol Abuse and Aolcoholism	Parallel RCT	24	8	Massachusetts, USA	Yes	No	143	24 (17)	70	1. NRT Patch (24hrs) High + Individual Counselling 2. Bupropion Standard + NRT Patch (24hrs) High + Individual Counselling	
Killen 1984 ¹⁹⁰	NIH, Merrell-Dow Pharmaceuticals Inc	Parallel RCT	42	7	California, USA	Yes	No	75	46 (61)		1. NRT Gum Standard 2. No Drug Treatment (Three arms collapsed into two)	
Killen 1990 ¹⁹¹	National Cancer Institute	Parallel RCT	52	8	California, USA	Yes	No	1218	630 (52)	86	1. NRT Gum Standard 2. NRT Gum Standard 3. Placebo 4. No Drug Treatment	
Killen 1997 ¹⁹²	National Heart, Lung, and Blood Institute	Parallel RCT	52	16	California, USA	Yes	No	424	210 (50)	82	1. Placebo 2. NRT Patch (24hrs) High 3. Placebo + Group Short Counselling 4. NRT Patch (24hrs) High + Group Short Counselling	
Killen 1999 ¹⁹³	National Cancer Institute	Parallel RCT	52	6	California, USA	Yes	No	408	169 (41)	83	1. NRT Patch (16hrs) Standard 2. NRT Patch (16hrs) High	
Killen 2006 ¹⁹⁴	National Cancer Institute	Open Label followed by Parallel RCT	52	25	California, USA	Yes	No	362	167 (46)	86	1. Bupropion Low + Individual Long Counselling 2. Placebo + Individual Long Counselling	
Klesges 2015 ¹⁹⁵	National Institutes of Health	Parallel RCT	52	8	Texas, USA	Yes	No	1298	562 (43)	77	1. NRT Choice + Telephone Long Counselling 2. NRT Choice + Telephone Long Counselling	
Koegelenberg 2014 ¹⁹⁶	Pfizer, New York, New York, and	Parallel RCT	24	14	Cape Town, Johannesburg, and	Yes	No	446			1. Varenicline Standard + NRT Patch (16hrs) Standard + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling	

	McNeil, Helsingborg, Sweden				Durban, South Africa							
Kornitzer 1987¹⁹⁷		Parallel RCT	52	12	Brussels, Belgium	Yes	No	199	0 (0)		1. NRT Gum High + Individual Short Counselling 2. NRT Gum Standard + Individual Short Counselling	
Kornitzer 1995¹⁹⁸	Pharmacia Consumer Pharma	Parallel RCT	52	24	Brussels, Belgium	Yes	No	374	146 (39)		1. NRT Combo Standard 2. NRT Patch (16hrs) Standard 3. Placebo	
Kralikova 2002¹⁹⁹	McNeil AB, Helsingborg, Sweden, Pharmacia CHC, Helsingborg, Sweden	Parallel RCT	52	36	Prague and Kutna Hora, Czech Republic	Not necessarily motivated to quit	No	314	183 (58)		1. NRT Choice + Individual Short Counselling 2. Placebo + Individual Short Counselling	
Krupski 2016²⁰⁰	New York State Smokers' Quitline (NYS Department of Health) and the Roswell Park Cancer Institute Cancer Center	Parallel RCT	28	2	New York, USA	Yes	No	3118	1467 (47)	71	1. NRT Combo + Telephone Counselling 2. NRT Patch (24hrs) + Telephone Counselling	
Lee 2013²⁰¹	University of Western Ontario Department of Anesthesia and Perioperative Medicine	Parallel RCT	52	6	Ontario, Canada	Yes	No	168	92 (55)		1. Usual Care 2. NRT Patch (24hrs) + Individual Short Counselling	
Lee 2018²⁰²	Internal UCSF Department of Anesthesia and Perioperative Care funds (San Francisco, California, United States of America) and the UCSF Resource Allocation Program grant, administered by the Helen Diller Family Comprehensiv e Cancer Center developmental funds from the	Parallel RCT	24	6	California, USA	Yes	No	30	3 (10)	53	1. NRT Patch (24hrs) + Individual Short Counselling 2. Electronic Cigarette Low + Individual Short Counselling	

	National Cancer Institute Cancer Center Support Grant (P30 CA 82103-16)											
Leischow 1996²⁰³	Pharmacia Upjohn, Helsingborg, Sweden	Parallel RCT	52	24	Arizona, USA	Yes	No	222	122 (55)		1. NRT Inhalator Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling	
Leischow 1999²⁰⁴	DHHS Gand Arizona Disease Control Commission	Parallel RCT	52	26	Arizona, USA	Yes	No	300	136 (45)	89	1. NRT Patch (16hrs) Standard 2. NRT Patch (16hrs) Standard + Individual Short Counselling	
Leischow 2004²⁰⁵	DHHS	Parallel RCT	52	12	Arizona, USA	Yes	No	520	261 (51)	90	1. NRT Inhalator Standard 2. NRT Inhalator Standard + Individual Short Counselling	
Lerman 2004²⁰⁶	National Cancer Institute and the National Institute on Drug Abuse and National Institutes of Health, Abramson Cancer Center and Annenberg Public Policy Center, University of California, San Francisco, Comprehensive Cancer Center. Nicotine nasal spray (Nicotrol) was provided by Pharmacia and Upjohn, Helsingborg, Sweden.	Parallel RCT	27	8	Washington, DC and Philadelphia, Pennsylvania, USA	Yes	No	350	213 (54)	64	1. NRT Patch (24hrs) High + Group Long Counselling 2. NRT Nasal Spray Standard + Group Long Counselling	
Lerman 2015²⁰⁷	National Institutes of Health, Canadian Institutes of Health Research,	Parallel RCT	52	12	Pennsylvania, New York, Texas, USA and Toronto, Canada	Yes	No	1246	543 (44)	55	1. Placebo + Group + Telephone Long Counselling 2. Placebo + Group + Telephone Long Counselling 3. NRT Patch (24hrs) High + Group + Telephone Long Counselling 4. NRT Patch (24hrs) High + Group + Telephone Long Counselling	

	Abramson Cancer Center, Centre for Addiction and Mental Health Foundation, and Pennsylvania Department of Health										5. Varenicline Standard + Group + Telephone Long Counselling 6. Varenicline Standard + Group + Telephone Long Counselling
Levine 2010 ²⁰⁸	National Institute on Drug Abuse	Parallel RCT	52	26	Pennsylvania , USA	Yes	No	349	349 (100)	86	1. Bupropion Standard + Group Long Counselling 2. Placebo + Group Long Counselling 3. Bupropion Standard + Group Long Counselling 4. Placebo + Group Long Counselling
Lewis 1998 ²⁰⁹	Elan Pharmaceutica l Research Corporation, Gainsville, Georgia, and Athlone, Ireland	Parallel RCT	24	6	Wisconsin, USA	Yes	No	185	85 (46)		1. Usual Care 2. Placebo + Telephone Short Counselling 3. NRT Patch (24hrs) High + Telephone Short Counselling
Littlewood 2017 ²¹⁰	NIDA 1R01DA02507 4-01A2	Parallel RCT	36	12	New Mexico, USA	Yes	No	205	70 (34)	70	1. Varenicline Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Llivina 1988 ²¹¹	El Fondo de Investigacione s Sanitarias de la Seguridad Social, la Sociedad Española de Patologia Respiratoria, and los Laboratorios PENSA-ESTEVE	Parallel RCT	52	4	Barcelona, Spain	Yes	No	216	71 (33)		1. NRT Gum + Group Counselling 2. Placebo + Group Counselling
Lloyd- Richardson 2009 ²¹²	National Institute of Drug Abuse, the National Heart, Lung and Blood Institute, the National Cancer Institute, NIH and the Robert Wood Johnson Foundation	Parallel RCT	24	8	New England, USA	Not necessarily motivated to quit	No	444	163 (37)	52	1. NRT Patch (24hrs) + Individual + Telephone Long Counselling 2. NRT Patch (24hrs) + Individual Short Counselling
Malcolm 1980 ²¹³	A B Leo & Company, Helsingborg, Sweden	Parallel RCT	24	12	London, UK	Yes	No	210	88 (42)		1. NRT Gum Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling 3. No Drug Treatment + Individual Short Counselling

Martin 1997²¹⁴	California Tobacco-Related Disease Research Program	Parallel RCT	52	24	California, USA	Yes	No	205	92 (45)	93	1. No Drug Treatment + Group Long Counselling 2. NRT Gum Standard + Group Long Counselling
McAfee 2008²¹⁵	Oregon Department of Human Services	Parallel RCT	24	8	Oregon, USA	Yes	No	1154	758 (66)	87	1. NRT Patch (24hrs) + Telephone Counselling 2. NRT Patch (24hrs) + Telephone Counselling
McCarthy 2008²¹⁶	National Cancer Institute and the National Institute on Drug Abuse	Parallel RCT	52	9	Wisconsin, USA	Yes	No	463	233 (50)	90	1. Placebo + Counselling 2. Bupropion Standard + Counselling (Four arms collapsed into two based on drug treatment)
McGovern 1992²¹⁷	Merrell-Dow Pharmaceuticals	Cluster RCT	52	12	Iowa, USA	Yes	No	273	146 (53)		1. NRT Gum Standard + Group Long Counselling 2. No Drug Treatment + Group Long Counselling
Mercie 2018²¹⁸	The French National Institute for Health and Medical Research (INSERM)– French National Agency for Research on AIDS and Viral Hepatitis (ANRS) and Pfizer	Parallel RCT	48	24	Saint-Etienne, Bordeaux, Paris, Le Kremlin Bicetre, Bondy, Bobigny, Suresnes, Fort de France (Martinique), Montpellier, Nice, St Brieuc, Strasbourg, Caen, Clermont Ferrand, Tourcoing, Vandoeuvre les Nancy, Créteil, Nîmes, France	Yes	No	248	43 (17)		1. Varenicline Standard + Individual Counselling 2. Placebo + Individual Counselling
Molyneux 2003²¹⁹	Pharmacia Consumer Healthcare, Helsingborg, Sweden and the Health	Parallel RCT	52	6	Nottingham, UK	Yes	No	274	111 (41)	96	1. Usual Care 2. No Drug Treatment + Individual Short Counselling 3. NRT Choice + Individual Short Counselling

	Education Authority, UK										
Mori 1992²²⁰		Parallel RCT	24	12	Tokyo, Japan	No	No	364			1. NRT Gum Standard 2. Placebo
Myles 2004²²¹	The Alfred Hospital Research Trust, GlaxoWellcome, Australia, Australian National Health and Medical Research Council	Parallel RCT	24	7	Australia	Yes	No	47	16 (34)		1. Bupropion Standard 2. Placebo
Myung 2007²²²		Parallel RCT	52	6	Goyang, South Korea	Yes	No	118			1. NRT Patch (24hrs) High + Individual Short Counselling 2. Placebo + Individual Short Counselling
Nahvi 2014²²³	National Center for Research Resources, and the National Institute on Drug Abuse	Parallel RCT	24	12	New York, USA	Yes	No	112	59 (53)	9	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Nakamura 1990²²⁴	Merrell-Dow Pharmaceuticals	Parallel RCT	24	8	Japan	Yes	No	60			1. NRT Gum Standard 2. No Drug Treatment + Counselling
Nakamura 2007²²⁵	Pfizer Inc.	Parallel RCT	52	12	Japan	Yes	No	619	155 (25)		1. Varenicline Low + Individual Short Counselling 2. Varenicline Low + Individual Short Counselling 3. Varenicline Standard + Individual Short Counselling 4. Placebo + Individual Short Counselling
NCT00365508²⁶	Fox Chase Cancer Center, National Cancer Institute (NCI)	Parallel RCT	24	12	Washington DC, Florida, Georgia, New Jersey, New York, Pennsylvania, Tennessee, USA	Yes	No	651	365 (56)		1. NRT Patch (24hrs) High + Counselling 2. NRT Lozenge + Counselling
NCT00828113²⁷	Pfizer	Parallel RCT	78	52	Wisconsin, USA		No	101	43 (43)		1. Varenicline Standard + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling
Nebot 1992²²⁸	Fondo de Investigaciones Sanitarias de la Seguridad Social	Parallel RCT	52	4	Barcelona, Catalonia, Spain	Yes	No	425			1. No Drug Treatment 2. NRT Gum 3. No Drug Treatment + Individual Short Counselling
Niaura 1994²²⁹	National Cancer Institute and National Heart, Lung,	Parallel RCT	52	16	Rhode Island, USA	Yes	No	173	86 (50)		1. No Drug Treatment + Individual Short Counselling 2. No Drug Treatment + Individual Short Counselling 3. NRT Gum Standard + Individual Short Counselling 4. NRT Gum Standard + Individual Short Counselling

	and Blood Institute											
Niaura 1999²³⁰	National Heart, Lung, and Blood Institute and the Medical Research Service of the Department of Veterans Affairs	Parallel RCT	52	11	Rhode Island, USA	Yes	No	129	65 (50)		1. No Drug Treatment + Individual Short Counselling 2. NRT Gum Standard + Individual Long Counselling 3. No Drug Treatment + Individual Long Counselling 4. NRT Gum Standard + Individual Long Counselling	
Niaura 2008²³¹	Pfizer, Inc.	Parallel RCT	52	12	USA	Yes	No	320	154 (48)	91	1. Varenicline + Individual Short Counselling 2. Placebo + Individual Short Counselling	
Nides 2006²³²	Pfizer	Parallel RCT	52	7	USA	Yes	No	638	332 (52)	87	1. Varenicline Low + Individual Short Counselling 2. Varenicline Low + Individual Short Counselling 3. Varenicline Standard + Individual Short Counselling 4. Bupropion Standard + Individual Short Counselling 5. Placebo + Individual Short Counselling	
Nides 2018²³³	GlaxoSmithKline/McNeil AB	Parallel RCT	26	12	USA	Yes	No	1198	651 (54)	60	1. NRT Mouth Spray Standard 2. Placebo	
Ockene 1991²³⁴	National Cancer Institute	Parallel RCT	52		Massachusetts, USA	Not necessarily motivated to quit	No	1286	733 (57)	92	1. No Drug Treatment 2. No Drug Treatment + Individual Short Counselling 3. NRT Gum Standard + Individual Short Counselling	
Okuyemi 2007²³⁵		Cluster RCT	24	8	Kansas and Missouri, USA	Yes	No	173	121 (70)	10	1. NRT Gum High + Individual + Telephone Counselling 2. No Drug Treatment	
Oncken 2006²³⁶	Pfizer Inc	Parallel RCT	52	12	USA	Yes	No	518	262 (51)	80	1. Varenicline Low + Individual Short Counselling 2. Varenicline Low + Individual Short Counselling 3. Varenicline Standard + Individual Short Counselling 4. Varenicline Standard + Individual Short Counselling 5. Placebo + Individual Short Counselling	
Oncken 2007²³⁷	The Patrick and Catherine Weldon Donaghue Foundation, The University of Connecticut Center on Aging, University of Connecticut General Clinical Research Center and the National Institute for Health	Parallel RCT	68	16	Connecticut, USA	Yes	No	152	152 (100)	89	1. NRT Patch (24hrs) High + Group Long Counselling 2. Placebo + Group Long Counselling	
Ortega 2011²³⁸		Parallel RCT	52	12	Seville, Spain	Yes	No	2560	307 (12)		1. No Drug Treatment + Individual + Telephone Long Counselling 2. NRT Choice + Individual + Telephone Long Counselling	

Pack 2008 ²³⁹	This research was supported by the National Cancer Institute Grant P50CA084724 and the National Institute on Drug Abuse Grant # P50DA19706	Parallel RCT	52	8	Wisconsin, USA	Yes	No	408	229 (56)	71	1. NRT Lozenge + Telephone or No Counselling 2. NRT Gum + Telephone or No Counselling (Four arms collapsed to two across drugs)
Page 1986 ²⁴⁰	Canadian College of Family Physicians of Canada and from the University of Waterloo	Parallel RCT	24		Ontario, Canada	Yes	No	289	196 (68)		1. No Drug Treatment 2. No Drug Treatment 3. NRT Gum Standard
Paoletti 1996 ²⁴¹	Pharmacia	Parallel RCT	52	18	Pisa, Tuscany, Italy	Yes	No	297	119 (40)		1. Placebo 2. NRT Patch (16hrs) Standard 3. NRT Patch (16hrs) Standard 4. NRT Patch (16hrs) High
Perng 1998 ²⁴²	Orient Europharma Company Limited, Taipei, Taiwan	Parallel RCT	52	6	Taiwan	Yes	No	62	4 (6)	0	1. NRT Patch (24hrs) High 2. Placebo
Piper 2007 ²⁴³	National Institutes of Health	Parallel RCT	52	9	USA	Yes	No	608	352 (58)	76	1. Bupropion Standard + NRT Gum High + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. Placebo + Individual Short Counselling
Piper 2009 ²⁴⁴	University of Wisconsin–Madison, the National Institute on Drug Abuse and the General Clinical Research Centers Program of the National Center for Research Resources	Parallel RCT	26	12	Wisconsin, USA	Yes	No	1504	876 (58)	84	1. Placebo + Individual Short Counselling 2. Bupropion Standard + Individual Short Counselling 3. NRT Lozenge + Individual Short Counselling 4. NRT Patch (24hrs) High + Individual Short Counselling 5. Bupropion Standard + NRT Lozenge + Individual Short Counselling 6. NRT Combo High + Individual Short Counselling
Piper 2018 ²⁴⁵	National Cancer Institute [grant P01CA180945]	Parallel RCT	55	29	Wisconsin, USA	Yes	No	623	357 (57)	69	1. NRT Patch (24hrs) + Individual Short Counselling 2. NRT Combo + Individual + Telephone Short Counselling

	, National Institute on Alcohol Abuse and Alcoholism [grant R01AA022931] , National Institute on Drug Abuse [grants R01DA040480 and P50DA039838] , and National Institute of Diabetes and Digestive and Kidney Disease [grant R01DK097364]									
Pirie 1992²⁴⁶	National Cancer Institute	Parallel RCT	52	20	Minneapolis, USA	Yes	No	417		1. No Drug Treatment 2. NRT Gum Standard 3. No Drug Treatment 4. NRT Gum Standard
Planer 2011²⁴⁷	GlaxoSmithKline	Parallel RCT	52	8	Jerusalem, Israel	Yes	No	151	30 (20)	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Prapavessis 2007²⁴⁸	National Heart Foundation of New Zealand	Parallel RCT	52	10	New Zealand	Yes	No	142		1. No Drug Treatment + Group Long Counselling 2. NRT Patch (24hrs) High + Group Long Counselling 3. NRT Patch (24hrs) High
Puska 1979²⁴⁹		Parallel RCT	24	3	North Karelia (Eastern Finland), Finland	Yes	No	229	39 (17)	1. NRT Gum High + Group Long Counselling 2. Placebo + Group Long Counselling
Puska 1995²⁵⁰		Parallel RCT	52	26	North Karelia (Eastern Finland), Finland	Yes	No	300	137 (46)	1. NRT Combo Standard 2. NRT Gum Standard
QuilezGarcia 1989²⁵¹		Parallel RCT	52	16	Alicante, Spain	Yes	No	106	43 (41)	1. NRT Gum Standard + Group Counselling 2. Placebo + Group Counselling 3. NRT Gum Standard + Individual Counselling
Ramon 2014²⁵²	Pfizer	Parallel RCT	24	12	Barcelona, Spain	Yes	No	341	144 (42)	1. Varenicline Standard + NRT Patch (24hrs) High + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling
Ratner 2004²⁵³	National Cancer Institute of Canada, Canadian Cancer Society, Canadian Institutes of	Parallel RCT	62	16	British Columbia, Canada	Yes	No	237	123 (52)	1. Usual Care 2. NRT Gum + Individual + Telephone Short Counselling

	Health Research, Social Sciences and Humanities Research Council of Canada and the Michael Smith Foundation for Health Research									
Reid 2003 ²⁵⁴		Parallel RCT	52	8	Ontario, Canada	Yes	No	254	49 (19)	1. No Drug Treatment + Individual Short Counselling 2. NRT Patch (16hrs) Low + Individual Short Counselling
Reid 2008 ²⁵⁵	National Institute on Drug Abuse (NIDA)	Parallel RCT	26	8	New York, Florida, Michigan, North Carolina, South Carolina, California, USA	Yes	No	225	109 (48)	39 1. NRT Patch (24hrs) High + Group Counselling 2. Waitlist
Rennard 2006 ²⁵⁶		Parallel RCT	64	52	Arizona, West Virginia, Nebraska, USA	No	No	429	237 (55)	1. NRT Inhalator Standard 2. Placebo
Rennard 2012 ²⁵⁷	Pfizer Inc.	Parallel RCT	24	12	Argentina, Brazil, Canada, China, Czech Republic, France, Germany, Hungary, Italy, Mexico, Republic of Korea, Taiwan, UK, USA	Yes	No	659	264 (40)	68 1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Richmond 1993 ²⁵⁸	Department of Health, Housing and Community Services, Community Health Anti-Tuberculosis Association, Glaxo Australia, and the Drug and	Parallel RCT	52	12	Sydney, Australia	Yes	No	450	270 (60)	1. NRT Gum + Individual Short Counselling 2. No Drug Treatment + Individual Short Counselling 3. NRT Gum

	Alcohol Directorate, NSW Department of Health											
Richmond 1994²⁵⁹	Marion Merrell Dow	Parallel RCT	520	10	Sydney, Australia	Yes	No	315	164 (52)		1. NRT Patch (24hrs) High + Group Long Counselling 2. Placebo + Group Long Counselling	
Rigotti 2006²⁶⁰	NHLBI, the NIH General Clinical Research Centers Program and GlaxoSmithKli ne, Inc (GSK)	Parallel RCT	52	12	Massachuset ts, USA	Yes	No	254	79 (31)	94	1. Bupropion Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling	
Rigotti 2010²⁶¹	Pfizer Inc.	Parallel RCT	52	12	Argentina, Australia, Brazil, Canada, Czech Republic, Denmark, France, Germany, Greece, Mexico, Netherlands, Republic of Korea, Taiwan, UK, USA	Yes	No	714	152 (21)	81	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling	
Rodriguez- Artalejo 2003²⁶²	Universidad del País Vasco	Parallel RCT	52	12	Bilbao, Spain	Yes	No	218	30 (14)		1. Usual Care 2. NRT Patch (24hrs) + Individual Short Counselling	
Rohsenow 2017²⁶³	National Institute on Drug Abuse and the Department of Veterans Affairs	Parallel RCT	24	13	Rhode Island, USA	Not necessarily motivated to quit	No	137	64 (47)	83	1. Varenicline Standard + Individual Long Counselling 2. NRT Patch (24hrs) High + Individual Long Counselling	
Rose 2013²⁶⁴	Philip Morris USA	Open Label followed by Parallel RCT	26	15	North Carolina, USA	Yes	No	570	253 (46)	63	1. NRT Patch (24hrs) High + Individual Short Counselling 2. Bupropion Standard + NRT Patch (24hrs) High + Individual Short Counselling 3. Varenicline Standard + NRT Patch (24hrs) High + Individual Short Counselling 4. NRT Patch (24hrs) High + Individual Short Counselling 5. NRT Patch (24hrs) High + Individual Short Counselling 6. Bupropion Standard + NRT Patch (24hrs) High + Individual Short Counselling 7. Varenicline Standard + NRT Patch (24hrs) High + Individual Short Counselling	
Roto 1987²⁶⁵		Parallel RCT	24		Finland		No	121	52 (43)		1. NRT Gum + Individual Short Counselling 2. No Drug Treatment + Individual Short Counselling	

Rovina 2009 ²⁶⁶		Parallel RCT	71	19	Athens, Greece	Yes	No	205	82 (40)	100	1. Bupropion Low + Individual Short Counselling 2. Bupropion Low + Group Long Counselling 3. Bupropion Low + Group Long Counselling 4. No Drug Treatment + Group Long Counselling
Russell 1983 ²⁶⁷	Medical Research Council and the AB Leo Research Foundation, Sweden	Parallel RCT	52		South London and Kent, UK	Yes	No	2106	1200 (57)		1. No Drug Treatment 2. No Drug Treatment 3. NRT Gum Standard
Sachs 1993 ²⁶⁸	National Institute on Drug Abuse and by Kabi Pharmacia AB and Parke-Davis	Parallel RCT	52	18	California, USA	Yes	No	220	130 (59)		1. NRT Patch (16hrs) Standard 2. Placebo
SadrAzodi 2009 ²⁶⁹	Swedish National Institute of Public Health and the Regional county council (Stockholm Lans Landsting), Olle Engkvist Byggmastare Foundation	Parallel RCT	60	8	Stockholm, Sweden	Yes	No	117	48 (47)		1. NRT Choice + Individual + Telephone Counselling 2. Usual Care
Schauffler 2001 ²⁷⁰	Robert Wood Johnson Foundation.	Parallel RCT	52	32	California, USA	Not necessarily motivated to quit	No	1204			1. NRT Choice + Group Counselling 2. No Drug Treatment
Schiller 2012 ²⁷¹	National Institute on Drug Abuse of the National Institutes of Health and the National Heart, Lung and Blood Institute of the National Institutes of Health	Parallel RCT	32	6	Minnesota, USA	No	Yes	332	1 (0.3)		1. NRT Patch (24hrs) High + Individual Counselling 2. NRT Lozenge High + Telephone Short Counselling
Schmitz 2007 ²⁷²	National Institute on Drug Abuse	Parallel RCT	52	7	Texas, USA	Yes	No	154	154 (100)	70	1. Placebo + Group Long Counselling 2. Placebo + Group Long Counselling 3. Bupropion Standard + Group Long Counselling 4. Bupropion Standard + Group Long Counselling
Schneider 1983A ²⁷³	National Institute on	Parallel RCT	52		California, USA	Yes	No	60	36 (60)		1. NRT Gum Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling

	Drug Abuse and the Medical Research Service of the Veterans Administration										
Schneider 1983B²⁷³	National Institute on Drug Abuse and by the Medical Research Service of the Veterans Administration	Parallel RCT	52		California, USA	Yes	No	36			1. NRT Gum Standard 2. Placebo
Schneider 1995²⁷⁴	VA Merit Review and Pharmacia (Sweden)	Parallel RCT	52	24	California, USA	Yes	No	255	114 (45)		1. NRT Nasal Spray Standard 2. Placebo
Schneider 1996²⁷⁵	VA Merit Review and by Pharmacia & Upjohn, Sweden	Parallel RCT	52	24	California, USA	Yes	No	223	83 (37)		1. NRT Inhalator Standard 2. Placebo
Schnoll 2010²⁷⁶	National Cancer Institute	Parallel RCT	27	9	Pennsylvania, USA	Yes	No	246	118 (48)	66	1. NRT Patch (24hrs) + Individual Counselling 2. NRT Patch (24hrs) + Individual Counselling 3. Bupropion Standard + NRT Patch (24hrs) + Individual Counselling 4. Bupropion Standard + NRT Patch (24hrs) + Individual Counselling
Schnoll 2010A²⁷⁷	National Cancer Institute and the National Institute on Drug Abuse	Parallel RCT	52	24	Pennsylvania, USA	Yes	No	575	257 (45)	85	1. NRT Patch (24hrs) High + Counselling 2. NRT Patch (24hrs) High + Counselling
Schnoll 2010B²⁷⁸	American Cancer Society and National Institutes of Health	Parallel RCT	24	12	Pennsylvania, New York, Washington DC, Louisiana, Georgia, Tennessee, Florida, New Jersey, USA	Yes	No	651	365 (57)	63	1. NRT Patch (24hrs) High + Individual Long Counselling 2. NRT Lozenge + Individual Long Counselling
Schnoll 2015²⁷⁹	National Institute on Drug Abuse and the National Cancer Institute	Parallel RCT	52	52	Pennsylvania and Illinois, USA	Yes	No	525	266 (51)	48	1. NRT Patch (24hrs) High + Individual + Telephone Counselling 2. NRT Patch (24hrs) High + Individual + Telephone Counselling 3. NRT Patch (24hrs) High + Individual + Telephone Counselling

Schnoll 2019 ²⁸⁰	NIH, Grant/Award Numbers: K24 DA045244 and R01 CA165001	Open Label followed by Parallel RCT	52	24	Pennsylvania, USA	Yes	No	207	105 (50)	70	1. Varenicline Standard + Individual + Telephone Counselling 2. Varenicline Standard + Individual + Telephone Counselling
Segnan 1991 ²⁸¹	SIMG (Italian Association of General Practice) and the Piedmont Health Authority (Adm. Act 4195/41/86)	Parallel RCT	52	12	Turin, Italy	Yes	No	923	354 (38)		1. No Drug Treatment + Individual Counselling 2. No Drug Treatment + Individual Counselling 3. NRT Gum Standard + Individual Counselling 4. No Drug Treatment + Individual Counselling
Selby 2003 ²⁸²	GlaxoSmithKline	Parallel RCT	52	12	Canada	Yes	No	284	146 (51)	98	1. Bupropion Standard + Counselling 2. Placebo + Counselling
SelmaBozkurt Zircir 2013 ²⁸³		Parallel RCT	28	12	Istanbul, Turkey	Yes	No	251			1. Bupropion Standard 2. Varenicline Standard 3. NRT Choice
Severson 2015 ²⁸⁴	National Cancer Institute of the National Institutes of Health	Parallel RCT	24	12	Oregon, USA	Yes	Yes	1067	26 (2)	96	1. No Drug Treatment + Telephone Long Counselling 2. NRT Lozenge High 3. NRT Lozenge High + Telephone Long Counselling
Sharifirad 2012 ²⁸⁵	Isfahan University of Medical Sciences	Parallel RCT	26	8	Golestan, Iran	Yes	No	110	2 (2)		1. No Drug Treatment 2. NRT Gum Standard + Counselling
Sharma 2018 ²⁸⁶	EU-FP7 and ICMR	Parallel RCT	24	6	National Capital Region of Delhi and Andhra Pradesh, India	Yes	No	800	2 (0.3)		1. NRT Gum + Individual Short Counselling 2. No Drug Treatment + Individual Short Counselling
Sherman 2008 ²⁸⁷	California Tobacco-Related Disease Research Program and by the VA Health Services Research and Development Center of Excellence for the Study of Health Care Provider Behavior	Parallel Quasi-RCT	26	8	California, USA	Yes	No	178			1. Bupropion Standard + NRT Patch (24hrs) High + Group Long Counselling 2. Bupropion Standard + Group Long Counselling

Shiffman 2002 ²⁸⁸	GlaxoSmithKline Consumer Healthcare, Parsippany, NJ	Parallel RCT	52	24	Bristol, London, Glasgow, Coventry, UK and Minnesota, Texas, Oklahoma, Utah, New Jersey, Kentucky, New York, North Carolina, USA	Yes	No	1818	1031 (57)	94	1. NRT Lozenge Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling 3. NRT Lozenge High + Individual Short Counselling 4. Placebo + Individual Short Counselling
Shiffman 2009 ²⁸⁹	SmithKline Beecham Consumer Healthcare, now GlaxoSmithKline Consumer Healthcare (GSKCH)	Parallel RCT	24	24	Texas, Washington, New Jersey, Oklahoma, Arizona, Oregon, Minnesota, Arkansas, New York, Utah, Florida, Illinois, California, Nebraska, Massachusetts, USA	Yes	No	3297	1878 (57)	87	1. Placebo 2. NRT Gum Standard 3. Placebo 4. NRT Gum High
Siddiqi 2013 ²⁹⁰	International Development Research Centre	Cluster RCT	25	7	Jhang and Sargodha, Pakistan	Yes	No	1955	90 (5)	0	1. Bupropion Low + Individual Long Counselling 2. No Drug Treatment + Individual Long Counselling 3. Usual Care
Simon 1997 ²⁹¹	California Tobacco-Related Disease Research Program, Oakland	Parallel RCT	52	12	California, USA	Yes	No	324		69	1. NRT Choice + Individual + Telephone Long Counselling 2. No Drug Treatment + Individual Short Counselling
Simon 2004 ²⁹²	California Tobacco-Related Disease Research Program, Oakland, Calif.	Parallel RCT	52	8	California, USA	Yes	No	244	34 (14)	69	1. Bupropion Standard + NRT Patch (24hrs) High + Individual + Telephone Long Counselling 2. NRT Patch (24hrs) High + Individual + Telephone Long Counselling
Simon 2009 ²⁹³	California Tobacco-Related Disease	Parallel RCT	24	7	California, USA	Yes	No	85	3 (4)	74	1. Bupropion Standard + Individual + Telephone Long Counselling 2. Placebo + Individual + Telephone Long Counselling

Smith 2009 ²⁹⁴	Research Program National Institutes of Health from the National Institute on Drug Abuse and the National Cancer Institute, UW-Madison	Parallel RCT	24	12	Wisconsin, USA	Yes	No	1346	753 (56)	87	1. Bupropion Standard + Telephone Counselling 2. NRT Lozenge + Telephone Counselling 3. NRT Patch (24hrs) High + Telephone Counselling 4. Bupropion Standard + NRT Lozenge + Telephone Counselling 5. NRT Combo High + Telephone Counselling
SMK20001 ²⁹⁵	GlaxoSmithKline	Parallel RCT	52	7	USA	Yes	No	286	138 (48)	93	1. Placebo 2. Bupropion Standard
Solomon 2000 ²⁹⁶	Vermont Department of Health	Parallel RCT	24	10	Vermont, USA	Yes	No	214	214 (100)	90	1. NRT Patch (24hrs) + Telephone Short Counselling 2. NRT Patch (24hrs)
Solomon 2005 ²⁹⁷	Vermont Department of Health.	Parallel RCT	24	10	Vermont, USA	Yes	No	330	330 (100)	93	1. NRT Patch (24hrs) + Telephone Short Counselling 2. NRT Patch (24hrs)
Sonderskov 1997 ²⁹⁸	Ciba-Geigy	Parallel RCT	26	12	Aarhus and Copenhagen, Denmark	Yes	No	522	330 (63)		1. NRT Patch (24hrs) 2. Placebo (Four arms collapsed into two across treatments)
Stapleton 1995 ²⁹⁹	Pharmacia AB, Medical Research Council and Imperial Cancer Research Fund	Parallel RCT	52	18	15 English counties, including London, UK	Yes	No	1200	686 (57)		1. NRT Patch (16hrs) + Individual Short Counselling 2. Placebo + Individual Short Counselling
Stapleton 2013 ³⁰⁰	Department of Health for England	Parallel RCT	24	12	London, Essex, UK	Yes	No	1071	570 (53)	79	1. NRT Choice + Group Long Counselling 2. Bupropion Standard + Group Long Counselling 3. Bupropion Standard + NRT Choice + Group Long Counselling
Stein 2013 ³⁰¹	National Cancer Institute, NIDA	Parallel RCT	24	24	New England, USA	Yes	No	315	159 (50)	79	1. NRT Combo High + Individual Short Counselling 2. Varenicline Standard + Individual Short Counselling 3. Placebo + Individual Short Counselling
Steinberg 2009 ³⁰²	Cancer Institute of New Jersey and the Robert Wood Johnson Foundation	Parallel RCT	26	26	New Jersey, USA	Yes	No	127	82 (65)	61	1. Bupropion Low + NRT Combo High 2. NRT Patch (24hrs) High
Steinberg 2011 ³⁰³	Robert Wood Johnson Foundation, Pfizer	Parallel RCT	24	12	Moderate-sized urban center, USA	Yes	No	79	32 (41)	72	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Stockings 2014 ³⁰⁴	Commonwealth Department of Health and Ageing, Australian Rotary Health,	Parallel RCT	24	14	New South Wales, Australia	Not necessarily motivated to quit	No	205	95 (46)		1. Usual Care 2. NRT Choice + Individual + Telephone Short Counselling

	and the Hunter Medical Research Institute										
Sutherland 1992 ³⁰⁵	Medical Research Council and Imperial Cancer Research Fund	Parallel RCT	182	12	London, UK	Yes	No	227	146 (64)		1. NRT Nasal Spray Standard + Group Long Counselling 2. Placebo + Group Long Counselling
Sutton 1987 ³⁰⁶	The Medical Research Council	Parallel RCT	52	8	London, UK	Yes	No	334	234 (70)		1. NRT Gum Standard + Individual Short Counselling 2. No Drug Treatment
Sutton 1988 ³⁰⁷	Medical Research Council, London, England	Parallel RCT	52	12	Cambridge, Sussex, West Sussex, London, UK	Yes	No	161	69 (43)		1. NRT Gum Standard + Individual Short Counselling 2. No Drug Treatment
Swan 2003 ³⁰⁸	National Cancer Institute, Bethesda, Md	Parallel RCT	52	8	Washington, USA	Yes	No	1524	875 (57)	90	1. Bupropion Low + Telephone Counselling 2. Bupropion Standard + Telephone Counselling (Four arms collapsed into two across treatments)
Swanson 2003 ³⁰⁹		Parallel RCT	52	9	Virginia, USA	Yes	No	140	9 (6)	80	1. NRT Patch (24hrs) + Group Long Counselling 2. Bupropion + Group Long Counselling 3. Bupropion + NRT Patch (24hrs) + Group Long Counselling 4. No Drug Treatment + Group Long Counselling
Tashkin 2001 ³¹⁰	Glaxo Wellcome Inc, USA	Parallel RCT	26	12	USA	Yes	No	411	185 (45)	95	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Tashkin 2011 ³¹¹	Pfizer Inc	Parallel RCT	52	12	USA, Spain, France, Italy	Yes	No	504	188 (38)	83	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Thomsen 2010 ³¹²	The Lundbeck Foundation, Doctor Fritz Karner and wife Edith Karner's Foundation, Aase og Einar Danielsen's Foundation, The Research Council at Herlev University Hospital, Civil Engineer Bent Bøgh and Wife Inge Bøgh's Foundation, and The Tryg Foundation	Parallel RCT	52	2	Denmark	Yes	No	130	130 (100)		1. NRT Choice + Individual Long Counselling 2. Usual Care

Tonnesen 1988 ³¹³	Danish National Tuberculosis Foundation	Parallel RCT	104	16	Copenhagen, Denmark	Yes	No	173	98 (57)	1. NRT Gum High + Group Long Counselling 2. NRT Gum Standard + Group Long Counselling 3. NRT Gum Standard + Group Long Counselling 4. Placebo + Group Long Counselling
Tonnesen 1988 ³¹⁴	H. Lundbeck A/S, Denmark and the Danish National Tuberculosis Society	Parallel RCT	92	12	Copenhagen, Denmark	Yes	No	172	95 (55)	1. NRT Gum Standard + Group Long Counselling 2. NRT Gum High + Group Long Counselling 3. No Drug Treatment
Tonnesen 1991 ³¹⁵	Kabi Pharmacia Therapeutics	Parallel RCT	156	16	Copenhagen, Denmark	Yes	No	289	202 (70)	1. NRT Patch (16hrs) Standard 2. Placebo
Tonnesen 1993 ³¹⁶	Kabi Pharmacia Therapeutics, Helsingborg, Sweden	Parallel RCT	52	24	Copenhagen, Denmark	Yes	No	286	172 (60)	1. NRT Inhalator Standard 2. Placebo
Tonnesen 1999 ³¹⁷	European Respiratory Society and Pharmacia & Upjohn, Sweden	Parallel RCT	52	26	Austria, Belgium, Denmark, England, Finland, France, Germany, Greece, Ireland, Italy, Norway, Poland, Portugal, Spain, Sweden, Switzerland, The Netherlands	Yes	No	3575	1716 (48)	1. NRT Patch (16hrs) High 2. NRT Patch (16hrs) Standard 3. Placebo (Five arms collapsed into three based on dosage)
Tonnesen 2000 ³¹⁸	Pharmacia & Upjohn, Helsingborg, Sweden and the Danish Lung Foundation	Parallel RCT	52	36	Hellerup, Denmark	Yes	No	446	232 (52)	1. NRT Patch (16hrs) Low + Individual Short Counselling 2. NRT Patch (16hrs) Standard + Individual Short Counselling 3. NRT Inhalator Standard + Individual Short Counselling 4. NRT Combo Standard + Individual Short Counselling
Tonnesen 2003 ³¹⁹	GlaxoSmithKline	Parallel RCT	52	7	Norway, Sweden, Denmark, the Netherlands, France, South Africa, Australia and New Zealand	Yes	No	710	362 (51)	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Tonnesen 2006 ³²⁰	The Danish Medical Research	Parallel RCT	52	12	Hellerup, Denmark	Yes	No	370	193 (52)	1. Placebo + Individual + Telephone Long Counselling 2. NRT Sublingual Tablet + Individual + Telephone Long Counselling

	Council and Pfizer Consumer Healthcare, Sweden									(Four arms collapsed into two based on dosage)
Tønnesen 2012 ³²¹	McNeil AB, Sweden	Parallel RCT	52	24	Copenhagen, Denmark and Mannheim, Tübingen, Germany	Yes	No	479	210 (44)	1. NRT Mouth Spray Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Tonstad 2003 ³²²	GlaxoSmithKline	Parallel RCT	52	7	Australia, Austria, Germany, Greece, Hungary, Netherlands, New Zealand, Norway, Switzerland, UK	Yes	No	629	145 (23)	99 1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Tonstad 2006 ³²³	Pfizer Inc	Parallel RCT	52	12	USA, Canada, Czech Republic, Denmark, Norway, Sweden, UK	Yes	No	1210	614 (51)	97 1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Tromeur 2018 ³²⁴		Parallel RCT	52	12	Brest, France		No	81		1. Varenicline + Long Counselling 2. Placebo + Long Counselling
Tsai 2007 ³²⁵	Pfizer Inc	Parallel RCT	24	12	Korea, Taiwan	Yes	No	250	28 (11)	0 1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Tsukahara 2010 ³²⁶	Ministry of Education, Science and Culture of Japan, Central Research Institute of Fukuoka University and FU-Global program	Parallel RCT	24	12	Nanakuma, Japan	Yes	No	32	5 (16)	0 1. Varenicline Standard + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling
Tuisku 2016 ³²⁷	Ministry of Social Affairs and Health, governmental subsidy, Finnish Research Foundation of the Pulmonary Diseases and The Finnish	Parallel RCT	26	12	Rovaniemi, Kemi and Tornio, municipality of Sodankyla, Finland	Yes	No	291	146 (50)	1. Placebo + Individual Long Counselling 2. NRT Patch (16hrs) Low + Individual Long Counselling 3. NRT Patch (16hrs) Standard + Individual Long Counselling 4. Varenicline Standard + Individual Long Counselling

Tulloch 2016 ³²⁸	Medical Society Duodecim Heart and Stroke Foundation of Ontario	Parallel RCT	52	24	Ontario, Canada	Yes	No	737	342 (47)	92	1. NRT Patch (24hrs) + Individual Short Counselling 2. NRT Combo + Individual Short Counselling 3. Varenicline Standard + Individual Short Counselling
University of Michigan 2011 ³²⁹		Parallel RCT	36	8	Michigan, USA	Yes	No	2485	1721 (69)	87	1. NRT Patch (24hrs) + Telephone Counselling 2. NRT Patch (24hrs) 3. No Drug Treatment
Urdapilleta-Herrera 2013 ³³⁰		Parallel RCT	52		Mexico, Mexico	Yes	No	94			1. Bupropion + Counselling 2. Placebo + Counselling
Uyar 2007 ³³¹		Parallel RCT	24	7	Turkey	Yes	No	131	25 (19)		1. Bupropion Standard + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling 3. No Drug Treatment + Individual Short Counselling
Vial 2002 ³³²	The Anti-Cancer Foundation of South Australia, The Queen Elizabeth Hospital Research Foundation and the University of South Australia	Parallel RCT	52	16	Adelaide, South Australia, Australia	Yes	No	102	45 (44)		1. NRT Patch (24hrs) 2. NRT Patch (24hrs) 3. No Drug Treatment
Villa 1999 ³³³		Parallel RCT	52		Oviedo, Spain		No	47	34 (72)		1. NRT Gum Standard + Group Long Counselling 2. No Drug Treatment + Group Long Counselling
Wagena 2005 ³³⁴	Netherlands Asthma Foundation, Leusden and the Netherlands Organization for Health Research and Development, The Hague. Lundbeck BV, Amsterdam, the Netherlands, provided the nortriptyline free	Parallel RCT	27.6	12	Nijmegen, Netherlands	Yes	No	255	131 (51)	100	1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo Individual + Telephone Short Counselling (Two out of three arms extracted)
Wallstrom 2000 ³³⁵	Pharmacia & Upjohn Consumer Health Care	Parallel RCT	52	24	Gothenburg, Sweden	Yes	No	247	146 (59)		1. NRT Sublingual Tablet + Individual Short Counselling 2. Placebo + Individual Short Counselling

Walsh 1999 ³³⁶	Tobacco Surtax Fund of the State of California	Cluster RCT	52		California, USA	Not necessarily motivated to quit	Yes	360			1. NRT Gum Standard + Individual + Telephone Short Counselling 2. No Drug Treatment
Wang 2009 ³³⁷	Pfizer Inc	Parallel RCT	24	12	Thailand, China, Singapore	Yes	No	334	11 (3)	0	1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Ward 2013 ³³⁸	PHS	Parallel RCT	52	6	Aleppo, Syria	Yes	No	269	58 (22)	0	1. NRT Patch (24hrs) + Individual + Telephone Long Counselling 2. Placebo + Individual + Telephone Long Counselling
Weaver 2015 ³³⁹	Wake Forest CCOP Research Base	Parallel RCT	24	6	USA	Yes	No	146	110 (75)	79	1. NRT + Individual + Telephone Short Counselling 2. Usual Care
Wennike 2003 ³⁴⁰	Pharmacia AB, Sweden	Parallel RCT	104	52	Copenhagen, Denmark	No	No	411	255 (62)		1. NRT Gum + Individual Long Counselling 2. Placebo + Individual Long Counselling
Westergaard 2015 ³⁴¹	Pfizer Inc.	Parallel RCT	24	12	Denmark		No	52	21 (40)		1. Varenicline Standard + Long Counselling 2. Placebo + Long Counselling
Westman 1993 ³⁴²	TBS Laboratories, Piscataway, NJ	Parallel RCT	24	6	North Carolina, USA	Yes	No	159	91 (57)	92	1. NRT Patch (24hrs) High + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Wewers 2000 ³⁴³	National Institutes of Health, National Institute of Allergy and Infectious Diseases, AdultAIDSClinicalTrials Group	Parallel RCT	32	6	Ohio, USA	Yes	No	15			1. NRT Patch (24hrs) High + Individual + Telephone Long Counselling 2. No Drug Treatment
Wiggers 2006 ³⁴⁴	The Netherlands Heart Foundation	Parallel RCT	52	8	Amsterdam, The Netherlands	Yes	No	385	139 (36)		1. NRT Patch (24hrs) + Individual Long Counselling 2. NRT Patch (24hrs)
Williams 2007 ³⁴⁵	Pfizer	Parallel RCT	53	52	USA, Australia	Yes	No	377	189 (50)	89	1. Varenicline Standard + Individual Short Counselling 2. Placebo + Individual Short Counselling
Williams 2012 ³⁴⁶	Pfizer	Parallel RCT	26	12	USA, Canada	Yes	No	128	29 (23)	59	1. Varenicline Standard + Individual Long Counselling 2. Placebo + Individual Long Counselling
Wilson 2008 ³⁴⁷		Parallel RCT	52	12	Northern Ireland, UK	Yes	No	91	47 (52)		1. No Drug Treatment + Individual Short Counselling 2. NRT Patch (16hrs) Standard + Individual Long Counselling 3. NRT Patch (16hrs) Standard + Group Long Counselling
Winhusen 2014 ³⁴⁸	National Institute on Drug Abuse	Parallel RCT	28	10.4	Oregon, Pennsylvania, South Carolina, Florida, Montana, Arizona, California, Texas, USA	Yes	No	538	258 (48)	60	1. Bupropion Standard + NRT Inhalator + Individual Short Counselling 2. Usual Care
Wiratmoko 2013 ³⁴⁹		Parallel RCT	24	12	Jakarta, Indonesia	Yes	No	80			1. Varenicline Standard + Counselling 2. Placebo + Counselling
Wittchen 2011 ³⁵⁰	Federal Ministry of	Parallel RCT	52	12	greater Dresden and	Yes	No	485	252 (52)		1. Bupropion Standard + Individual Long Counselling 2. No Drug Treatment + Individual Long Counselling

	Education and Research, GlaxoSmithKline GmbH & Co. KG (Munich), GlaxoSmithKline Consumer Health Care GmbH & Co KG (Buehl) and Pharmacia GmbH (Erlangen)				Munich, Germany						3. NRT Choice + Individual Long Counselling 4. No Drug Treatment + Individual Short Counselling
Wong 1999³⁵¹	DuPont Merck Pharmaceutical Company, Wilmington, Delaware	Parallel RCT	24	12	Minnesota, USA	Yes	No	100	53 (53)		1. Placebo + Individual Short Counselling 2. NRT Patch (24hrs) High + Individual Short Counselling
Wong 2012³⁵²	Department of Anesthesia, Toronto Western Hospital, University Health Network, University of Toronto; University Health Network Foundation, Toronto, Ontario, Canada; and Pfizer Canada Incorporated	Parallel RCT	52	12	Ontario, Canada	Yes	No	286	135 (47)		1. Varenicline Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling
Wong 2017³⁵³	Funding from the Department of Anesthesia, Toronto Western Hospital, University Health Network, University of Toronto, Ontario, Canada; University Health	Parallel RCT	52	12	Ontario, Canada	Yes	No	296	111 (38)		1. No Drug Treatment 2. Varenicline Standard + Individual + Telephone Short Counselling

	Network Foundation, Toronto, Ontario, Canada; and an investigator-initiated research grant from Pfizer Inc											
Yang 2016 ³⁵⁴		Parallel RCT	24		Shanghai, China	Yes	No	146	0 (0)	0	1. Usual Care + Counselling 2. Varenicline Standard + Counselling 3. Varenicline Standard + Counselling	
Yuhongxia 2011 ³⁵⁵		Parallel RCT	52	12	Beijing, China	Yes	No	220			1. Varenicline + Telephone Counselling 2. Varenicline	
Zellweger 2005 ³⁵⁶	GlaxoSmithKline	Parallel RCT	52	7	Austria, Estonia, Finland, Greece, Germany, Israel, Italy, Latvia, Lithuania, Poland, Spain, Switzerland	Yes	No	690	442 (64)		1. Bupropion Standard + Individual + Telephone Short Counselling 2. Placebo + Individual + Telephone Short Counselling	
Zelman 1992 ³⁵⁷	National Institutes of Health	Parallel RCT	52		Wisconsin, USA	Yes	No	126	68 (54)		1. NRT Gum Standard + Group Long Counselling 2. NRT Gum Standard + Group Long Counselling 3. No Drug Treatment + Group Long Counselling 4. No Drug Treatment + Group Long Counselling	
Zernig 2008 ³⁵⁸	Styrian Regional Health Care System (Steiermaerkische Gebietskrankenkasse, STGKK), Austrian Science Fund	Parallel RCT	52	9	Graz, Austria	Yes	No	779	447 (57)		1. No Drug Treatment + Group Long Counselling 2. Bupropion Standard	
ZYB 30011 ³⁵⁹	GlaxoSmithKline	Parallel RCT	24	7	Italy	Yes	No	254	87 (34)		1. Bupropion Standard 2. Placebo	
ZYB40005 ³⁶⁰	GlaxoSmithKline	Parallel RCT	52	33	USA	No	No	609	273 (45)	85	1. Bupropion Standard 2. Placebo	
ZYBAKIA402 ³⁶¹	GlaxoSmithKline	Parallel RCT	52	12	USA	Yes	No	190	30 (16)	84	1. Bupropion Standard 2. Placebo	

Table 2 Additional study characteristics for randomised controlled trials reporting effectiveness outcomes

Study	Trial Registration	Population Studied	Smoking History M(SD)
Abdullah 2013 ¹			18.5 (10.9)
Abelin 1989 ²			22.2 (10.3)
Ahluwalia 1998 ³		Patients at a large inner-city hospital serving a low-income, predominantly African–American population	30
Ahluwalia 2002 ⁴		African–American smokers	
Ahluwalia 2006 ⁵		Light smokers	23.9 (12)
Anderson 2018 ⁶	NCT01502306		
Andrews 2016 ⁷	NCT01035151	Female smokers from subsidized housing neighbourhoods	
Anthenelli 2013 ⁸	NCT01078298	Smokers with current or past depression (major depressive disorder)	26.7 (11.8)
Anthenelli 2016A ⁹	NCT01456936		28.1 (12.8)
Anthenelli 2016B ⁹	NCT01456936	Smokers with psychiatric disorders	28.6 (11.9)
Anthonisen 1994 ¹⁰	NCT00000568	Smokers at high risk for chronic obstructive pulmonary disease	
Areechon 1988 ¹¹			20.1
Aryanpur 2016 ¹²	IRCT2013062613783N1	Newly-diagnosed pulmonary tuberculosis patients	
Aubin 2004 ¹³			
Aubin 2008 ¹⁴	NCT00143325		25.6
Baker 2006 ¹⁵		Smokers with a non-acute psychotic disorder	
Baker 2016 ¹⁶	NCT01553084		28.6 (12)
Baldassarri 2018 ¹⁷	NCT02498145		
Batra 2005 ¹⁸		Smokers who had made at least 1 failed quit attempt within 2 years before the study but not within the previous 6 months	
Bernstein 2015 ¹⁹	NCT01328431	Low-income smokers	
Binnie 2007 ²⁰			23.9 (8.1)
Bjurlin 2013 ²¹		Smokers who were urology patients	
Blondal 1989 ²²		Smokers included pipe & cigar users	
Blondal 1997 ²³			
Blondal 1999 ²⁴			
Bohadana 2000 ²⁵			20.6 (7.9)
Bolliger 2000 ²⁶		Smokers who have failed at least one serious attempt to quit within past year and want to use inhaler to reduce smoking	
Bolliger 2007 ²⁷		Smokers with 1 or more quit attempts in the last year	
Bolliger 2011 ²⁸	NCT00594204		
Bonevski 2018 ²⁹	ISRCTN85202510		
Boyle 1992 ³⁰		Smokeless tobacco users who had made at least one previous attempt to quit tobacco	12 (7.2)
Brown 2007 ³¹			26 (10.64)
Buchkremer 1988 ³²			
Buchkremer 1989 ³³			
Bullen 2010 ³⁴	ACTRN12605000373673		
Bullen 2013 ³⁵	ACTRN12610000866000		

Study	Trial Registration	Population Studied	Smoking History M(SD)
Burns 2016 ³⁶	NCT01889771	Smokers who were Quitline users	
Caldwell 2014 ³⁷			
Caldwell 2016 ³⁸	ACTRN12609000481279		
Caldwell 2018 ³⁹	NCT01164306		
Campbell 1983 ⁴⁰		Smokers with a condition related to or aggravated by smoking (chronic bronchitis and emphysema, asthma, repeated respiratory infections, industrial lung disease, ischaemic heart disease, hypertension, peripheral vascular disease, and peptic ulcer)	
Campbell 1987 ⁴¹		Smokers who were primary care patients	
Campbell 1991 ⁴²		Former hospital inpatients (now outpatients) with smoking-related diseases; distribution of diagnoses (categories: heart disease, lung disease, peripheral vascular disease, peptic ulcer)	
Campbell 1996 ⁴³		Hospital inpatients and outpatients with smoking related respiratory or cardiovascular disease	31 (13)
Caponnetto 2013 ⁴⁴	NCT01164072	Smokers not currently or intending to quit smoking in the next 30 days	
Carpenter 2011 ⁴⁵	NCT00706979	Smokers who were unmotivated to quit	
Carson 2014 ⁴⁶		Smokers admitted to hospital with acute smoking-related illnesses	37.4 (2.9)
Chan 2011 ⁴⁷	ISRCTN05172176	Smokers with no intention to quit/ in the next 4 weeks	
Chengappa 2014 ⁴⁸	NCT01010204	Smokers with bipolar disorder	29.2 (11.2)
Cinciripini 1996 ⁴⁹			25.3 (11.4)
Cinciripini 2013 ⁵⁰	NCT00507728		
Cinciripini 2018 ⁵¹	NCT00943618		
Clavel 1985 ⁵²			
Clavelchapelon 1992 ⁵³			18 (9)
Collins 2004 ⁵⁴			25.16 (11.93)
Cooney 2007 ⁵⁵		Alcohol-dependent smokers	28.1 (10)
Cooney 2009 ⁵⁶	NCT00064844	Alcohol-dependent tobacco smokers	
Cooper 2005 ⁵⁷		Female smokers	19.1 (9.8)
Cooperman 2017 ⁵⁸		Smokers who were opioid-dependent and on methadone	
Covey 2007 ⁵⁹		Smokers who had a previous quit attempt who were abstainers during the last 4 weeks of open-label treatment	
Cox 2012 ⁶⁰	NCT00666978	Light smokers	
Croghan 2003 ⁶¹			23.3 (10.7)
Cropsey 2015 ⁶²	NCT01257490	Smokers under criminal justice supervision	
Cummings 2011 ⁶³			
Cummins 2016 ⁶⁴	NCT01289275	Hospitalised smokers	
Cunningham 2016 ⁶⁵	NCT01429129		25.1 (14)
Dale 1995 ⁶⁶	NCT00235313		29.3 (11.7)
Dale 2002 ⁶⁷		Spit tobacco users	17.1 (11.4)
Dale 2007 ⁶⁸	NCT00414180	Smokeless tobacco users	19 (8.7)

Study	Trial Registration	Population Studied	Smoking History M(SD)
Dalsgarð 2004 ⁶⁹		Smokers including physicians, nurses, other hospital service and admin staff	
Daughton 1991 ⁷⁰			23.9
Daughton 1998 ⁷¹			19.6 (9.2)
Daughton 1999/TNSG 1991 ⁷²		Smokers who had made at least one attempt to quit	24.1 (10.1)
Dautzenberg 2001 ⁷³			
Davidson 1998 ⁷⁴		Smokers who almost all reported at least 1 underlying illness at randomization (many of them reported several)	21 (11.5)
De Dios 2012 ⁷⁵		Latino/Hispanic light smokers	
Dogar 2018 ⁷⁶	ISRCTN94103375	Smokers using waterpipes	27.1 (15.9)
Ebbert 2007 ⁷⁷		Smokeless tobacco users	17 (7.5)
Ebbert 2009 ⁷⁸	NCT00392379	Smokeless tobacco users	16.3 (10.3)
Ebbert 2010 ⁷⁹	NCT00888459	Smokeless tobacco users	17.8 (9.8)
Ebbert 2011 ⁸⁰	NCT00813917	Smokeless tobacco users	18.8 (11.3)
Ebbert 2013 ⁸¹	NCT00939029	Smokeless tobacco users	18 (10)
Ebbert 2014 ⁸²	NCT00935818		23.4 (12.1)
Ebbert 2015 ⁸³	NCT01370356	Adult smokers unwilling to quit abruptly	
Ebbert 2017 ⁸⁴	NCT01639560	Light smokers	16.7 (11.3)
Ehram 1991 ⁸⁵			8.2 (3.3)
Eisenberg 2013 ⁸⁶	NCT00689611	Smokers hospitalized with enzyme positive acute myocardial infarction	32.9 (12.4)
Eisenberg 2016 ⁸⁷	NCT00794573	Smokers hospitalised for acute coronary syndrome (myocardial infarction or unstable angina)	36 (12)
Eisenberg 2016 ⁸⁷	NCT02148445	Smokers with chronic lung disease/physician-diagnosed chronic obstructive pulmonary disease	
Ellerbeck 2018 ⁸⁸			
Etter 2002 ⁸⁹		Smokers who are unwilling to quit	
Etter 2009 ⁹⁰	ISRCTN60585119		
Evins 2001 ⁹¹		Smokers with schizophrenia	
Evins 2005 ⁹²		Smokers with schizophrenia or schizoaffective disorder depressed type	
Evins 2007 ⁹³	NCT00307203	Smokers with schizophrenia	26 (10.6)
Evins 2014 ⁹⁴	NCT00621777	Smokers with schizophrenia, schizoaffective disorder or bipolar disorder	
Fagerstrom 1982 ⁹⁵			
Fagerstrom 1984 ⁹⁶			
Fagerstrom 2010 ⁹⁷	NCT00717093	Smokeless tobacco users	21 (11.4)
Fee 1982 ⁹⁸			
FernandezArias 2014 ⁹⁹			
Ferry 1992 ¹⁰⁰			
Ferry 1994 ¹⁰¹		Non-depressed smokers	
Fiore 1994A ¹⁰²			24.8
Fiore 1994B ¹⁰²			25.1
Fiore 2004 ¹⁰³		Smokers who were primary care patients	
Fortmann 1995 ¹⁰⁴		Smokers who reported success at quitting for 24 hours	
Fossati 2007 ¹⁰⁵		Smokers who were primary care patients	

Study	Trial Registration	Population Studied	Smoking History M(SD)
Fouz-Rosón 2017 ¹⁰⁶			
Gallagher 2007 ¹⁰⁷		Smokers with serious mental illness	
Gariti 2009 ¹⁰⁸	NCT00086411	Light smokers	
Garvey 2000 ¹⁰⁹			
George 2002 ¹¹⁰		Smokers with schizophrenia or schizoaffective disorder	
George 2008 ¹¹¹	NCT00124683	Smokers with schizophrenia or schizoaffective disorder	22.6 (9.5)
Gifford 2004 ¹¹²		Smokers with at least one 24 hour quit attempt	
Gilbert 1989 ¹¹³		Smokers who were primary care patients	
Ginsberg 1992 ¹¹⁴			
Glavas 2003A ¹¹⁵		Healthcare professionals (doctors and nurses)	16.5 (4.4)
Glavas 2003B ¹¹⁶			25 (5)
GlaxoSmithKline 2009 ¹¹⁷	NCT00985985		
Glover 2002 ¹¹⁸			25 (10.9)
Goldstein 1989 ¹¹⁹			23.5 (9)
Gonzales 2001 ¹²⁰		Smokers who previously used bupropion for at least 2 weeks without adverse effects	
Gonzales 2006 ¹²¹	NCT00141206		24 (11.7)
Gonzales 2014 ¹²²	NCT01244061	Smokers who had been previously treated with varenicline	30 (11.9)
Gorecka 2003 ¹²³		Smokers with chronic obstructive pulmonary disease	
Gourlay 1995 ¹²⁴		Recently relapsed smokers (who had failed to quit in phase 1 of the trial)	23.7 (10.3)
Graham 2017 ¹²⁵	NCT01544153; ISRCTN45127327		
Grant 2007 ¹²⁶		Smokers meeting DSM-IV criteria for alcohol dependence/abuse	
Gross 1995 ¹²⁷			
Haas 2015 ¹²⁸	NCT01156610	Low-SES adult smokers who described their race and/or ethnicity as black, Hispanic, or white	
Haggström 2006 ¹²⁹			
Hajek 2019 ¹³⁰	ISRCTN60477608		
Hall 1985 ¹³¹			
Hall 1987 ¹³²			
Hall 1996 ¹³³		22% of participants were diagnosed as having a major depressive disorder history	21
Hall 2002 ¹³⁴			21.7 (10.9)
Hall 2006 ¹³⁵		Smokers with unipolar depression	
Hall 2009 ¹³⁶	NCT00086385	Older cigarette smokers	37.8 (8.23)
Hall 2011 ¹³⁷			22.9 (10.1)
Halpern 2018 ¹³⁸	NCT02328794		
Hand 2002 ¹³⁹		Hospital inpatients or outpatients with smoking related disease	
Hanioka 2010 ¹⁴⁰			
Harackiewicz 1988 ¹⁴¹			17
Hatsukami 1996 ¹⁴²		Smokeless tobacco users	9.9 (5.8)
Hatsukami 2000 ¹⁴³		Smokeless tobacco users	10.7 (5.9)

Study	Trial Registration	Population Studied	Smoking History M(SD)
Hatsukami 2004 ¹⁴⁴		Smokers who want to reduce but not quit, at least 2 failed quit attempts including 1 with NRT	
Hays 1999 ¹⁴⁵			25.6 (11.6)
Hays 2001 ¹⁴⁶	NCT00000457	Smokers who quit after 7 weeks open label bupropion	
Hays 2009 ¹⁴⁷		Smokers with a history of alcohol abuse or dependence and had at least 1 year of continuous abstinence from alcohol and drugs	25.5 (10.5)
Herrera 1995 ¹⁴⁸		Smokers scoring ≥ 4 on FTND, no serious illness. Only those who were ready to quit after 4 weeks of behavioural treatment were randomized	
Hertzberg 2001 ¹⁴⁹		Male veteran smokers with PTSD	
Heydari 2012 ¹⁵⁰	IRCT138901111878N2	Previous quit-attempters	
Heydari 2013 ¹⁵¹	IRCT138901111878N1	Smokers with a history of drug abuse seeking treatment	22.1 (11.3)
Hilberink 2011 ¹⁵²	NCT00628225	Smokers with chronic obstructive pulmonary disease and were medicated	
Hilleman 1994 ¹⁵³		Smokers with a Fagerstrom score > 8 and at least one serious attempt to stop smoking in the past year	19.8 (9.1)
Hjalmarson 1984 ¹⁵⁴			
Hjalmarson 1994 ¹⁵⁵			26.8 (10.1)
Hjalmarson 1997 ¹⁵⁶		Smokers who have made a previous serious attempt to quit smoking using nicotine chewing gum	29.5 (9.5)
Hollis 2007 ¹⁵⁷			
Holt 2005 ¹⁵⁸		Indigenous Maori smokers	
Horst 2005 ¹⁵⁹		Smokers with a diagnosis of schizophrenia or schizoaffective disorder who successfully quit tobacco use after 90 days (open label phase)	
Howard-Pitney 1999 ¹⁶⁰		Smokeless tobacco users	
Huber 1988 ¹⁶¹			
Hughes 1989 ¹⁶²			
Hughes 1990 ¹⁶³		Smokers who met DSM-III criteria for tobacco dependence	20.8 (10.4)
Hughes 1999 ¹⁶⁴		Smokers who had made a prior attempt to stop smoking and were motivated to try again	26 (10)
Hughes 2003 ¹⁶⁵		Smokers with past alcohol dependence but no alcohol or illicit drug intake for last 30 days	
Hughes 2010 ¹⁶⁶	NCT00297492	Smokers wanting to quit in the next 30 days	
Hughes 2011 ¹⁶⁷	NCT00595868	Smokers who wished to quit at some point but had no current plans to quit smoking	26.4
Hurt 1990 ¹⁶⁸			
Hurt 1994 ¹⁶⁹			24.8 (10.6)
Hurt 1997 ¹⁷⁰			
Hurt 2003 ¹⁷¹			
Hurt 2018 ¹⁷²	NCT01347112	Smokers with alcohol dependence or abuse	
ICRF 1994 ¹⁷³			25
Ikonomidis 2017 ¹⁷⁴	NCT02307045		

Study	Trial Registration	Population Studied	Smoking History M(SD)
Jamrozik 1984 ¹⁷⁵ Jarvis 1982 ¹⁷⁶		Smokers from an earlier study of the effect of physician advice who had made one or more unsuccessful attempts to stop smoking over the preceding 12 months	
Jensen 1991 ¹⁷⁷			22.5 (8.5)
Johns 2016 ¹⁷⁸		Smokers prone to lung cancer	
Johns 2017 ¹⁷⁹		Smokers prone to lung cancer (previous lung disease/family history of lung cancer/past cancer treatment/lowered immunity/previous smoking-related cancers/exposure to certain chemicals/radon gas)	
Johns 2017 ¹⁸⁰		Smokers prone to lung cancer	
Jorenby 1995 ¹⁸¹			
Jorenby 1999 ¹⁸²			
Jorenby 2006 ¹⁸³	NCT00143364		25.6 (11.7)
Joseph 1996 ¹⁸⁴		Smokers with a history of cardiac disease who had made a minimum of two previous attempts to quit; All subjects had one or more of the following diagnosed conditions: a history of myocardial infarction, a history of coronary-artery bypass surgery or angioplasty, stenosis of at least 50 percent in at least one major coronary artery as seen with coronary angiography, or a clinical history of angina, congestive heart failure, cor pulmonale, arrhythmia, peripheral vascular disease, or cerebrovascular disease.	44
Joseph 2004 ¹⁸⁵		Smokers with alcohol dependence or abuse undergoing alcoholism treatment	21.2 (10.3)
Joseph 2011 ¹⁸⁶	NCT00309296		
Joyce 2008 ¹⁸⁷		Elderly smokers who were Medicare beneficiaries	
Kalman 2006 ¹⁸⁸		Smokers with a history of alcohol dependence & ≥2m abstinence from alcohol & illicit drugs	
Kalman 2011 ¹⁸⁹	NCT00304707	Smokers with history of alcohol abuse or dependence with 2 to 12 months alcohol abstinence	
Killen 1984 ¹⁹⁰			23.8 (10.4)
Killen 1990 ¹⁹¹		Smokers who quit smoking for 48 hours	24.5 (10.8)
Killen 1997 ¹⁹²			
Killen 1999 ¹⁹³		Heavy smokers	
Killen 2006 ¹⁹⁴			
Klesges 2015 ¹⁹⁵	NCT00632411	Smokers who were active duty Armed Forces personnel, or eligible reservists, National Guard members, retirees, or family members	18.9 (13.1)
Koegelenberg 2014 ¹⁹⁶	NCT01444131		26.4 (11.5)
Kornitzer 1987 ¹⁹⁷			
Kornitzer 1995 ¹⁹⁸			
Kralikova 2002 ¹⁹⁹		Smokers who wanted to reduce their smoking, and had previously made at least one failed quit attempt	

Study	Trial Registration	Population Studied	Smoking History M(SD)
Krupski 2016 ²⁰⁰		Heavy smokers	
	NCT01260233	Smokers were patients seen in the preadmission clinic at least 3 weeks preoperatively	27 (13.4)
Lee 2013 ²⁰¹			
Lee 2018 ²⁰²	NCT02482233	Smokers awaiting elective surgery	32 (16)
Leischow 1996 ²⁰³			25.9 (11.5)
Leischow 1999 ²⁰⁴			
Leischow 2004 ²⁰⁵			30 (12.7)
Lerman 2004 ²⁰⁶			
Lerman 2015 ²⁰⁷	NCT01314001		
	NCT00006170	Female smokers who endorsed concern about postcessation weight gain	
Levine 2010 ²⁰⁸			
Lewis 1998 ²⁰⁹		Smokers who were hospital patients	26.4 (13.3)
Littlewood 2017 ²¹⁰			16.6 (10.1)
Llivina 1988 ²¹¹			20.5 (12.5)
Lloyd-Richardson 2009 ²¹²	NCT00551720	Smokers who were HIV positive	
Malcolm 1980 ²¹³			
		Smokers with significant histories of alcohol abuse and dependence	24.4 (10.2)
Martin 1997 ²¹⁴			
McAfee 2008 ²¹⁵			
	NCT01621009; NCT01120704		
McCarthy 2008 ²¹⁶			
McGovern 1992 ²¹⁷			
Mercie 2018 ²¹⁸	NCT00918307	Smokers with HIV	26 (9)
		Smokers admitted to medical and surgical wards	33.5 (16.2)
Molyneux 2003 ²¹⁹			
Mori 1992 ²²⁰		Smokers with smoking related illnesses	
Myles 2004 ²²¹		Smokers awaiting surgery	25 (12.5)
Myung 2007 ²²²			16.8 (5.8)
	NCT01027754	Smokers in methadone treatment for substance abuse	
Nahvi 2014 ²²³			
Nakamura 1990 ²²⁴			
Nakamura 2007 ²²⁵	NCT00139750		20.9 (11.4)
NCT00365508 ²²⁶	NCT00365508	Smokers who were cancer patients	
NCT00828113 ²²⁷	NCT00828113		
Nebot 1992 ²²⁸			
Niaura 1994 ²²⁹			24 (11)
Niaura 1999 ²³⁰			26.9 (10.4)
Niaura 2008 ²³¹	NCT00150228		25.3
Nides 2006 ²³²	NCT00150241		24.1 (10.7)
Nides 2018 ²³³	NCT02355665		
Ockene 1991 ²³⁴			
Okuyemi 2007 ²³⁵		Smokers living in low-income housing	
Oncken 2006 ²³⁶	NCT00150254		25 (10.6)
		Postmenopausal women (i.e., with no menstruation for at least 1 year)	
Oncken 2007 ²³⁷			
Ortega 2011 ²³⁸		Smokers who were hospital inpatients	
Pack 2008 ²³⁹			25.8 (11.9)
Page 1986 ²⁴⁰			

Study	Trial Registration	Population Studied	Smoking History M(SD)
Paoletti 1996 ²⁴¹			
Perng 1998 ²⁴²			34
Piper 2007 ²⁴³			
Piper 2009 ²⁴⁴	NCT00332644		
Piper 2018 ²⁴⁵	NCT02301403	Smokers who were primary care patients	
Pirie 1992 ²⁴⁶		Female smokers concerned about weight	
Planer 2011 ²⁴⁷		Smokers with diagnosis of acute coronary syndrome	
	NCT01305447	Inactive female smokers (engaged in less than 30 min of moderate to vigorous exercise twice per week for the past 6 months)	
Prapavessis 2007 ²⁴⁸			
Puska 1979 ²⁴⁹			
Puska 1995 ²⁵⁰			21.3 (8.6)
QuilezGarcia 1989 ²⁵¹		Smokers who were primary care patients	15.8 (9.4)
Ramon 2014 ²⁵²	NCT01538394		
Ratner 2004 ²⁵³		Smokers who were patients admitted for pre-surgical assessment	34.2 (14)
Reid 2003 ²⁵⁴		Smokers hospitalized for coronary artery disease	37.3 (9.3)
		Smokers enrolled in their respective substance abuse treatment programs for current drug or alcohol dependence	
Reid 2008 ²⁵⁵			
Rennard 2006 ²⁵⁶			
	NCT00691483	Smokers from research centres, private practice offices and research clinics	
Rennard 2012 ²⁵⁷			
Richmond 1993 ²⁵⁸			
Richmond 1994 ²⁵⁹			24 (10.8)
	NCT00181818	Smokers hospitalised with cardiovascular disease	37.7 (11)
Rigotti 2006 ²⁶⁰			
	NCT00282984	Smokers with stable documented cardiovascular disease	40
Rigotti 2010 ²⁶¹			
Rodriguez-Artalejo 2003 ²⁶²			26.8 (8.6)
	NCT00756275	Smokers diagnosed with substance use disorders	
Rohsenow 2017 ²⁶³			
Rose 2013 ²⁶⁴	NCT00894166		
Roto 1987 ²⁶⁵			
Rovina 2009 ²⁶⁶			
Russell 1983 ²⁶⁷			
Sachs 1993 ²⁶⁸			28.6 (10.8)
SadrAzodi 2009 ²⁶⁹	NCT00533000	Smokers scheduled for surgery	
Schauffler 2001 ²⁷⁰			
	NCT00218296	Smokeless tobacco users interested in reducing ST use but not quitting (having an established quit date) within the next 90 days	11.8 (8.2)
Schiller 2012 ²⁷¹			
Schmitz 2007 ²⁷²		Female smokers	28.5 (10.6)
Schneider 1983A ²⁷³			21.5
Schneider 1983B ²⁷³			
Schneider 1995 ²⁷⁴			22.3 (8.1)
Schneider 1996 ²⁷⁵			25.7 (11)
Schnoll 2010 ²⁷⁶		Smokers who were cancer patients	

Study	Trial Registration	Population Studied	Smoking History M(SD)
Schnoll 2010A ²⁷⁷	NCT00364156		
Schnoll 2010B ²⁷⁸			26.7 (12.9)
Schnoll 2015 ²⁷⁹	NCT01047527		28.8 (12.6)
Schnoll 2019 ²⁸⁰	NCT01756885	Smokers with cancer	40.4 (11.3)
Segnan 1991 ²⁸¹			
		Smokers who were unable to quit or relapsed after previously taking bupropion for at least 2 weeks, not quit for more than 24 hours in the previous month	
Selby 2003 ²⁸²			
SelmaBozkurtZincir 2013 ²⁸³			
Severson 2015 ²⁸⁴	NCT01341938	Smokeless tobacco users	15.2 (9.8)
Sharifirad 2012 ²⁸⁵	IRCT201011025074N1		20.64 (9.51)
Sharma 2018 ²⁸⁶	NCT01517022	Smokers with tuberculosis	
Sherman 2008 ²⁸⁷		Smokers in the Veterans Health Administration	45
Shiffman 2002 ²⁸⁸			
Shiffman 2009 ²⁸⁹			26.8 (12.4)
Siddiqi 2013 ²⁹⁰	ISRCTN08829879	Smokers with suspected tuberculosis	20.5 (12.3)
		Smokers who underwent noncardiac surgery and who were hospitalized for a minimum of 2 days	
Simon 1997 ²⁹¹			
Simon 2004 ²⁹²		Smokers who were mostly (79%) veterans	
Simon 2009 ²⁹³	NCT00261170	Hospitalised smokers	
Smith 2009 ²⁹⁴	NCT00296647	Smokers who were primary care patients	
SMK20001 ²⁹⁵			
Solomon 2000 ²⁹⁶		Female low-income smokers	
Solomon 2005 ²⁹⁷		Female low-income smokers	
Sonderskov 1997 ²⁹⁸			21.2 (10.9)
Stapleton 1995 ²⁹⁹			
Stapleton 2013 ³⁰⁰	ISRCTN91464711		
	NCT00790569	Methadone maintained opiate dependent smokers	23.3 (10.2)
Stein 2013 ³⁰¹			
Steinberg 2009 ³⁰²	NCT00770666	Medically ill smokers	
Steinberg 2011 ³⁰³		Hospitalised smokers	
Stockings 2014 ³⁰⁴	ACTRN1260900046525	Inpatient psychiatric patient smokers	
Sutherland 1992 ³⁰⁵			22.6 (10)
Sutton 1987 ³⁰⁶			
Sutton 1988 ³⁰⁷			
Swan 2003 ³⁰⁸			26.6 (11.9)
Swanson 2003 ³⁰⁹		Smokers who were active duty Navy sailors	10 (6.7)
		Smokers with stage I or stage II chronic obstructive pulmonary disease	
Tashkin 2001 ³¹⁰			
	NCT00285012	Smokers with mild to moderate chronic obstructive pulmonary disease	40.5
Tashkin 2011 ³¹¹			
		Female smokers patients scheduled for breast cancer surgery	
Thomsen 2010 ³¹²			
Tonnesen 1988 ³¹³			
Tonnesen 1988 ³¹⁴			
Tonnesen 1991 ³¹⁵			26.3
Tonnesen 1993 ³¹⁶			21 (11)

Study	Trial Registration	Population Studied	Smoking History M(SD)
Tonnesen 1999 ³¹⁷		Smokers who have made at least one prior quit attempt	
Tonnesen 2000 ³¹⁸			
Tonnesen 2003 ³¹⁹			
Tonnesen 2006 ³²⁰		Smokers with chronic obstructive pulmonary disease	
Tønnesen 2012 ³²¹	NCT00882375		
Tonstad 2003 ³²²		Smokers with stable cardiovascular disease	
Tonstad 2006 ³²³	NCT00143286	Smokers from medical clinics	28.2 (10.5)
Tromeur 2018 ³²⁴		Smokers hospitalized for chronic obstructive pulmonary disease exacerbation	
Tsai 2007 ³²⁵	NCT00141167	Asian smokers	21.2
Tsukahara 2010 ³²⁶			26.3 (11.2)
Tuisku 2016 ³²⁷	NCT01531049	Young adult smokers	6.4 (3)
Tulloch 2016 ³²⁸	NCT01623505		31 (11.7)
UniversityofMichigan 2011 ³²⁹	NCT00534404		
Urdapilleta-Herrera 2013 ³³⁰			
Uyar 2007 ³³¹			
Vial 2002 ³³²		Smokers who were inpatients	
Villa 1999 ³³³			18.3
Wagena 2005 ³³⁴		Smokers at risk for or with chronic obstructive pulmonary disease	
Wallstrom 2000 ³³⁵			26.5 (10.1)
Walsh 1999 ³³⁶		Smokeless tobacco users	
Wang 2009 ³³⁷	NCT00371813		20.1
Ward 2013 ³³⁸	NCT01085032	Smokers who were primary care patients	
Weaver 2015 ³³⁹		Smokers who were cancer survivors	
Wennike 2003 ³⁴⁰		Smokers wanting to reduce smoking who failed a quit attempt in the last 24 months	28 (9.5)
Westergaard 2015 ³⁴¹	NCT02233231	Young smokers with asthma	
Westman 1993 ³⁴²			22.6 (9)
Wewers 2000 ³⁴³		Smokers who were HIV positive	20 (8)
Wiggers 2006 ³⁴⁴		Smokers suffering from documented peripheral arterial disease or coronary artery disease	
Williams 2007 ³⁴⁵	NCT00143299		30.3
Williams 2012 ³⁴⁶	NCT00644969	Smokers with schizophrenia/schizoaffective disorder	24.3
Wilson 2008 ³⁴⁷		Smokers with chronic obstructive pulmonary disease	
Winhusen 2014 ³⁴⁸		Stimulant dependent smokers with substance use disorders	19.7 (9.9)
Wiratmoko 2013 ³⁴⁹			
Wittchen 2011 ³⁵⁰			
Wong 1999 ³⁵¹			24.5 (10.6)
Wong 2012 ³⁵²	NCT00937508; NCT01320462 NCT01320462	Smokers from preoperative clinics who will undergo surgery in 8 to 30 days	
Wong 2017 ³⁵³		Smokers in the preoperative clinics scheduled for elective ambulatory or inpatient surgery	
Yang 2016 ³⁵⁴		Male smokers with chronic obstructive pulmonary disease	

Study	Trial Registration	Population Studied	Smoking History M(SD)
Yuhongxia 2011 ³⁵⁵		Healthcare professionals (qualified practising physician or nurse)	
Zellweger 2005 ³⁵⁶			
Zelman 1992 ³⁵⁷			
Zernig 2008 ³⁵⁸	NCT00484692; EudraCT-Nr. 2005-006189-32		26.2 (11)
ZYB 30011 ³⁵⁹		Smokers with at least one cardiovascular risk factor	
ZYB40005 ³⁶⁰		Smokers who were not motivated to quit smoking	
ZYBAKIA402 ³⁶¹		Smokers with ≥2 previous attempts to stop smoking	

1. Abdullah AS, Hedley AJ, Chan SS, Lam TH. A randomized controlled trial of two different lengths of nicotine replacement therapy for smoking cessation. *Biomed Res Int.* 2013;2013(961751):961751.
2. Abelin T, Buehler A, Muller P, Vesananen K, Imhof PR. Controlled trial of transdermal nicotine patch in tobacco withdrawal. *Lancet.* 1989;1(8628):7-10.
3. Ahluwalia JS, McNagny SE, Clark WS. Smoking cessation among inner-city African Americans using the nicotine transdermal patch. *J Gen Intern Med.* 1998;13(1):1-8.
4. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, Mayo MS. Sustained-release bupropion for smoking cessation in African Americans: a randomized controlled trial. *JAMA.* 2002;288(4):468-74.
5. Ahluwalia JS, Okuyemi K, Nollen N, Choi WS, Kaur H, Pulvers K, et al. The effects of nicotine gum and counseling among African American light smokers: a 2 x 2 factorial design. *Addiction.* 2006;101(6):883-91.
6. Anderson CM, Cummins SE, Kohatsu ND, Gamst AC, Zhu SH. Incentives and Patches for Medicaid Smokers: An RCT. *Am J Prev Med.* 2018;55(6 Suppl 2):S138-S47.
7. Andrews JO, Mueller M, Dooley M, Newman SD, Magwood GS, Tinggen MS. Effect of a smoking cessation intervention for women in subsidized neighborhoods: A randomized controlled trial. *Prev Med.* 2016;90:170-6.
8. Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. *Ann Intern Med.* 2013;159(6):390-400.
9. Anthenelli RM, Benowitz NL, West R, St Aubin L, McRae T, Lawrence D, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. *Lancet.* 2016;387(10037):2507-20.
10. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. *Jama.* 1994;272(19):1497-505.
11. Areechon W, Punnotok J. Smoking Cessation through the Use of Nicotine Chewing Gum - a Double-Blind Trial in Thailand. *Clinical Therapeutics.* 1988;10(2):183-6.
12. Aryanpur M, Hosseini M, Masjedi MR, Mortaz E, Tabarsi P, Soori H, et al. A randomized controlled trial of smoking cessation methods in patients newly-diagnosed with pulmonary tuberculosis. *BMC Infect Dis.* 2016;16(369):369.
13. Aubin HJ, Leborgy F, Berlin I, Bidaut-Mazel C, Chemali-Hudry J, Lagrue G. Efficacy of bupropion and predictors of successful outcome in a sample of French smokers: a randomized placebo-controlled trial. *Addiction.* 2004;99(9):1206-18.
14. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB, Jr., Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. *Thorax.* 2008;63(8):717-24.
15. Baker A, Richmond R, Haile M, Lewin TJ, Carr VJ, Taylor RL, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. *American Journal of Psychiatry.* 2006;163(11):1934-42.
16. Baker TB, Piper ME, Stein JH, Smith SS, Bolt DM, Fraser DL, et al. Effects of Nicotine Patch vs Varenicline vs Combination Nicotine Replacement Therapy on Smoking Cessation at 26 Weeks: A Randomized Clinical Trial. *JAMA.* 2016;315(4):371-9.
17. Baldassarri SR, Bernstein SL, Chupp GL, Slade MD, Fucito LM, Toll BA. Electronic cigarettes for adults with tobacco dependence enrolled in a tobacco treatment program: A pilot study. *Addict Behav.* 2018;80:1-5.
18. Batra A, Klingler K, Landfeldt B, Friederich HM, Westin A, Danielsson T. Smoking reduction treatment with 4-mg nicotine gum: a double-blind, randomized, placebo-controlled study. *Clin Pharmacol Ther.* 2005;78(6):689-96.
19. Bernstein SL, D'Onofrio G, Rosner J, O'Malley S, Makuch R, Busch S, et al. Successful Tobacco Dependence Treatment in Low-Income Emergency Department Patients: A Randomized Trial. *Ann Emerg Med.* 2015;66(2):140-7.
20. Binnie VI, McHugh S, Jenkins W, Borland W, Macpherson LM. A randomised controlled trial of a smoking cessation intervention delivered by dental hygienists: a feasibility study. *BMC Oral Health.* 2007;7:5.
21. Bjurlin MA, Cohn MR, Kim DY, Freeman VL, Lombardo L, Hurley SD, et al. Brief smoking cessation intervention: a prospective trial in the urology setting. *J Urol.* 2013;189(5):1843-9.
22. Blondal T. Controlled trial of nicotine polacrilex gum with supportive measures. *Arch Intern Med.* 1989;149(8):1818-21.
23. Blondal T, Franzon M, Westin A. A double-blind randomized trial of nicotine nasal spray as an aid in smoking cessation. *Eur Respir J.* 1997;10(7):1585-90.
24. Blondal T, Gudmundsson LJ, Olafsdottir I, Gustavsson G, Westin A. Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up. *BMJ.* 1999;318(7179):285-8.
25. Bohadana A, Nilsson F, Rasmussen T, Martinet Y. Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial. *Arch Intern Med.* 2000;160(20):3128-34.
26. Bolliger CT, Zellweger JP, Danielsson T, van Biljon X, Robidou A, Westin A, et al. Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety. *BMJ.* 2000;321(7257):329-33.
27. Bolliger CT, van Biljon X, Axelsson A. A nicotine mouth spray for smoking cessation: a pilot study of preference, safety and efficacy. *Respiration.* 2007;74(2):196-201.
28. Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, et al. Effects of varenicline in adult smokers: a multinational, 24-week, randomized, double-blind, placebo-controlled study. *Clin Ther.* 2011;33(4):465-77.
29. Bonevski B, Twyman L, Paul C, D'Este C, West R, Siahpush M, et al. Smoking cessation intervention delivered by social service organisations for a diverse population of Australian disadvantaged smokers: A pragmatic randomised controlled trial. *Prev Med.* 2018;112:38-44.
30. Boyle R, Severson H, Lichtenstein E, et al. Smokeless tobacco cessation with nicotine reduction: A placebo controlled trial [abstract]. Paper presented at: 121st Annual Meeting Location: San Francisco, CA. 1992.
31. Brown RA, Niaura R, Lloyd-Richardson EE, Strong DR, Kahler CW, Abrantes AM, et al. Bupropion and cognitive-behavioral treatment for depression in smoking cessation. *Nicotine Tob Res.* 2007;9(7):721-30.
32. Buchkremer G, Bents H, Horstmann M, Opitz K, Tölle R. Combination of behavioral smoking cessation with transdermal nicotine substitution. *Addictive Behaviors.* 1989;14(2):229-38.

33. Buchkremer G, Minneker E. Efficiency of multimodal smoking cessation therapy combining transdermal nicotine substitution with behavioral therapy. *Methods and findings in experimental and clinical pharmacology*. 1989;11(3):215-8.
34. Bullen C, Howe C, Lin RB, Grigg M, Laugesen M, McRobbie H, et al. Pre-cessation nicotine replacement therapy: pragmatic randomized trial. *Addiction*. 2010;105(8):1474-83.
35. Bullen C, Howe C, Laugesen M, McRobbie H, Parag V, Williman J, et al. Electronic cigarettes for smoking cessation: A randomised controlled trial. *The Lancet*. 2013;382(9905):1629-37.
36. Burns EK, Hood NE, Goforth E, Levinson AH. Randomised trial of two nicotine patch protocols distributed through a state quitline. *Tob Control*. 2016;25(2):218-23.
37. Caldwell BO, Adamson SJ, Crane J. Combination rapid-acting nicotine mouth spray and nicotine patch therapy in smoking cessation. *Nicotine Tob Res*. 2014;16(10):1356-64.
38. Caldwell BO, Crane J. Combination Nicotine Metered Dose Inhaler and Nicotine Patch for Smoking Cessation: A Randomized Controlled Trial. *Nicotine Tob Res*. 2016;18(10):1944-51.
39. Caldwell AL, Tingen MS, Nguyen JT, Andrews JO, Heath J, Waller JL, et al. Parental Smoking Cessation: Impacting Children's Tobacco Smoke Exposure in the Home. *Pediatrics*. 2018;141(Suppl 1):S96-S106.
40. Campbell IA. Comparison of 4 Methods of Smoking Withdrawal in Patients with Smoking Related Diseases. *British Medical Journal*. 1983;286(6365):595-7.
41. Campbell IA, Lyons E, Prescott RJ. Stopping Smoking - Do Nicotine Chewing-Gum and Postal Encouragement Add to Doctors Advice. *Practitioner*. 1987;231(1423):114-7.
42. Campbell IA, Prescott RJ, Tjeder-Burton SM. Smoking cessation in hospital patients given repeated advice plus nicotine or placebo chewing gum. *Respir Med*. 1991;85(2):155-7.
43. Campbell IA, Prescott RJ, Tjeder-Burton SM. Transdermal nicotine plus support in patients attending hospital with smoking-related diseases: a placebo-controlled study. *Respir Med*. 1996;90(1):47-51.
44. Caponnetto P, Campagna D, Cibella F, Morjaria JB, Caruso M, Russo C, et al. Efficiency and Safety of an eElectronic cigarette (ECLAT) as tobacco cigarettes substitute: a prospective 12-month randomized control design study. *PLoS One*. 2013;8(6):e66317.
45. Carpenter MJ, Hughes JR, Gray KM, Wahlquist AE, Saladin ME, Alberg AJ. Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. *Arch Intern Med*. 2011;171(21):1901-7.
46. Carson KV, Smith BJ, Brinn MP, Peters MJ, Fitridge R, Koblar SA, et al. Safety of varenicline tartrate and counseling versus counseling alone for smoking cessation: a randomized controlled trial for inpatients (STOP study). *Nicotine Tob Res*. 2014;16(11):1495-502.
47. Chan SS, Leung DY, Abdullah AS, Wong VT, Hedley AJ, Lam TH. A randomized controlled trial of a smoking reduction plus nicotine replacement therapy intervention for smokers not willing to quit smoking. *Addiction*. 2011;106(6):1155-63.
48. Chengappa KN, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, Hetrick ML, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. *J Clin Psychiatry*. 2014;75(7):765-72.
49. Cinciripini PM, Cinciripini LG, Wallfisch A, Haque W, Van Vunakis H. Behavior therapy and the transdermal nicotine patch: effects on cessation outcome, affect, and coping. *J Consult Clin Psychol*. 1996;64(2):314-23.
50. Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace F, et al. Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawal. *JAMA Psychiatry*. 2013;70(5):522-33.
51. Cinciripini PM, Minnix JA, Green CE, Robinson JD, Engelmann JM, Versace F, et al. An RCT with the combination of varenicline and bupropion for smoking cessation: clinical implications for front line use. *Addiction*. 2018.
52. Clavel F, Benhamou S, Companyhuertas A, Flamant R. Helping People to Stop Smoking - Randomized Comparison of Groups Being Treated with Acupuncture and Nicotine Gum with Control-Group. *British Medical Journal*. 1985;291(6508):1538-9.
53. Clavelchapelon F, Paoletti C, Benhamou S. A Randomized 2x2 Factorial Design to Evaluate Different Smoking Cessation Methods. *Revue D Epidemiologie Et De Sante Publique*. 1992;40(3):187-90.
54. Collins BN, Wileyto EP, Patterson F, Rukstalis M, Audrain-McGovern J, Kaufmann V, et al. Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling. *Nicotine Tob Res*. 2004;6(1):27-37.
55. Cooney NL, Litt MD, Cooney JL, Pilkey DT, Steinberg HR, Oncken CA. Concurrent brief versus intensive smoking intervention during alcohol dependence treatment. *Psychol Addict Behav*. 2007;21(4):570-5.
56. Cooney NL, Cooney JL, Perry BL, Carbone M, Cohen EH, Steinberg HR, et al. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. *Addiction*. 2009;104(9):1588-96.
57. Cooper TV, Klesges RC, Debon MW, Zbikowski SM, Johnson KC, Clemens LH. A placebo controlled randomized trial of the effects of phenylpropanolamine and nicotine gum on cessation rates and postcessation weight gain in women. *Addict Behav*. 2005;30(1):61-75.
58. Cooperman NA, Lu SE, Richter KP, Bernstein SL, Williams JM. Pilot Study of a Tailored Smoking Cessation Intervention for Individuals in Treatment for Opioid Dependence. *Nicotine Tob Res*. 2018;20(9):1152-6.
59. Covey LS, Glassman AH, Jiang H, Fried J, Masmela J, LoDuca C, et al. A randomized trial of bupropion and/or nicotine gum as maintenance treatment for preventing smoking relapse. *Addiction*. 2007;102(8):1292-302.
60. Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, et al. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. *J Natl Cancer Inst*. 2012;104(4):290-8.
61. Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, et al. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multicenter trial in a nonspecialized setting. *Nicotine Tob Res*. 2003;5(2):181-7.
62. Cropsey KL, Clark CB, Zhang X, Hendricks PS, Jardin BF, Lahti AC. Race and Medication Adherence Moderate Cessation Outcomes in Criminal Justice Smokers. *Am J Prev Med*. 2015;49(3):335-44.
63. Cummings KM, Hyland A, Carlin-Menter S, Mahoney MC, Willett J, Juster HR. Costs of giving out free nicotine patches through a telephone quit line. *J Public Health Manag Pract*. 2011;17(3):E16-23.
64. Cummins SE, Gamst AC, Brandstein K, Seymann GB, Klonoff-Cohen H, Kirby CA, et al. Helping Hospitalized Smokers: A Factorial RCT of Nicotine Patches and Counseling. *Am J Prev Med*. 2016;51(4):578-86.
65. Cunningham JA, Kushnir V, Selby P, Tyndale RF, Zawertailo L, Leatherdale ST. Effect of Mailing Nicotine Patches on Tobacco Cessation Among Adult Smokers: A Randomized Clinical Trial. *JAMA Intern Med*. 2016;176(2):184-90.
66. Dale LC, Hurt RD, Offord KP, Lawson GM, Croghan IT, Schroeder DR. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. *JAMA*. 1995;274(17):1353-8.
67. Dale LC, Ebbert JO, Schroeder DR, Croghan IT, Rasmussen DF, Trautman JA, et al. Bupropion for the treatment of nicotine dependence in spit tobacco users: a pilot study. *Nicotine Tob Res*. 2002;4(3):267-74.
68. Dale LC, Ebbert JO, Glover ED, Croghan IT, Schroeder DR, Severson HH, et al. Bupropion SR for the treatment of smokeless tobacco use. *Drug Alcohol Depend*. 2007;90(1):56-63.
69. Dalsgareth OJ, Hansen NC, Soes-Petersen U, Evald T, Hoegholm A, Barber J, et al. A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees. *Nicotine Tob Res*. 2004;6(1):55-61.
70. Doughton DM, Heatley SA, Prendergast JJ, Causey D, Knowles M, Rolf CN, et al. Effect of Transdermal Nicotine Delivery as an Adjunct to Low-Intervention Smoking Cessation Therapy - a Randomized, Placebo-Controlled, Double-Blind-Study. *Archives of Internal Medicine*. 1991;151(4):749-52.
71. Doughton D, Susman J, Sitorius M, Belenky S, Millatmal T, Nowak R, et al. Transdermal nicotine therapy and primary care. Importance of counseling, demographic, and participant selection factors on 1-year quit rates. The Nebraska Primary Practice Smoking Cessation Trial Group. *Arch Fam Med*. 1998;7(5):425-30.
72. Doughton DM, Fortmann SP, Glover ED, Hatsukami DK, Heatley SA, Lichtenstein E, et al. The smoking cessation efficacy of varying doses of nicotine patch delivery systems 4 to 5 years post-quit day. *Prev Med*. 1999;28(2):113-8.
73. Dautzenberg B, Ruff F, Vaucher M, Maillon P, Jacob N, Kienzler JL, et al. First demonstration of the good efficacy/safety ratio of Nicotinell® 1mg Lozenge (NL 1mg), a new form of nicotine substitution, by randomised clinical trial. *European Respiratory Journal*. 2001;18 Suppl 33:12s.
74. Davidson M, Epstein M, Burt R, Schaefer C, Whitworth G, McDonald A. Efficacy and safety of an over-the-counter transdermal nicotine patch as an aid for smoking cessation. *Archives of Family Medicine*. 1998;7(6):569-74.
75. de Dios MA, Anderson BJ, Stanton C, Audet DA, Stein M. Project Impact: a pharmacotherapy pilot trial investigating the abstinence and treatment adherence of Latino light smokers. *J Subst Abuse Treat*. 2012;43(3):322-30.
76. Dogar O, Zahid R, Mansoor S, Kanaan M, Ahluwalia JS, Jawad M, et al. Varenicline versus placebo for waterpipe smoking cessation: a double-blind randomized controlled trial. *Addiction*. 2018;113(12):2290-9.
77. Ebbert JO, Dale LC, Patten CA, Croghan IT, Schroeder DR, Moyer TP, et al. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. *Nicotine Tob Res*. 2007;9(1):43-52.

78. Ebbert JO, Severson HH, Croghan IT, Danaher BG, Schroeder DR. A randomized clinical trial of nicotine lozenge for smokeless tobacco use. *Nicotine Tob Res.* 2009;11(12):1415-23.
79. Ebbert JO, Severson HH, Croghan IT, Danaher BG, Schroeder DR. A pilot study of mailed nicotine lozenges with assisted self-help for the treatment of smokeless tobacco users. *Addict Behav.* 2010;35(5):522-5.
80. Ebbert JO, Croghan IT, Severson HH, Schroeder DR, Hays JT. A pilot study of the efficacy of varenicline for the treatment of smokeless tobacco users in Midwestern United States. *Nicotine Tob Res.* 2011;13(9):820-6.
81. Ebbert JO, Croghan IT, Schroeder DR, Hurt RD. A randomized phase II clinical trial of high-dose nicotine patch therapy for smokeless tobacco users. *Nicotine Tob Res.* 2013;15(12):2037-44.
82. Ebbert JO, Hatsukami DK, Croghan IT, Schroeder DR, Allen SS, Hays JT, et al. Combination varenicline and bupropion SR for tobacco-dependence treatment in cigarette smokers: a randomized trial. *JAMA.* 2014;311(2):155-63.
83. Ebbert JO, Hughes JR, West RJ, Rennard SI, Russ C, McRae TD, et al. Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. *JAMA.* 2015;313(7):687-94.
84. Ebbert J, Croghan I, Hurt R, Schroeder D, Hays J. Varenicline for smoking cessation in light smokers 2017; 18(10):[2031-5 pp.]. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/1471-2575.tl100001>
85. Ehrensam RE, Buhler A, Muller P, Mauli D, Schumacher PM, Howald H, et al. [Weaning of young smokers using a transdermal nicotine patch]. *Schweiz Rundsch Med Prax.* 1991;80(7):145-50.
86. Eisenberg MJ, Grandi SM, Gervais A, O'Loughlin J, Paradis G, Rinfret S, et al. Bupropion for smoking cessation in patients hospitalized with acute myocardial infarction: a randomized, placebo-controlled trial. *J Am Coll Cardiol.* 2013;61(5):524-32.
87. Eisenberg MJ, Windle SB, Roy N, Old W, Grondin FR, Bata I, et al. Varenicline for Smoking Cessation in Hospitalized Patients With Acute Coronary Syndrome. *Circulation.* 2016;133(1):21-30.
88. Ellerbeck EF, Nollen N, Hutcheson TD, Phadnis M, Fitzgerald SA, Vacek J, et al. Effect of Long-term Nicotine Replacement Therapy vs Standard Smoking Cessation for Smokers With Chronic Lung Disease: A Randomized Clinical Trial. *JAMA Netw Open.* 2018;1(5):e181843.
89. Etter JF, Laszlo E, Zellweger JP, Perrot C, Perneger TV. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. *J Clin Psychopharmacol.* 2002;22(5):487-95.
90. Etter JF, Huguelet P, Perneger TV, Cornuz J. Nicotine Gum Treatment Before Smoking Cessation A Randomized Trial. *Archives of Internal Medicine.* 2009;169(11):1028-34.
91. Evins AE, Mays VK, Rigotti NA, Tisdale T, Cather C, Goff DC. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. *Nicotine Tob Res.* 2001;3(4):397-403.
92. Evins AE, Cather C, Deckersbach T, Freudenreich O, Culhane MA, Olm-Shipman CM, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. *J Clin Psychopharmacol.* 2005;25(3):218-25.
93. Evins AE, Cather C, Culhane MA, Birnbaum A, Horowitz J, Hsieh E, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. *J Clin Psychopharmacol.* 2007;27(4):380-6.
94. Evins AE, Cather C, Pratt SA, Pachas GN, Hoepfner SS, Goff DC, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. *JAMA.* 2014;311(2):145-54.
95. Fagerstrom KO. A comparison of psychological and pharmacological treatment in smoking cessation. *J Behav Med.* 1982;5(3):343-51.
96. Fagerstrom KO. Effects of nicotine chewing gum and follow-up appointments in physician-based smoking cessation. *Prev Med.* 1984;13(5):517-27.
97. Fagerstrom K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping smokeless tobacco with varenicline: randomised double blind placebo controlled trial. *BMJ.* 2010;341:c6549.
98. Fee WM, Stewart MJ. A controlled trial of nicotine chewing gum in a smoking withdrawal clinic. *Practitioner.* 1982;226(1363):148-51.
99. Fernandez Arias IG, Garcia-Vera MP, Sanz J. The more psychology, the better: The efficacy of smoking cessation treatment using intensive cognitive-behavioral therapy versus a combination of nicotine patches plus intensive or less intensive cognitive-behavioral therapy: First prize of the 20th "Rafael Burgaleta" Applied Psychology Awards 2013. *Clinica y Salud.* 2014;25(1):1-10.
100. Ferry LH, Robbins AS, Scariati PD, Masterson A, Abbey DE, Burchette RJ. Enhancement of smoking cessation using the antidepressant bupropion hydrochloride [abstract 2670]. *Circulation.* 1992;86(4 Suppl 1):I-671.
101. Ferry LH, Burchette RJ. Efficacy of Bupropion for Smoking Cessation in Non Depressed Smokers. *Journal of Addictive Diseases.* 1994;13(4):249-.
102. Fiore MC, Kenford SL, Jorenby DE, Wetter DW, Smith SS, Baker TB. Two studies of the clinical effectiveness of the nicotine patch with different counseling treatments. *Chest.* 1994;105(2):524-33.
103. Fiore MC, McCarthy DE, Jackson TC, Zehner ME, Jorenby DE, Mielke M, et al. Integrating smoking cessation treatment into primary care: an effectiveness study. *Prev Med.* 2004;38(4):412-20.
104. Fortmann SP, Killen JD. Nicotine Gum and Self-Help Behavioral Treatment for Smoking Relapse Prevention - Results from a Trial Using Population-Based Recruitment. *Journal of Consulting and Clinical Psychology.* 1995;63(3):460-8.
105. Fossati R, Apolone G, Negri E, Compagnoni A, La Vecchia C, Mangano S, et al. A double-blind, placebo-controlled, randomized trial of bupropion for smoking cessation in primary care. *Arch Intern Med.* 2007;167(16):1791-7.
106. Fouz-Roson N, Montemayor-Rubio T, Almadana-Pacheco V, Montserrat-Garcia S, Gomez-Bastero AP, Romero-Munoz C, et al. Effect of 0.5 mg versus 1 mg varenicline for smoking cessation: a randomized controlled trial. *Addiction.* 2017;112(9):1610-9.
107. Gallagher SM, Penn PE, Schindler E, Layne W. A comparison of smoking cessation treatments for persons with schizophrenia and other serious mental illnesses. *J Psychoactive Drugs.* 2007;39(4):487-97.
108. Gariti P, Lynch K, Alterman A, Kampman K, Xie H, Varillo K. Comparing smoking treatment programs for lighter smokers with and without a history of heavier smoking. *J Subst Abuse Treat.* 2009;37(3):247-55.
109. Garvey AJ, Kinnunen T, Nordstrom BL, Utman CH, Doherty K, Rosner B, et al. Effects of nicotine gum dose by level of nicotine dependence. *Nicotine Tob Res.* 2000;2(1):53-63.
110. George TP, Vessicchio JC, Termine A, Bregartner TA, Feingold A, Rounsaville BJ, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. *Biol Psychiatry.* 2002;52(1):53-61.
111. George TP, Vessicchio JC, Sacco KA, Weinberger AH, Dudas MM, Allen TM, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. *Biol Psychiatry.* 2008;63(11):1092-6.
112. Gifford EV, Kohlenberg BS, Hayes SC, Antonuccio DO, Piasecki MM, Rasmussen-Hall ML, et al. Acceptance-based treatment for smoking cessation. *Behavior Therapy.* 2004;35(4):689-705.
113. Gilbert JR, Wilson DM, Best JA, Taylor DW, Lindsay EA, Singer J, et al. Smoking cessation in primary care. A randomized controlled trial of nicotine-bearing chewing gum. *J Fam Pract.* 1989;28(1):49-55.
114. Ginsberg D, Hall SM, Rosinski M. Partner support, psychological treatment, and nicotine gum in smoking treatment: an incremental study. *Int J Addict.* 1992;27(5):503-14.
115. Glavas D, Rumboldt M, Rumboldt Z. Smoking cessation with nicotine replacement therapy among health care workers: Randomized double-blind study. *Croatian Medical Journal.* 2003;44(2):219-24.
116. Glavas D, Rumboldt Z. [Smoking cessation using the transdermal nicotine system]. *Lijec Vjesn.* 2003;125(1-2):8-12.
117. GlaxoSmithKline. Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation. <https://ClinicalTrials.gov/show/NCT00985985>; 2009.
118. Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CC, Howell RM, et al. A comparison of a nicotine sublingual tablet and placebo for smoking cessation. *Nicotine Tob Res.* 2002;4(4):441-50.
119. Goldstein MG, Niaura R, Follick MJ, Abrams DB. Effects of behavioral skills training and schedule of nicotine gum administration on smoking cessation. *Am J Psychiatry.* 1989;146(1):56-60.
120. Gonzales DH, Nides MA, Ferry LH, Kustra RP, Jamerson BD, Segall N, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. *Clin Pharmacol Ther.* 2001;69(6):438-44.
121. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. *JAMA.* 2006;296(1):47-55.
122. Gonzales D, Hajek P, Pliamm L, Nackaerts K, Tseng LJ, McRae TD, et al. Retreatment with varenicline for smoking cessation in smokers who have previously taken varenicline: a randomized, placebo-controlled trial. *Clin Pharmacol Ther.* 2014;96(3):390-6.
123. Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J. [Effect of treatment for nicotine dependence in patients with COPD]. *Pneumonol Alergol Pol.* 2003;71(9-10):411-7.

124. Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ. Double blind trial of repeated treatment with transdermal nicotine for relapsed smokers. *BMJ*. 1995;311(7001):363-6.
125. Graham AL, Papandonatos GD, Cha S, Erar B, Amato MS, Cobb NK, et al. Improving Adherence to Smoking Cessation Treatment: Intervention Effects in a Web-Based Randomized Trial. *Nicotine Tob Res*. 2017;19(3):324-32.
126. Grant KM, Kelley SS, Smith LM, Agrawal S, Meyer JR, Romberger DJ. Bupropion and nicotine patch as smoking cessation aids in alcoholics. *Alcohol*. 2007;41(5):381-91.
127. Gross J, Johnson J, Sigler L, Stitzer ML. Dose effects of nicotine gum. *Addict Behav*. 1995;20(3):371-81.
128. Haas JS, Linder JA, Park ER, Gonzalez I, Rigotti NA, Klinger EV, et al. Proactive tobacco cessation outreach to smokers of low socioeconomic status: a randomized clinical trial. *JAMA Intern Med*. 2015;175(2):218-26.
129. Haggstram FM, Chatkin JM, Sussenbach-Vaz E, Cesari DH, Fam CF, Fritscher CC. A controlled trial of nortriptyline, sustained-release bupropion and placebo for smoking cessation: preliminary results. *Pulm Pharmacol Ther*. 2006;19(3):205-9.
130. Hajek P, Phillips-Waller A, Przulj D, Pesola F, Myers Smith K, Bisal N, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. *N Engl J Med*. 2019;380(7):629-37.
131. Hall SM, Tunstall C, Rugg D, Jones RT, Benowitz N. Nicotine gum and behavioral treatment in smoking cessation. *J Consult Clin Psychol*. 1985;53(2):256-8.
132. Hall SM, Tunstall CD, Ginsberg D, Benowitz NL, Jones RT. Nicotine gum and behavioral treatment: a placebo controlled trial. *J Consult Clin Psychol*. 1987;55(4):603-5.
133. Hall SM, Munoz RF, Reus VI, Sees KL, Duncan C, Humfleet GL, et al. Mood management and nicotine gum in smoking treatment: a therapeutic contact and placebo-controlled study. *J Consult Clin Psychol*. 1996;64(5):1003-9.
134. Hall SM, Humfleet GL, Reus VI, Munoz RF, Hartz DT, Maude-Griffin R. Psychological intervention and antidepressant treatment in smoking cessation. *Arch Gen Psychiatry*. 2002;59(10):930-6.
135. Hall SM, Tsoh JY, Prochaska JJ, Eisendrath S, Rossi JS, Redding CA, et al. Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. *Am J Public Health*. 2006;96(10):1808-14.
136. Hall SM, Humfleet GL, Munoz RF, Reus VI, Robbins JA, Prochaska JJ. Extended treatment of older cigarette smokers. *Addiction*. 2009;104(6):1043-52.
137. Hall SM, Humfleet GL, Munoz RF, Reus VI, Prochaska JJ, Robbins JA. Using extended cognitive behavioral treatment and medication to treat dependent smokers. *Am J Public Health*. 2011;101(12):2349-56.
138. Halpern SD, Harhay MO, Saulsgiver K, Brophy C, Troxel AB, Volpp KG. A Pragmatic Trial of E-Cigarettes, Incentives, and Drugs for Smoking Cessation. *N Engl J Med*. 2018;378(24):2302-10.
139. Hand S, Edwards S, Campbell IA, Cannings R. Controlled trial of three weeks nicotine replacement treatment in hospital patients also given advice and support. *Thorax*. 2002;57(8):715-8.
140. Hanioka T, Ojima M, Tanaka H, Naito M, Hamajima N, Matsuse R. Intensive smoking-cessation intervention in the dental setting. *J Dent Res*. 2010;89(1):66-70.
141. Harackiewicz JM, Blair LW, Sansone C, Epstein JA, Stuchell RN. Nicotine gum and self-help manuals in smoking cessation: an evaluation in a medical context. *Addict Behav*. 1988;13(4):319-30.
142. Hatsukami D, Jensen J, Allen S, Grillo M, Bliss R. Effects of behavioral and pharmacological treatment on smokeless tobacco users. *J Consult Clin Psychol*. 1996;64(1):153-61.
143. Hatsukami DK, Grillo M, Boyle R, Allen S, Jensen J, Bliss R, et al. Treatment of spit tobacco users with transdermal nicotine system and mint snuff. *J Consult Clin Psychol*. 2000;68(2):241-9.
144. Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA, et al. Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking. *Am J Med*. 2004;116(3):151-7.
145. Hays JT, Croghan IT, Schroeder DR, Offord KP, Hurt RD, Wolter TD, et al. Over-the-counter nicotine patch therapy for smoking cessation: results from randomized, double-blind, placebo-controlled, and open label trials. *Am J Public Health*. 1999;89(11):1701-7.
146. Hays JT, Hurt RD, Rigotti NA, Niaura R, Gonzales D, Durcan MJ, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial. *Ann Intern Med*. 2001;135(6):423-33.
147. Hays JT, Hurt RD, Decker PA, Croghan IT, Offord KP, Patten CA. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. *Nicotine Tob Res*. 2009;11(7):859-67.
148. Herrera N, Franco R, Herrera L, Partidas A, Rolando R, Fagerstrom KO. Nicotine gum, 2 and 4 mg, for nicotine dependence. A double-blind placebo-controlled trial within a behavior modification support program. *Chest*. 1995;108(2):447-51.
149. Hertzberg MA, Moore SD, Feldman ME, Beckham JC. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder. *J Clin Psychopharmacol*. 2001;21(1):94-8.
150. Heydari G, Talischi F, Tafti SF, Masjedi MR. Quitting smoking with varenicline: parallel, randomised efficacy trial in Iran. *Int J Tuberc Lung Dis*. 2012;16(2):268-72.
151. Heydari G, Talischi F, Batmanghelidj E, Pajoo M, Boroomand A, Zamani M, et al. Dual addictions, parallel treatments: Nicotine replacement therapy for patients receiving methadone treatment in the Islamic Republic of Iran 2013. Available from: <http://onlinelibrary.wiley.com/doi/10.1111/cla.12288>.
152. Hilberink SR, Jacobs JE, Breteler MH, de Vries H, Grol RP. General practice counseling for patients with chronic obstructive pulmonary disease to quit smoking: impact after 1 year of two complex interventions. *Patient Educ Couns*. 2011;83(1):120-4.
153. Hilleman DE, Mohiuddin SM, Delcore MG. Comparison of fixed-dose transdermal nicotine, tapered-dose transdermal nicotine, and buspirone in smoking cessation. *J Clin Pharmacol*. 1994;34(3):222-4.
154. Hjalmarson AI. Effect of nicotine chewing gum in smoking cessation. A randomized, placebo-controlled, double-blind study. *JAMA*. 1984;252(20):2835-8.
155. Hjalmarson A, Franzon M, Westin A, Wiklund O. Effect of nicotine nasal spray on smoking cessation. A randomized, placebo-controlled, double-blind study. *Arch Intern Med*. 1994;154(22):2567-72.
156. Hjalmarson A, Nilsson F, Sjostrom L, Wiklund O. The nicotine inhaler in smoking cessation. *Arch Intern Med*. 1997;157(15):1721-8.
157. Hollis JF, McAfee TA, Fellows JL, Zbikowski SM, Stark M, Riedlinger K. The effectiveness and cost effectiveness of telephone counselling and the nicotine patch in a state tobacco quitline. *Tob Control*. 2007;16 Suppl 1(SUPPL. 1):i53-9.
158. Holt S, Timu-Parata C, Ryder-Lewis S, Weatherall M, Beasley R. Efficacy of bupropion in the indigenous Maori population in New Zealand. *Thorax*. 2005;60(2):120-3.
159. Dale Horst W, Klein MW, Williams D, Werder SF. Extended use of nicotine replacement therapy to maintain smoking cessation in persons with schizophrenia. *Neuropsychiatr Dis Treat*. 2005;1(4):349-55.
160. Howard-Pitney B, Killen JD, Fortmann SP. Quitting chew: results from a randomized trial using nicotine patches. *Exp Clin Psychopharmacol*. 1999;7(4):362-71.
161. Huber D. Combined and separate treatment effects of nicotine chewing gum and self-control method. *Pharmacopsychiatry*. 1988;21(6):461-2.
162. Hughes JR, Gust SW, Keenan RM, Fenwick JW, Healey ML. Nicotine vs placebo gum in general medical practice. *JAMA*. 1989;261(9):1300-5.
163. Hughes JR, Gust SW, Keenan RM, Fenwick JW. Effect of Dose on Nicotines Reinforcing, Withdrawal-Suppression and Self-Reported Effects. *Journal of Pharmacology and Experimental Therapeutics*. 1990;252(3):1175-83.
164. Hughes JR, Lesmes GR, Hatsukami DK, Richmond RL, Lichtenstein E, Jorenby DE, et al. Are higher doses of nicotine replacement more effective for smoking cessation? *Nicotine Tob Res*. 1999;1(2):169-74.
165. Hughes JR, Novy P, Hatsukami DK, Jensen J, Callas PW. Efficacy of nicotine patch in smokers with a history of alcoholism. *Alcohol Clin Exp Res*. 2003;27(6):946-54.
166. Hughes JR, Solomon LJ, Livingston AE, Callas PW, Peters EN. A randomized, controlled trial of NRT-aided gradual vs. abrupt cessation in smokers actively trying to quit. *Drug Alcohol Depend*. 2010;111(1-2):105-13.
167. Hughes JR, Rennard SI, Fingar JR, Talbot SK, Callas PW, Fagerstrom KO. Efficacy of varenicline to prompt quit attempts in smokers not currently trying to quit: a randomized placebo-controlled trial. *Nicotine Tob Res*. 2011;13(10):955-64.
168. Hurt RD, Lauger GG, Offord KP, Kottke TE, Dale LC. Nicotine-Replacement Therapy with Use of a Transdermal Nicotine Patch - a Randomized Double-Blind Placebo-Controlled Trial. *Mayo Clinic Proceedings*. 1990;65(12):1529-37.
169. Hurt RD, Dale LC, Fredrickson PA, Caldwell CC, Lee GA, Offord KP, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. *JAMA*. 1994;271(8):595-600.
170. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. *N Engl J Med*. 1997;337(17):1195-202.
171. Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, et al. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. *J Clin Oncol*. 2003;21(5):914-20.
172. Hurt RT, Ebbert JO, Croghan IT, Schroeder DR, Hurt RD, Hays JT. Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial. *Drug Alcohol Depend*. 2018;184:12-7.

173. Randomised trial of nicotine patches in general practice: results at one year. Imperial Cancer Research Fund General Practice Research Group. *BMJ*. 1994;308(6942):1476-7.
174. Ikonomidis I, Marinou M, Vlastos D, Kourea K, Andreadou I, Liarakos N, et al. Effects of varenicline and nicotine replacement therapy on arterial elasticity, endothelial glycocalyx and oxidative stress during a 3-month smoking cessation program. *Atherosclerosis*. 2017;262:123-30.
175. Jamrozik K, Fowler G, Vessey M, Wald N. Placebo controlled trial of nicotine chewing gum in general practice. *Br Med J (Clin Res Ed)*. 1984;289(6448):794-7.
176. Jarvis MJ, Raw M, Russell MAH, Feyerabend C. Randomized Controlled Trial of Nicotine Chewing-Gum. *British Medical Journal*. 1982;285(6341):537-40.
177. Jensen EJ, Schmidt E, Pedersen B, Dahl R. The effect of nicotine, silver acetate, and placebo chewing gum on the cessation of smoking. The influence of smoking type and nicotine dependence. *Int J Addict*. 1991;26(11):1223-31.
178. Johns DA. Randomised controlled trial comparing nicotine replacement therapy (NRT) plus brief counselling and brief counselling alone on smoking cessation in patients prone to lung cancer using a breath carbon monoxide (CO) monitor. *Annals of Oncology*. 2016;27:ix177.
179. Johns D. Randomised controlled trial comparing nicotine replacement therapy (nrt) and counselling on smoking cessation in patients prone to lung cancer using bed font micro-smokerlyzer. *Support Care Cancer*. 2017;25 (2 Supplement 1):21-266.
180. Johns D. Randomised controlled trial comparing varenicline plus counselling and brief counselling alone on smoking cessation in patients prone to lung cancer using carbon monoxide monitor. *Support Care Cancer*. 2017;25 (2 Supplement 1):21-266.
181. Jorenby DE, Smith SS, Fiore MC, Hurt RD, Offord KP, Croghan IT, et al. Varying nicotine patch dose and type of smoking cessation counseling. *JAMA*. 1995;274(17):1347-52.
182. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. *N Engl J Med*. 1999;340(9):685-91.
183. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. *JAMA*. 2006;296(1):56-63.
184. Joseph AM, Norman SM, Ferry LH, Prochazka AV, Westman EC, Steele BG, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. *N Engl J Med*. 1996;335(24):1792-8.
185. Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. *J Stud Alcohol*. 2004;65(6):681-91.
186. Joseph AM, Fu SS, Lindgren B, Rothman AJ, Kodl M, Lando H, et al. Chronic disease management for tobacco dependence: a randomized, controlled trial. *Arch Intern Med*. 2011;171(21):1894-900.
187. Joyce GF, Niaura R, Maglione M, Mongoven J, Larson-Rotter C, Coan J, et al. The effectiveness of covering smoking cessation services for medicare beneficiaries. *Health Serv Res*. 2008;43(6):2106-23.
188. Kalman D, Kahler CW, Garvey AJ, Monti PM. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes. *J Subst Abuse Treat*. 2006;30(3):213-7.
189. Kalman D, Herz L, Monti P, Kahler CW, Mooney M, Rodrigues S, et al. Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. *Drug Alcohol Depend*. 2011;118(2-3):111-8.
190. Killen JD, Maccoby N, Taylor CB. Nicotine Gum and Self-Regulation Training in Smoking Relapse Prevention. *Behavior Therapy*. 1984;15(3):234-48.
191. Killen JD, Fortmann SP, Newman B, Varady A. Evaluation of a treatment approach combining nicotine gum with self-guided behavioral treatments for smoking relapse prevention. *J Consult Clin Psychol*. 1990;58(1):85-92.
192. Killen JD, Fortmann SP, Davis L, Varady A. Nicotine patch and self-help video for cigarette smoking cessation. *J Consult Clin Psychol*. 1997;65(4):663-72.
193. Killen JD, Fortmann SP, Davis L, Strausberg L, Varady A. Do heavy smokers benefit from higher dose nicotine patch therapy? *Experimental and Clinical Psychopharmacology*. 1999;7(3):226-33.
194. Killen JD, Fortmann SP, Murphy GM, Jr., Hayward C, Arredondo C, Crompton D, et al. Extended treatment with bupropion SR for cigarette smoking cessation. *J Consult Clin Psychol*. 2006;74(2):286-94.
195. Klesges RC, Ebbert JO, Talcott GW, Thomas F, Richey PA, Womack C, et al. Efficacy of a Tobacco Quitline in Active Duty Military and TRICARE Beneficiaries: A Randomized Trial. *Mil Med*. 2015;180(8):917-25.
196. Koegelenberg CF, Noor F, Bateman ED, van Zyl-Smit RN, Bruning A, O'Brien JA, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. *JAMA*. 2014;312(2):155-61.
197. Kornitzer M, Kittel F, Dramaix M, Bourdoux P. A Double-Blind-Study of 2 Mg Versus 4 Mg Nicotine-Gum in an Industrial-Setting. *Journal of Psychosomatic Research*. 1987;31(2):171-6.
198. Kornitzer M, Boutsen M, Dramaix M, Thijs J, Gustavsson G. Combined use of nicotine patch and gum in smoking cessation: a placebo-controlled clinical trial. *Prev Med*. 1995;24(1):41-7.
199. Kralikova E, Kozak J, Rasmussen T, Cort N. The clinical benefits of NRT-supported smoking reduction. *Nicotine Tob Res*. 2002;4(243):20.
200. Krupski L, Cummings KM, Hyland A, Mahoney MC, Toll BA, Carpenter MJ, et al. Cost and Effectiveness of Combination Nicotine Replacement Therapy Among Heavy Smokers Contacting a Quitline. *Journal of Smoking Cessation*. 2016;11(1):50-9.
201. Lee SM, Landry J, Jones PM, Buhrmann O, Morley-Forster P. The effectiveness of a perioperative smoking cessation program: a randomized clinical trial. *Anesth Analg*. 2013;117(3):605-13.
202. Lee SM, Tenney R, Wallace AW, Arjomandi M. E-cigarettes versus nicotine patches for perioperative smoking cessation: a pilot randomized trial. *PeerJ*. 2018;6:e5609.
203. Leischow SJ, Nilsson F, Franzon M, Hill A, Otte P, Merikle EP. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. *American Journal of Health Behavior*. 1996;20(5):364-71.
204. Leischow SJ, Muramoto ML, Cook GN, Merikle EP, Castellini SM, Otte PS. OTC nicotine patch: Effectiveness alone and with brief physician intervention. *American Journal of Health Behavior*. 1999;23(1):61-9.
205. Leischow SJ, Ranger-Moore J, Muramoto ML, Matthews E. Effectiveness of the nicotine inhaler for smoking cessation in an OTC setting. *Am J Health Behav*. 2004;28(4):291-301.
206. Lerman C, Kaufmann V, Rukstalis M, Patterson F, Perkins K, Audrain-McGovern J, et al. Individualizing nicotine replacement therapy for the treatment of tobacco dependence: a randomized trial. *Ann Intern Med*. 2004;140(6):426-33.
207. Lerman C, Schnoll RA, Hawk LW, Jr., Cinciripini P, George TP, Wileyto EP, et al. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. *Lancet Respir Med*. 2015;3(2):131-8.
208. Levine MD, Perkins KA, Kalarchian MA, Cheng Y, Houck PR, Slane JD, et al. Bupropion and cognitive behavioral therapy for weight-concerned women smokers. *Arch Intern Med*. 2010;170(6):543-50.
209. Lewis SF, Piasecki TM, Fiore MC, Anderson JE, Baker TB. Transdermal nicotine replacement for hospitalized patients: a randomized clinical trial. *Prev Med*. 1998;27(2):296-303.
210. Littlewood RA, Claus ED, Wilcox CE, Mickey J, Arenella PB, Bryan AD, et al. Moderators of smoking cessation outcomes in a randomized-controlled trial of varenicline versus placebo. *Psychopharmacology (Berl)*. 2017;234(23-24):3417-29.
211. Llivina TS, Tuya DM, Quintana JG, Torres CI, Barrera EC, Saez CM, et al. Smoking Cessation - Effectiveness of Nicotine Containing Chewing Gum - a Double-Blind Trial. *Medicina Clinica*. 1988;90(16):646-50.
212. Lloyd-Richardson EE, Stanton CA, Papandonatos GD, Shadel WG, Stein M, Tashima K, et al. Motivation and patch treatment for HIV+ smokers: a randomized controlled trial. *Addiction*. 2009;104(11):1891-900.
213. Malcolm RE, Sillett RW, Turner JA, Ball KP. The use of nicotine chewing gum as an aid to stopping smoking. *Psychopharmacology (Berl)*. 1980;70(3):295-6.
214. Martin JE, Calfas KJ, Patten CA, Polarek M, Hofstetter CR, Noto J, et al. Prospective evaluation of three smoking interventions in 205 recovering alcoholics: one-year results of Project SCRAP-Tobacco. *J Consult Clin Psychol*. 1997;65(1):190-4.
215. McAfee TA, Bush T, Deprey TM, Mahoney LD, Zbikowski SM, Fellows JL, et al. Nicotine patches and uninsured quitline callers: a randomized trial of two versus eight weeks (Provisional abstract)2008; 35(2):[103-10 pp.]. Available from: <http://onlinelibrary.wiley.com/doi/10.1002/14651914.cochrane.cd008101/frame.html>.
216. McCarthy DE, Piasecki TM, Lawrence DL, Jorenby DE, Shiffman S, Fiore MC, et al. A randomized controlled clinical trial of bupropion SR and individual smoking cessation counseling. *Nicotine Tob Res*. 2008;10(4):717-29.
217. MCGovern PG, Lando HA. An Assessment of Nicotine Gum as an Adjunct to Freedom from Smoking Cessation Clinics. *Addictive Behaviors*. 1992;17(2):137-47.

218. Mercie P, Arsandaux J, Katlama C, Ferret S, Beuscart A, Spadone C, et al. Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial. *Lancet HIV*. 2018;5(3):E126-E35.
219. Molyneux A, Lewis S, Leivers U, Anderton A, Antoniak M, Brackenridge A, et al. Clinical trial comparing nicotine replacement therapy (NRT) plus brief counselling, brief counselling alone, and minimal intervention on smoking cessation in hospital inpatients. *Thorax*. 2003;58(6):484-8.
220. Mori T STYGNMHT. A clinical trial of nicotine chewing gum for smoking cessation [abstract 428]. 1992.
221. Myles PS, Leslie K, Angliss M, Mezzavia P, Lee L. Effectiveness of bupropion as an aid to stopping smoking before elective surgery: a randomised controlled trial. *Anaesthesia*. 2004;59(11):1053-8.
222. Myung SK, Seo HG, Park S, Kim Y, Kim DJ, Lee DH, et al. Sociodemographic and smoking behavioral predictors associated with smoking cessation according to follow-up periods: a randomized, double-blind, placebo-controlled trial of transdermal nicotine patches. *J Korean Med Sci*. 2007;22(6):1065-70.
223. Nahvi S, Ning Y, Segal KS, Richter KP, Arnsten JH. Varenicline efficacy and safety among methadone maintained smokers: a randomized placebo-controlled trial. *Addiction*. 2014;109(9):1554-63.
224. Nakamura M, J. S, A. O, M. M, A. M, S. E. Effect of nicotine chewing gun in smoking cessation classes. *The Global War*. 1990:665-7.
225. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. *Clin Ther*. 2007;29(6):1040-56.
226. Fox Chase Cancer Center, National Cancer Institute. Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking. <https://ClinicalTrials.gov/show/NCT00365508>; 2006.
227. Pfizer. Long-term Varenicline Treatment for Smoking Cessation. University of Wisconsin, Madison: <https://ClinicalTrials.gov/show/NCT00828113>; 2009.
228. Nebot M, Cabezas C. Does nurse counseling or offer of nicotine gum improve the effectiveness of physician smoking-cessation advice? *Fam Pract Res J*. 1992;12(3):263-70.
229. Niaura R, Goldstein MG, Abrams DB. Matching high- and low-dependence smokers to self-help treatment with or without nicotine replacement. *Prev Med*. 1994;23(1):70-7.
230. Niaura R, Abrams DB, Shadel WG, Rohsenow DJ, Monti PM, Sirota AD. Cue exposure treatment for smoking relapse prevention: a controlled clinical trial. *Addiction*. 1999;94(5):685-95.
231. Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, et al. The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial. *Curr Med Res Opin*. 2008;24(7):1931-41.
232. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. *Arch Intern Med*. 2006;166(15):1561-8.
233. Nides M, Danielsson T, Saunders F, Perfekt R, Kapikian R, Solla J, et al. Efficacy and safety of a nicotine mouth spray for smoking cessation; a randomized, multicenter, controlled study in a naturalistic setting. *Nicotine Tob Res*. 2018;18:18.
234. Ockene JK, Kristeller J, Goldberg R, Amick TL, Pekow PS, Hosmer D, et al. Increasing the efficacy of physician-delivered smoking interventions: a randomized clinical trial. *J Gen Intern Med*. 1991;6(1):1-8.
235. Okuyemi KS, James AS, Mayo MS, Nollen N, Catley D, Choi WS, et al. Pathways to health: a cluster randomized trial of nicotine gum and motivational interviewing for smoking cessation in low-income housing. *Health Educ Behav*. 2007;34(1):43-54.
236. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. *Arch Intern Med*. 2006;166(15):1571-7.
237. Oncken C, Cooney J, Feinn R, Lando H, Kranzler HR. Transdermal nicotine for smoking cessation in postmenopausal women. *Addict Behav*. 2007;32(2):296-309.
238. Ortega F, Vellisco A, Marquez E, Lopez-Campos JL, Rodriguez A, de los Angeles Sanchez M, et al. Effectiveness of a cognitive orientation program with and without nicotine replacement therapy in stopping smoking in hospitalised patients. *Arch Bronconeumol*. 2011;47(1):3-9.
239. Pack QR, Jorenby DE, Fiore MC, Jackson T, Weston P, Piper ME, et al. A comparison of the nicotine lozenge and nicotine gum: an effectiveness randomized controlled trial. *WMJ*. 2008;107(5):237-43.
240. Page AR, Walters DJ, Schlegel RP, Best JA. Smoking cessation in family practice: the effects of advice and nicotine chewing gum prescription. *Addict Behav*. 1986;11(4):443-6.
241. Paoletti P, Fornai E, Maggiorelli F, Puntoni R, Viegi G, Carrozzi L, et al. Importance of baseline cotinine plasma values in smoking cessation: results from a double-blind study with nicotine patch. *Eur Respir J*. 1996;9(4):643-51.
242. Perng RP, Hsieh WC, Chen YM, Lu CC, Chiang SJ. Randomized, double-blind, placebo-controlled study of transdermal nicotine patch for smoking cessation. *J Formos Med Assoc*. 1998;97(8):547-51.
243. Piper ME, Federman EB, McCarthy DE, Bolt DM, Smith SS, Fiore MC, et al. Efficacy of bupropion alone and in combination with nicotine gum. *Nicotine Tob Res*. 2007;9(9):947-54.
244. Piper ME, Smith SS, Schlam TR, Fiore MC, Jorenby DE, Fraser D, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. *Arch Gen Psychiatry*. 2009;66(11):1253-62.
245. Piper ME, Cook JW, Schlam TR, Jorenby DE, Smith SS, Collins LM, et al. A Randomized Controlled Trial of an Optimized Smoking Treatment Delivered in Primary Care. *Ann Behav Med*. 2018;52(10):854-64.
246. Pirie PL, McBride CM, Hellerstedt W, Jeffery RW, Hatsukami D, Allen S, et al. Smoking cessation in women concerned about weight. *Am J Public Health*. 1992;82(9):1238-43.
247. Planer D, Lev I, Elizur Y, Sharon N, Ouzan E, Pugatsch T, et al. Bupropion for smoking cessation in patients with acute coronary syndrome. *Arch Intern Med*. 2011;171(12):1055-60.
248. Prapavessis H, Cameron L, Baldi JC, Robinson S, Borrie K, Harper T, et al. The effects of exercise and nicotine replacement therapy on smoking rates in women. *Addict Behav*. 2007;32(7):1416-32.
249. Puska P, Bjorkqvist S, Koskela K. Nicotine-containing chewing gum in smoking cessation: a double blind trial with half year follow-up. *Addict Behav*. 1979;4(2):141-6.
250. Puska P, Korhonen HJ, Vartiainen E, Urjanheimo EL, Gustavsson G, Westin A. Combined use of nicotine patch and gum compared with gum alone in smoking cessation - a clinical trial in North Karelia. *Tobacco Control*. 1995;4(3):231-5.
251. Quilez Garcia C, Hernando Arizaleta L, Rubio Diaz A, Granero Fernandez EJ, Vila Coll MA, Estruch Riba J. [Double-blind study of the efficacy of nicotine chewing gum for smoking cessation in the primary care setting]. *Aten Primaria*. 1989;6(10):719-26.
252. Ramon JM, Morchon S, Baena A, Masuet-Aumatell C. Combining varenicline and nicotine patches: a randomized controlled trial study in smoking cessation. *BMC Med*. 2014;12(172):172.
253. Ratner PA, Johnson JL, Richardson CG, Bottorff JL, Moffat B, Mackay M, et al. Efficacy of a smoking-cessation intervention for elective-surgical patients. *Res Nurs Health*. 2004;27(3):148-61.
254. Reid R, Pipe A, Higginson L, Johnson K, D'Angelo MS, Cooke D, et al. Stepped care approach to smoking cessation in patients hospitalized for coronary artery disease. *J Cardiopulm Rehabil*. 2003;23(3):176-82.
255. Reid MS, Fallon B, Sonne S, Flammino F, Nunes EV, Jiang H, et al. Smoking cessation treatment in community-based substance abuse rehabilitation programs. *J Subst Abuse Treat*. 2008;35(1):68-77.
256. Rennard SI, Glover ED, Leischow S, Daughton DM, Glover PN, Muramoto M, et al. Efficacy of the nicotine inhaler in smoking reduction: A double-blind, randomized trial. *Nicotine Tob Res*. 2006;8(4):555-64.
257. Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, et al. A randomized placebo-controlled trial of varenicline for smoking cessation allowing flexible quit dates. *Nicotine Tob Res*. 2012;14(3):343-50.
258. Richmond RL, Makinson RJ, Kehoe LA, Giugni AA, Webster IW. One-year evaluation of three smoking cessation interventions administered by general practitioners. *Addict Behav*. 1993;18(2):187-99.
259. Richmond RL, Harris K, Dealmeidaneto A. The Transdermal Nicotine Patch - Results of a Randomized Placebo-Controlled Trial. *Medical Journal of Australia*. 1994;161(2):130-&.
260. Rigotti NA, Thorndike AN, Regan S, McKool K, Pasternak RC, Chang Y, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. *Am J Med*. 2006;119(12):1080-7.
261. Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. *Circulation*. 2010;121(2):221-9.

262. Rodriguez-Artalejo F, Lafuente Urdinguio P, Guallar-Castillon P, Garteizurrekoa Dublang P, Sainz Martinez O, Diez Azcarate JI, et al. One year effectiveness of an individualised smoking cessation intervention at the workplace: a randomised controlled trial. *Occup Environ Med*. 2003;60(5):358-63.
263. Rohsenow DJ, Tidey JW, Martin RA, Colby SM, Swift RM, Leggio L, et al. Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms. *Addiction*. 2017;112(10):1808-20.
264. Rose JE, Behm FM. Adapting smoking cessation treatment according to initial response to precessation nicotine patch. *Am J Psychiatry*. 2013;170(8):860-7.
265. Roto P OASKJKPR. Nicotine gum and withdrawal from smoking. *Suomen Laakarlehti*. 1987;36:3445-8.
266. Rovina N, Nikoloutsou I, Katsani G, Dima E, Fransis K, Roussos C, et al. Effectiveness of pharmacotherapy and behavioral interventions for smoking cessation in actual clinical practice. *Ther Adv Respir Dis*. 2009;3(6):279-87.
267. Russell MAH, Merriman R, Stapleton J, Taylor W. Effect of Nicotine Chewing Gum as an Adjunct to General-Practitioners Advice against Smoking. *British Medical Journal*. 1983;287(6407):1782-5.
268. Sachs DPL, Sawe U, Leischow SJ. Effectiveness of a 16-Hour Transdermal Nicotine Patch in a Medical-Practice Setting, without Intensive Group-Counseling. *Archives of Internal Medicine*. 1993;153(16):1881-90.
269. Sadr Azodi O, Lindstrom D, Adami J, Tonnesen H, Nasell H, Gilljam H, et al. The efficacy of a smoking cessation programme in patients undergoing elective surgery: a randomised clinical trial. *Anaesthesia*. 2009;64(3):259-65.
270. Schaffler HH, McMenamin S, Olson K, Boyce-Smith G, Rideout JA, Kamil J. Variations in treatment benefits influence smoking cessation: results of a randomised controlled trial. *Tob Control*. 2001;10(2):175-80.
271. Schiller KR, Luo X, Anderson AJ, Jensen JA, Allen SS, Hatsukami DK. Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation. *Nicotine Tob Res*. 2012;14(8):902-9.
272. Schmitz JM, Stotts AL, Mooney ME, Delaune KA, Moeller GF. Bupropion and cognitive-behavioral therapy for smoking cessation in women. *Nicotine Tob Res*. 2007;9(6):699-709.
273. Schneider NG, Jarvik ME, Forsythe AB, Read LL, Elliott ML, Schweiger A. Nicotine gum in smoking cessation: a placebo-controlled, double-blind trial. *Addict Behav*. 1983;8(3):253-61.
274. Schneider NG, Olmstead R, Mody FV, Doan K, Franzon M, Jarvik ME, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. *Addiction*. 1995;90(12):1671-82.
275. Schneider NG, Olmstead R, Nilsson F, Mody FV, Franzon M, Doan K. Efficacy of a nicotine inhaler in smoking cessation: a double-blind, placebo-controlled trial. *Addiction*. 1996;91(9):1293-306.
276. Schnoll RA, Martinez E, Tatum KL, Weber DM, Kuzla N, Glass M, et al. A bupropion smoking cessation clinical trial for cancer patients. *Cancer Causes Control*. 2010;21(6):811-20.
277. Schnoll RA, Patterson F, Wileyto EP, Heitjan DF, Shields AE, Asch DA, et al. Effectiveness of extended-duration transdermal nicotine therapy: a randomized trial. *Ann Intern Med*. 2010;152(3):144-51.
278. Schnoll RA, Martinez E, Tatum KL, Glass M, Bernath A, Ferris D, et al. Nicotine patch vs. nicotine lozenge for smoking cessation: an effectiveness trial coordinated by the Community Clinical Oncology Program. *Drug Alcohol Depend*. 2010;107(2-3):237-43.
279. Schnoll RA, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L, Leone FT, et al. Long-term nicotine replacement therapy: a randomized clinical trial. *JAMA Intern Med*. 2015;175(4):504-11.
280. Schnoll R, Leone F, Veluz-Wilkins A, Miele A, Hole A, Jao NC, et al. A randomized controlled trial of 24 weeks of varenicline for tobacco use among cancer patients: Efficacy, safety, and adherence. *Psychooncology*. 2019;28(3):561-9.
281. Segnan N, Ponti A, Battista RN, Senore C, Rosso S, Shapiro SH, et al. A randomized trial of smoking cessation interventions in general practice in Italy. *Cancer Causes Control*. 1991;2(4):239-46.
282. Selby P BBSN. Retreatment with ZYban SR: 52 week follow-up of a Canadian Multicentre trial (POS3-63). 2003.
283. Selma Bozkurt Z, Serkan Z, Esra K, Esra Aydin S. Comparison of the effectiveness of varenicline, extended-release bupropion and nicotine replacement therapy on the success and the maintenance of a smoking cessation program. *Klinik Psikofarmakoloji Bulteni-Bulletin of Clinical Psychopharmacology*. 2013;23(3):224-30.
284. Severson HH, Danaher BG, Ebbert JO, van Meter N, Lichtenstein E, Widdop C, et al. Randomized trial of nicotine lozenges and phone counseling for smokeless tobacco cessation. *Nicotine Tob Res*. 2015;17(3):309-15.
285. Sharifirad GR, Eslami AA, Charkazi A, Mostafavi F, Shahnazi H. The effect of individual counseling, line follow-up, and free nicotine replacement therapy on smoking cessation in the samples of Iranian smokers: Examination of transtheoretical model. *J Res Med Sci*. 2012;17(12):1128-36.
286. Sharma SK, Mohan A, Singh AD, Mishra H, Jhanjee S, Pandey RM, et al. Impact of nicotine replacement therapy as an adjunct to anti-tuberculosis treatment and behaviour change counselling in newly diagnosed pulmonary tuberculosis patients: an open-label, randomised controlled trial. *Sci Rep*. 2018;8(1):8828.
287. Sherman SE, Aldana I, Estrada M, York L. Comparing the tolerability and effectiveness of two treatment regimens in a smoking clinic. *Mil Med*. 2008;173(6):550-4.
288. Shiffman S, Dresler CM, Hajek P, Gilbert SJ, Targett DA, Strahs KR. Efficacy of a nicotine lozenge for smoking cessation. *Arch Intern Med*. 2002;162(11):1267-76.
289. Shiffman S, Ferguson SG, Strahs KR. Quitting by gradual smoking reduction using nicotine gum: a randomized controlled trial. *Am J Prev Med*. 2009;36(2):96-104 e1.
290. Siddiqi K, Khan A, Ahmad M, Dogar O, Kanaan M, Newell JN, et al. Action to stop smoking in suspected tuberculosis (ASSIST) in Pakistan: a cluster randomized, controlled trial. *Ann Intern Med*. 2013;158(9):667-75.
291. Simon JA, Solkowitz SN, Carmody TP, Browner WS. Smoking cessation after surgery. A randomized trial. *Arch Intern Med*. 1997;157(12):1371-6.
292. Simon JA, Duncan C, Carmody TP, Hudes ES. Bupropion for smoking cessation: a randomized trial. *Arch Intern Med*. 2004;164(16):1797-803.
293. Simon JA, Duncan C, Huggins J, Solkowitz S, Carmody TP. Sustained-release bupropion for hospital-based smoking cessation: a randomized trial. *Nicotine Tob Res*. 2009;11(6):663-9.
294. Smith SS, McCarthy DE, Japuntich SJ, Christiansen B, Piper ME, Jorenby DE, et al. Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics. *Arch Intern Med*. 2009;169(22):2148-55.
295. SMK20001:A Multi-Center, Double-Blind, Double-Dummy, Placebo-Controlled, Randomized, Parallel Group, Dose Response Evaluation of a New Chemical Entity (NCE) and ZYBAN (bupropion hydrochloride) Sustained Release (300mg/day) versus Placebo As Aids to Smoking Cessation.
296. Solomon LJ, Scharoun GM, Flynn BS, Secker-Walker RH, Sepinwall D. Free nicotine patches plus proactive telephone peer support to help low-income women stop smoking. *Prev Med*. 2000;31(1):68-74.
297. Solomon LJ, Marcy TW, Howe KD, Skelly JM, Reinier K, Flynn BS. Does extended proactive telephone support increase smoking cessation among low-income women using nicotine patches? *Prev Med*. 2005;40(3):306-13.
298. Sonderskov J, Olsen J, Sabroe S, Meillier L, Overvad K. Nicotine patches in smoking cessation: A randomized trial among over-the-counter customers in Denmark. *American Journal of Epidemiology*. 1997;145(4):309-18.
299. Stapleton JA, Russell MA, Feyerabend C, Wiseman SM, Gustavsson G, Sawe U, et al. Dose effects and predictors of outcome in a randomized trial of transdermal nicotine patches in general practice. *Addiction*. 1995;90(1):31-42.
300. Stapleton J, West R, Hajek P, Wheeler J, Vangeli E, Abdi Z, et al. Randomized trial of nicotine replacement therapy (NRT), bupropion and NRT plus bupropion for smoking cessation: effectiveness in clinical practice. *Addiction*. 2013;108(12):2193-201.
301. Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. *Drug Alcohol Depend*. 2013;133(2):486-93.
302. Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. *Ann Intern Med*. 2009;150(7):447-54.
303. Steinberg MB, Randall J, Greenhaus S, Schmelzer AC, Richardson DL, Carson JL. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline. *Addict Behav*. 2011;36(12):1127-32.
304. Stockings EA, Bowman JA, Baker AL, Terry M, Clancy R, Wye PM, et al. 2014 world congress abstracts, 3-6 december 2014, melbourne, australia. *Asia Pac J Clin Oncol*. 2014;10 Suppl 9:1-263.
305. Sutherland G, Stapleton JA, Russell MAH, Jarvis MJ, Hajek P, Belcher M, et al. Randomized Controlled Trial of Nasal Nicotine Spray in Smoking Cessation. *Lancet*. 1992;340(8815):324-9.
306. Sutton S, Hallett R. Randomized trial of brief individual treatment for smoking using nicotine chewing gum in a workplace setting. *Am J Public Health*. 1987;77(9):1210-1.
307. Sutton S, Hallett R. Smoking intervention in the workplace using videotapes and nicotine chewing gum. *Prev Med*. 1988;17(1):48-59.
308. Swan GE, McAfee T, Curry SJ, Jack LM, Javitz H, Dacey S, et al. Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial. *Arch Intern Med*. 2003;163(19):2337-44.
309. Swanson NA, Burroughs CC, Long MA, Lee RW. Controlled trial for smoking cessation in a navy shipboard population using nicotine patch, sustained-release bupropion, or both. *Military Medicine*. 2003;168(10):830-4.

310. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. *Lancet*. 2001;357(9268):1571-5.
311. Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. *Chest*. 2011;139(3):591-9.
312. Thomsen T, Tonnesen H, Okholm M, Kroman N, Maibom A, Sauerberg ML, et al. Brief smoking cessation intervention in relation to breast cancer surgery: a randomized controlled trial. *Nicotine Tob Res*. 2010;12(11):1118-24.
313. Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnarsen AB, Forchammer H, et al. Effect of nicotine chewing gum in combination with group counseling on the cessation of smoking. *N Engl J Med*. 1988;318(1):15-8.
314. Tonnesen P, Fryd V, Hansen M, Helsted J, Gunnarsen AB, Forchammer H, et al. Two and four mg nicotine chewing gum and group counselling in smoking cessation: an open, randomized, controlled trial with a 22 month follow-up. *Addict Behav*. 1988;13(1):17-27.
315. Tonnesen P, Norregaard J, Simonsen K, Sawe U. A double-blind trial of a 16-hour transdermal nicotine patch in smoking cessation. *N Engl J Med*. 1991;325(5):311-5.
316. Tonnesen P, Norregaard J, Mikkelsen K, Jorgensen S, Nilsson F. A double-blind trial of a nicotine inhaler for smoking cessation. *JAMA*. 1993;269(10):1268-71.
317. Tonnesen P, Paoletti P, Gustavsson G, Russell MA, Saracci R, Gulsvik A, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. *European Respiratory Society. Eur Respir J*. 1999;13(2):238-46.
318. Tonnesen P, Mikkelsen KL. Smoking cessation with four nicotine replacement regimes in a lung clinic. *Eur Respir J*. 2000;16(4):717-22.
319. Tonnesen P, Tonstad S, Hjalmarson A, Leborgy F, Van Spiegel PI, Hider A, et al. A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation. *J Intern Med*. 2003;254(2):184-92.
320. Tonnesen P, Mikkelsen K, Bremann L. Nurse-conducted smoking cessation in patients with COPD using nicotine sublingual tablets and behavioral support. *Chest*. 2006;130(2):334-42.
321. Tonnesen P, Lauri H, Perfekt R, Mann K, Batra A. Efficacy of a nicotine mouth spray in smoking cessation: a randomised, double-blind trial. *Eur Respir J*. 2012;40(3):548-54.
322. Tonstad S, Farsang C, Klaene G, Lewis K, Manolis A, Perruchoud AP, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. *Eur Heart J*. 2003;24(10):946-55.
323. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. *JAMA*. 2006;296(1):64-71.
324. Tromeur C, Le Mao R, Couturand F. Effect of varenicline on smoking cessation in COPD patients recovering from exacerbation: a randomized trial. *Fundamental & Clinical Pharmacology*. 2018;32:32-.
325. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB, Jr., et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. *Clin Ther*. 2007;29(6):1027-39.
326. Tsukahara H, Noda K, Saku K. A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers: efficacy, safety and withdrawal symptoms (the VN-SEESAW study). *Circ J*. 2010;74(4):771-8.
327. Tuisku A, Salmela M, Nieminen P, Toljamo T. Varenicline and Nicotine Patch Therapies in Young Adults Motivated to Quit Smoking: A Randomized, Placebo-controlled, Prospective Study. *Basic Clin Pharmacol Toxicol*. 2016;119(1):78-84.
328. Tulloch HE, Pipe AL, Els C, Clyde MJ, Reid RD. Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial. *BMC Med*. 2016;14(80):80.
329. University of Michigan, National Heart LaBI. A Randomized Trial of Internet Access to Nicotine Patches. <https://ClinicalTrials.gov/show/NCT00534404>; 2011.
330. Urdapilleta-Herrera E, Pina-Rosales MF, Vargas-Rojas MI, Ramirez-Venegas A, Sansores-Martinez R. Bupropion together with cognitive-conductual therapy (CBT) is an alternative for a long-term abstinence of smoking. *European Respiratory Journal*. 2013;42(no pagination).
331. Uyar M, Filiz A, Bayram N, Elbek O, Herken H, Topcu A, et al. A randomized trial of smoking cessation. Medication versus motivation. *Saudi Med J*. 2007;28(6):922-6.
332. Vial RJ, Jones TE, Ruffin RE, Gilbert AL. Smoking cessation program using nicotine patches linking hospital to the community. *Journal of Pharmacy Practice and Research*. 2002;32(1):57-62.
333. Villa RS, Alvarez ABD, Hermida JRF. Effectiveness of a multicomponent program to quit smoking with and without nicotine chewing gum. *Psicologia Conductual*. 1999;7(1):107-18.
334. Wagena EJ, Knipschild PG, Huibers MJH, Wouters EFM, Schayck CPR. Efficacy of bupropion and nortriptyline for smoking cessation among people who are at risk for or have chronic obstructive pulmonary disease: Results from a randomized, placebo-controlled trial. *Nicotine & Tobacco Research*. 2005;7(4):683-4.
335. Wallstrom M, Nilsson F, Hirsch JM. A randomized, double-blind, placebo-controlled clinical evaluation of a nicotine sublingual tablet in smoking cessation. *Addiction*. 2000;95(8):1161-71.
336. Walsh MM, Hilton JF, Masouredis CM, Gee L, Chesney MA, Ernster VL. Smokeless tobacco cessation intervention for college athletes: results after 1 year. *Am J Public Health*. 1999;89(2):228-34.
337. Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. *Respirology*. 2009;14(3):384-92.
338. Ward KD, Asfar T, Al Ali R, Rastam S, Weg MW, Eissenberg T, et al. Randomized trial of the effectiveness of combined behavioral/pharmacological smoking cessation treatment in Syrian primary care clinics. *Addiction*. 2013;108(2):394-403.
339. Weaver K, Kaplan S, Urbanic J, Case D, Zbikowski S, Dakhil C, et al. Incorporating evidence-based smoking cessation into community oncology practices: Feasibility and preliminary efficacy of an enhanced quitline-based smoking cessation intervention for cancer survivors 2015; 24:[32 p.]. Available from: <http://onlinelibrary.wiley.com/doi/10.1111/147997/frame.html>.
340. Wennike P, Danielsson T, Landfeldt B, Westin A, Tonnesen P. Smoking reduction promotes smoking cessation: results from a double blind, randomized, placebo-controlled trial of nicotine gum with 2-year follow-up. *Addiction*. 2003;98(10):1395-402.
341. Westergaard CG, Porsbjerg C, Backer V. The effect of Varenicline on smoking cessation in a group of young asthma patients. *Respir Med*. 2015;109(11):1416-22.
342. Westman EC, Levin ED, Rose JE. The nicotine patch in smoking cessation. A randomized trial with telephone counseling. *Arch Intern Med*. 1993;153(16):1917-23.
343. Wewers ME, Neidig JL, Kihm KE. The feasibility of a nurse-managed, peer-led tobacco cessation intervention among HIV-positive smokers. *J Assoc Nurses AIDS Care*. 2000;11(6):37-44.
344. Wiggers LC, Smets EM, Oort FJ, Peters RJ, Storm-Versloot MN, Vermeulen H, et al. The effect of a minimal intervention strategy in addition to nicotine replacement therapy to support smoking cessation in cardiovascular outpatients: a randomized clinical trial. *Eur J Cardiovasc Prev Rehabil*. 2006;13(6):931-7.
345. Williams KE, Reeves KR, Billing CB, Jr., Pennington AM, Gong J. A double-blind study evaluating the long-term safety of varenicline for smoking cessation. *Curr Med Res Opin*. 2007;23(4):793-801.
346. Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis C, et al. A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. *J Clin Psychiatry*. 2012;73(5):654-60.
347. Wilson JS, Fitzsimons D, Bradbury I, Stuart Elborn J. Does additional support by nurses enhance the effect of a brief smoking cessation intervention in people with moderate to severe chronic obstructive pulmonary disease? A randomised controlled trial. *Int J Nurs Stud*. 2008;45(4):508-17.
348. Winhusen TM, Brigham GS, Kropp F, Lindblad R, Gardin JG, 2nd, Penn P, et al. A randomized trial of concurrent smoking-cessation and substance use disorder treatment in stimulant-dependent smokers. *J Clin Psychiatry*. 2014;75(4):336-43.
349. Wiratmoko MR, Yunus F, Susanto AD, Ginting TT, Kekalih A. Efficacy of Varenicline, an Nicotinic Acetylcholine Receptor Partial Agonist, Vs Placebo for Smoking Cessation. A Randomized Controlled Trial. *Respirology*. 2013;18:66-.
350. Wittchen HU, Hoch E, Klotsche J, Muehlig S. Smoking cessation in primary care - a randomized controlled trial of bupropione, nicotine replacements, CBT and a minimal intervention. *Int J Methods Psychiatr Res*. 2011;20(1):28-39.
351. Wong GY, Wolter TD, Croghan GA, Croghan IT, Offord KP, Hurt RD. A randomized trial of naltrexone for smoking cessation. *Addiction*. 1999;94(8):1227-37.
352. Wong J, Abrishami A, Yang Y, Zaki A, Friedman Z, Selby P, et al. A perioperative smoking cessation intervention with varenicline: a double-blind, randomized, placebo-controlled trial. *Anesthesiology*. 2012;117(4):755-64.

353. Wong J, Abrishami A, Riazi S, Siddiqui N, You-Ten E, Korman J, et al. A Perioperative Smoking Cessation Intervention With Varenicline, Counseling, and Fax Referral to a Telephone Quitline Versus a Brief Intervention: A Randomized Controlled Trial. *Anesth Analg*. 2017;125(2):571-9.
354. Yang DX, Gu CJ, Ni L, Li N, Li QY, Zhou JP. Assessment of efficacy of medication combined with WeChat platform for quitting smoking in patients with chronic obstructive pulmonary disease. [Chinese]. *Journal of Shanghai Jiaotong University (Medical Science)*. 2016;36(3):385-9.
355. Yuhongxia L. The Compliance of Varenicline Usage and the Smoking Abstinence Rate Via Mobile Phone Text Messaging Combine with Varenicline: A Single-Blind, Randomised Control Trial. *Respirology*. 2011;16:46-7.
356. Zellweger JP, Boelcskei PL, Carrozzi L, Sepper R, Sweet R, Hider AZ. Bupropion SR vs placebo for smoking cessation in health care professionals. *Am J Health Behav*. 2005;29(3):240-9.
357. Zelman DC, Brandon TH, Jorenby DE, Baker TB. Measures of affect and nicotine dependence predict differential response to smoking cessation treatments. *J Consult Clin Psychol*. 1992;60(6):943-52.
358. Zernig G, Wallner R, Grohs U, Kriechbaum N, Kemmler G, Saria A. A randomized trial of short psychotherapy versus sustained-release bupropion for smoking cessation. *Addiction*. 2008;103(12):2024-31.
359. ZYB 30011: A multicentre, randomised, double-blind, placebo controlled study to evaluate the efficacy and tolerability of bupropion hydrochloride (SR) sustained release (2 x 150mg per day) versus placebo as an aid to smoking cessation in smokers with at least one cardiovascular (CV) risk factor.
360. ZYB40005: The effect of sustained-release bupropion HCl vs. placebo as an aid to smoking reduction leading to cessation among smokers unwilling and unable to quit smoking.
361. ZYBAKIA402: A single center evaluation of Wellbutrin (bupropion hydrochloride) versus placebo as an aid to smoking cessation (study 402).